Category: Blog

Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine

Nov 19, 2020 by OTC PR

Generex Worldwide Licensing Deal

  • $2.5 million upfront for the Ii-Key-H1 vaccine from NuGenerex-Immuno-Oncology (NGIO) and to initiate epitope identification for Ii-Key vaccine development against the emerging swine flu in China G4EA H1N1
  • 100% funding for manufacturing, development and commercial registration and approval of an Ii-Key-H1 vaccine in China
  • Plans to incorporate Ii-Key-H1 vaccine into universal seasonal influenza vaccine
  • An 8K will be filed on the contract today

MIRAMAR, Fla., Nov. 19, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) is pleased to announce that the company has signed a worldwide Licensing and Development Agreement with a consortium of partners in China to utilize the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO) for developing a vaccine against the G4 EA H1N1 swine influenza that is rapidly emerging in China. Under the terms of the deal, Generex will receive an upfront payment of $2.5 million to initiate the Ii-Key vaccine development work to identify swine flu epitopes for a new Ii-Key vaccine. The partnership will provide full funding for product development, regulatory approval, and commercialization worldwide. The current plan is to incorporate the Ii-Key-H1 vaccine into the seasonal influenza vaccine to create a Complete Vaccine across influenza strains. Upon commercialization, Generex will receive a royalty on sales of the influenza vaccine. The consortium of China partners has been previously announced as part of the company’s Framework Agreement. Generex is filing an 8K with the SEC, including details on the deal, as well as copies of the final agreements.

Generex Worldwide Licensing Deal

Generex originally developed the Ii-Key-H5 vaccine in 2003 in response to the avian influenza (bird flu), bringing that ii-Key vaccine through pre-clinical and Phase I clinical trials before the pandemic threat faded. Then, with the 2009 swine flu outbreak, Generex revitalized the Ii-Key vaccine program with the Ii-Key-H1 vaccine, using the H5 vaccine which is 100% homologous (the same) between the avian and swine influenza strains. Again, the pandemic threat faded before serious development work could be furthered. With the current outbreak of G4 EA H1N1 swine influenza in China, Generex and our partners will restart the work on the Ii-Key-H1 vaccine, expanding the effort to evaluate the current strain to identify additional H1 epitopes that can be linked with the Ii-Key to target the immune response for an effective vaccine.

The Ii-Key-SARS-CoV-2 vaccine is designed as a “Complete Vaccine” that has the potential to induce the T-Cell and antibody immune responses in a highly specific manner that can provide protective immunity with long-lasting immunologic memory against SARS-CoV-2 and other pandemic threats like swine flu.

Generex Worldwide Licensing Deal

Generex CEO, Joseph Moscato said, “This licensing deal with our Chinese partners clearly demonstrates the potential power of the Ii-Key platform to be part of an international pandemic preparedness program for rapid response to emerging infectious diseases. As the G4 EA H1N1 swine flu is emerging among swine workers, our partners have recognized the need to act decisively and we are taking proactive steps to prevent an epidemic through early vaccine development. To that end, the goal of our Ii-Key-H1 vaccine program is to incorporate the Ii-Key-H1 vaccine into the standard annual influenza vaccine to protect the population from not only seasonal flu, but also the emerging swine flu. We are extremely proud to have our Ii-Key vaccine platform selected as part of an international pandemic preparedness effort to prevent future viral epidemics. With the two licensing deals completed for our Ii-Key-SARS-CoV-2 vaccine and Ii-Key-H1 vaccine, we are demonstrating to the world how the Ii-Key technology from our subsidiary NuGenerex Immuno-Oncology can change the face of vaccine development for infectious disease.”

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Read more:

Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform

Nov 18, 2020 by OTC PR

Generex Inks $50 Million Licensing

  • $50 million licensing deal for the Ii-Key platform to develop vaccines for infectious diseases and cancer
  • Deal includes first contract for Ii-Key- SARS-CoV-2 vaccine against COVID-19 in China with a $5 million upfront licensing fee, 100% funding for manufacturing, development and commercial registration and a $20 million success fee for approval Ii-Key- SARS-CoV-2 vaccine in China
  • Royalty payments for COVID vaccine with billion-dollar royalty potential
  • Framework agreement for the development of additional Ii-Key vaccines for cancer & infectious diseases under separate licensing deals with fees, milestones, and royalties on sales
  • An 8K will be filed on the contract today

MIRAMAR, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) is pleased to announce that the company has closed a $50 million Licensing and Development Agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO).

Generex Inks $50 Million Licensing

Under the terms of the deal, Generex will receive a licensing fee of up to $50 million for the exclusive use of the Ii-Key vaccine platform for infectious disease and cancer in China and its territories. For each product developed using the Ii-Key technology under the platform license, Generex will receive an upfront payment, full funding for product development, regulatory approval, and commercialization in China, a success fee upon product approval, and a royalty to be determined on a case-by-case basis.

The agreement incorporates the first Ii-Key platform project for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China, with a $5 million upfront licensing fee, 100% funding for manufacturing, development and commercial registration, a $20 million success fee for approval Ii-Key- SARS-CoV-2 vaccine in China, and royalty payments for COVID vaccine sales in China with the potential to reach several billion dollars. The Agreement incorporates provisions to advance the development of other Ii-Key vaccines for infectious diseases and cancer under separate contracts that are currently being finalized. The partnering groups have been previously announced as part of the company’s Framework Agreement. Generex is filing an 8K with the SEC, including details on the deal, as well as copies of the final agreements.

Generex Inks $50 Million Licensing

“The Ii-Key-SARS-CoV-2 vaccine is designed as a “Complete Vaccine” that has the potential to induce the T-Cell and antibody immune responses in a highly specific manner that can provide protective immunity with long-lasting immunologic memory against SARS-CoV-2 and other pandemic threats like swine flu,” said Richard Purcell, Executive Vice President of R&D for Generex and NuGenerex Immuno-Oncology. “We have a proprietary approach to vaccine development that enables us to understand how our Ii-Key vaccines regulate the proper immune response because of the specificity of our Ii-Key-SARS-CoV-2 epitopes. We are able to generate a detailed immune activation profile of our Ii-Key vaccine candidates by screening blood samples from COVID-19 recovered patients. This unique ex-vivo human study approach enables us to know, prior to even Phase I clinical trials, whether the Ii-Key epitopes will activate CD4+ T helper cell and CD8+ T lymphocytes without activating the detrimental Th2 response that can lead to disease enhancement and the cytokine storm. Further, we can screen the patient samples for antibody binding to our Ii-Key vaccine candidates to ensure that our Ii-Key vaccines contain the appropriate coronavirus epitopes for a Complete Vaccine that activates targeted immune response. We are very happy with our blood screening data to date, as numerous Ii-Key vaccine candidates have been shown to activate the Th1 T-Helper response (as measured by gamma interferon) and the CD8+ response (as measured by Granzyme B) with no indication of Th2 activation (as measured by IL-5). Plus, we have positive antibody binding from patient serum. So, as we move toward the clinic, we already have data to demonstrate the potential for our Ii-Key technology to deliver a safe and targeted vaccine that is designed to limit off-target immune responses that can lead to the complications of COVID-19.”

Generex CEO, Joseph Moscato said, “Our partners in China understand the science and the power of the Ii-Key technology for the regulation of the immune system to develop safe and effective vaccines for infectious disease and cancer, and with this agreement, we cement our partnership to realize the full potential of our Ii-Key vaccine technology. With this partnership, Generex is perfectly positioned in China to deploy the Ii-Key platform as the leading technology for rapid response to emerging infectious diseases. We look forward to working in mutual collaboration with our partners to advance the Ii-Key vaccine development platform.”

Mr. Moscato continued, “This is probably the biggest deal Generex could even imagine and we are all too happy to be partners with these acclaimed institutions to help China and the world alleviate the threat of pandemic infections. Plus, we now have the ability to advance our Ii-Key cancer platform to realize the full potential of Ii-Key immunotherapies to target tumor biomarkers across oncology indications. The Ii-Key-SARS-CoV-2 vaccine is the first product under this Ii-Key platform license, and in the coming days, we will announce agreements for additional Ii-Key vaccine development projects as well as licensing deals for other products from the NuGenerex family of companies.”

Generex Inks $50 Million Licensing

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Read more:

SmallCapStockPick

Halberd on Money TV-Halberd Corp. CEO Interviewed on Money TV

Nov 2, 2020 by OTC PR

Halberd on Money TV-In Case You Missed It – Mr. Hartman discusses recent accomplishments and new opportunities.

JACKSON CENTER, PA / ACCESSWIRE / November 2, 2020 / Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided an update on the company’s latest activities, and new efforts underway.

Mr. Baillargeon began the interview by asking how Halberd decided on its university research partner. Mr. Hartman explained that Halberd reviewed several prestigious universities and selected Arizona State University due to its top ranking in innovation among research universities.

Hartman continued, “We are extremely satisfied with the choice of ASU, as their progress to date has exceeded our most optimistic expectations. Some of those details, by necessity, have been withheld, subject to the upcoming patent application filing.”

Hartman then discussed Halberd’s strategy in the patenting of new intellectual property. Although it may take the US Patent Office many months, or even years to issue a patent, by filing a provisional patent application immediately, the company establishes its priority date with that filing very soon after innovative products or processes are discovered. This protects our intellectual property while the technology and actual patent application are developed and refined. During the time between the filing of a provisional patent application and issuance of a patent, we will claim “patent pending” status while safeguarding the key components of the technology.

Halberd on Money TV

Hartman then outlined the importance of creating Covid-19 antibodies. Not only are antibodies important in fighting the disease in infected patients, but also as a rapid, accurate diagnostic tool. Additionally, our antibodies deployed in a nasal spray form could act as a potential preventative measure. Since a significant percentage of the population is reluctant to use a vaccine, this may be an effective alternative, and a huge market success.

Hartman explained, Halberd Corporation is debt-free and has the funding available to implement their entire Coronavirus project.

Describing another completely different application for its antibodies in potential projects, Hartman indicated that Halberd is well positioned to apply its unique, patented extracorporeal technology to diseases beyond the immediate necessity of addressing Covid-19. Halberd believes this technology to be a key element in potentially treating numerous other diseases, such as blood sepsis, PTSD, Alzheimer’s Disease, heart attacks/strokes, and others. Hartman indicated that cooperation with larger pharmaceutical entities would be considered on a case-by-case basis to expedite manufacture and distribution of Halberd’s technology products and processes to the market. However, Hartman clarified that these other implementations will not distract Halberd’s current Covid-19 focus.

Hartman ended the interview stating, “Halberd developed prototypes of a proposed Anti-Addiction Patch utilizing its patented ingredients that could be an effective tool in the war on alcohol and chemical addiction. The patch is intended to be worn continuously for multiple days to reduce the addictive craving for opioids, heroin, cocaine, and fentanyl. Hartman projected that this product could be a billion-dollar market success with demand emanating from the entire world.

Halberd on Money TV

You can view the entire interview video here.

About Halberd Corporation.

Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus”, and, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

Halberd on Money TV

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

Read more:

SmallCapNewsAlert:

Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19 Vaccine Development Program

Oct 30, 2020 by OTC PR

-Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children’s of Alabama, Professor of Pediatrics and Internal Medicine, Director of the University of Alabama at Birmingham Division of Adolescent Medicine, and Vice Chair of Pediatrics for Community Engagement

MIRAMAR, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that Dr. Tamera-Coyne Beasley has joined the NGIO COVID-19 Vaccine Scientific & Clinical Advisory Board (SAB) to help guide the company’s efforts in developing clinical research protocols that address the unmet medical and social needs of adolescents and young adults, who have been shown to transmit the coronavirus. She will also be instrumental in helping the company with community outreach programs, particularly in communities of color who are at increased risk of infection and the serious complications of COVID-19.

Dr. Coyne-Beasley completed her undergraduate work at Brown University before receiving her Master’s in Public Health in Epidemiology at the University of North Carolina at Chapel Hill and graduating from Duke University Medical School. She is currently a Professor of Pediatrics and Internal Medicine, practicing physician in the William A. Daniel, Jr. Adolescent Health Center at Children’s of Alabama and Director of the University of Alabama at Birmingham Division of Adolescent Medicine. Dr. Coyne-Beasley is also the Vice Chair of Pediatrics for Community Engagement. As a key opinion leader in the field of adolescent medicine, Dr. Coyne-Beasley is Past President of the Society for Adolescent Health and Medicine.

Generex CEO, Joseph Moscato said, “We are honored that Dr. Coyne-Beasley has joined our scientific and clinical advisory board. Her extensive experience and expertise in treating adolescents is especially important at this time of the coronavirus pandemic, as the opening of schools and universities has resulted in nationwide COVID spikes, clearly demonstrating the need for a vaccine that can be safely administered to children, adolescents, and young adults. And through her work in community engagement, we will further our efforts to include underserved communities who have been disproportionately impacted by the pandemic. We look forward to working closely with Dr. Coyne-Beasley as we advance the Ii-Key-SARS-CoV-2 vaccine into the clinic.”

About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Read more:

SmallCapNewsAlert:

RJD Green Inc. Executes an Acquisition Letter of Intent for the Silex Holdings Division

Oct 27, 2020 by OTC PR

TULSA, OK, Oct. 27, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — RJD Green Inc. (OTCPK: RJDG) announced they have completed a letter of intent with a premier mid-west regional fabricator of stone and engineered stone products.

The Company, formed in 1995, is a leading regional provider of premium quality natural stone and engineered stone products, with totally automated fabrication systems in place to achieve highest quality control and premium products.

The Company combined with the existing Silex Interiors fabrication operations creates over $10,000,000 in annual revenues for the Silex Holdings Division prior to the immediate growth opportunities.

Ron Brewer, CEO, stated, “We feel this is a great opportunity to combine two excellent profit centers with symmetrical regional markets. The synergistic operational and administrative opportunities available can offer substantial efficiencies and greater customer outreach. Immediate growth can occur through the planned introduction of new products and services by both operations, which enhance the proficiencies and profitability of the Silex Holdings Division.

“RJG Green can now continue its outreach to possible acquisitions in the healthcare sector and green environmental products and services to continue completing its business model.”

About Silex Holdings Inc.

Silex Holdings

Silex Holdings is engaged in specialty construction and industrial services sectors and fills a market niche between the Home Depots and local contractors. Silex offers installed stone and engineered stone counter tops, cabinets and related products for the residential builders, commercial projects, remodel contractors, and retail customers on a regional basis.

About RJD Green Inc.

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which owns IOSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers; Earthlinc Environmental Services Division, which provides green environmental services and technologies; and Silex Holdings Division, which is focused in specialty construction and industrial services. The initial operations, Silex Interiors, fills a market niche between the Home Depots and local contractors. Silex manufactures and installs granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and DIY customer.

Forward-looking Statement:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Company Contact:

RJD Green Inc.

Ron Brewer, CEO

918.551.7883

ronb@rjdgreen.com

Read more:

Halberd Corp. (HALB) Retains Prestigious Patent Law Firm on Covid-19-Related and Other Disease Technologies

Oct 27, 2020 by OTC PR

Halberd Corp. (HALB)

JACKSON CENTER, PA / ACCESSWIRE / October 27, 2020 / Halberd Corporation (OTC PINK:HALB) has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates, to handle its intellectual property matters. The initial application focuses on patenting Halberd’s base Covid-19 antibody as well as an entire new class of antibody conjugate. The primary attorney on the Halberd account is Dr. Darwin King, Esq., who has extensive experience in dealing with intellectual property matters in microbiology and antibody patents.

William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, “We are excited to have Dr. King’s experience in guiding us in protecting our valuable intellectual property. We currently have two issued patents and four provisional patents filed with the U.S. Patent Office, and have forwarded these to Dr. King. We are also working on a fifth provisional patent application which we expect to file within the next several weeks.”

Mr. Hartman noted, “Although four provisional patents are currently filed, the allowance and issuance of a patent by the US Patent Office is a process that can take several years. The filing of a provisional patent establishes Halberd’s priority date to preserve their property rights under the patent office’s ‘first to file’ policy. The patent issuance process will not delay or prevent us from continuing our pursuit of Covid-19 prevention, diagnostic and treatment research or other disease treatments associated with our patented extracorporeal technology.”

Halberd Corp. (HALB)

The details of the Halberd-ASU research contract can be viewed here.

You can hear Mr. Hartman’s latest The Stock Day Podcast interview here.

If you would like to be added to our email subscriber list, click here and submit the form.

For more information please contact:

William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC

About Ference & Associates.

Ference & Associates is a leading Pittsburgh, PA intellectual property boutique law firm that provides a full range of legal services relating to patents, trademarks and copyrights. They handle complex intellectual property portfolios and litigation for both local and global companies.

Their attorneys have deep expertise in science and engineering, and prepare and prosecute patents, trademarks and copyrights across a broad array of technical areas including: computer hardware and software, chemical, electronics, life science/biotech, mechanical and electro-mechanical. Further information about the firm may be found at: www.ferencelaw.com.

About Halberd Corporation.

Halberd Corp. (HALB)

Halberd Corp. (HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus”, and, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

Halberd Corp. (HALB)

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corp. (HALB)

Read more:

SmllCapNewsAlert:

Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm’s U.S. Manufacturing Facility

Oct 26, 2020 by OTC PR

Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm’s U.S. Manufacturing Facility

RR&D to lead site selection and design

Site analyses to begin immediately

PR Newswire

PHILADELPHIA and NEW YORK, Oct. 26, 2020

PHILADELPHIA and NEW YORK , Oct. 26, 2020 /PRNewswire/ — Rapid Reshore & Development (RR&D) , an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S.

BrainStorm_Logo

BrainStorm is investigating NurOwn as a potential treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). BrainStorm’s most advanced clinical program for NurOwn is in ALS, which is currently being evaluated in a pivotal Phase 3 clinical trial.

BrainStorm seeks to locate, design and construct a new commercial manufacturing facility in the U.S. to prepare for potential commercialization. RR&D, a three-firm services alliance consisting of EwingCole Facility Logix and Biggins, Lacy, Shapiro & Company , will identify the location and develop the design of BrainStorm’s new commercial manufacturing facility.

“We’re thrilled to be working with BrainStorm on this project and to have the opportunity to deliver this critical work to our region,” said EwingCole CEO, Jared Loos, PE, AIA. “We embrace the spirit of creating potentially life-changing technology and we will do everything we can to move the project forward in an efficient and yet responsible manner.”

BrainStorm intends to use the facility primarily for cell therapy production. RR&D will provide custom, streamlined project management, site selection analysis and design/construction management services throughout the project’s lifecycle.

Chaim Lebovits , Chief Executive Officer of BrainStorm Cell Therapeutics commented, “Our decision to partner with RR&D was driven by the strong capabilities of the individual partners and their holistic approach to planning, site selection and design services. The expansion of BrainStorm’s manufacturing capabilities is a key part of our broader corporate strategy to prepare for potential regulatory approvals of NurOwn and becoming a commercial organization. This new partnership follows our recently announced agreement with Catalent Pharma Solutions to manufacture NurOwn at a scale large enough to meet potential commercial needs at the time of launch. The dedicated, state-of-the-art manufacturing facility developed by RR&D will provide us with important long-term autonomy and strategic flexibility, including the capacity to supply NurOwn for additional disease indications beyond ALS.  Together these two partnerships will help ensure that BrainStorm has the manufacturing capacity to meet the needs of patients today and well into the future.”

Site selection analyses will begin immediately with the goal of identifying locations that offer a cost-effective solution for BrainStorm’s new manufacturing facility. At the same time, the design team will begin developing a conceptual design of the manufacturing facility, based upon input from BrainStorm’s process, engineering, and scientific staff, by defining the main steps of the production process and Current Good Manufacturing Practices (cGMP) requirements. The approximately 50,000 square-foot building will contain manufacturing suites, complementary support and infrastructure, and the ability to expand the facility to 100,000 square feet to anticipate future programmatic needs.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment in August 2020. For more information, visit the company’s website at www.brainstorm-cell.com .

About Rapid Reshore & Development:

Rapid Reshore & Development is an alliance of expert firms providing confidence and support throughout the life sciences industry, representing an evolution from transaction-driven service models to a holistic focus on client needs, integrating an interdisciplinary team customized for a variety of individual projects. To optimize and strengthen confidence in decision-making and speed-to-market, Rapid Reshore & Development alliance was formed to deliver best-in-class professionals with deep experience in all aspects of life sciences’ project planning, site selection, design and execution including financial, labor market, development incentives, real estate, design and engineering, and construction management. For additional information, visit: www.rapidreshore.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov . These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Read more:

SmallCapStockPick

Arizona State University/ Halberd Corporation Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody

Oct 19, 2020 by OTC PR

JACKSON CENTER, PA / ACCESSWIRE / October 19, 2020 / Halberd Corporation (OTC PINK:HALB) today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. The discovery is the result of Halberd’s research in conjunction with Arizona State University’s Dr. Qiang “Shawn” Chen, utilizing Halberd’s intellectual property created by Mitchel S. Felder, MD. Halberd and ASU have begun the process of filing the first of multiple planned joint patent applications for this new class of antibody.

This engineered monoclonal antibody against the Covid-19 virus spike protein may allow for an extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, blood and urine. It may also potentially allow for the rapid identification of the Covid-19 virus present on surfaces, such as food, cell phones, door handles, etc., through testing only a small sample. Details concerning this rapid identification methodology will not be publicly disclosed until appropriate patent protections are in place. Halberd scientists believe that this breakthrough may help solve the Covid-19 pandemic by accelerating the identification of the Covid-19 virus, and the scientific analysis of the effectiveness of Covid-19 therapeutics.

Scientists from both Arizona State University and Halberd believe that rapid identification is essential to permit effectively initiating therapeutics in the earliest phases of Covid-19. Early identification and treatment could substantially curtail the spread of COVID-19.

Dr. Patricio Reyes, Chief Technical Officer of Halberd Corporation, stated, “The progress over the past month has been phenomenal and is already yielding patentable intellectual property. We foresee this as just the first of many potential patent applications to address the rapid detection, prevention, and treatment of Covid-19.”

The details of the Halberd-ASU research contract can be viewed here.

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC

About Arizona State University.

Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona. It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.

About Halberd Corporation.

Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus”, and, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

Read more;

Penny Stock Picks:

Halberd Corporation (HALB) Arizona State University/Halberd Develop Antibody Against Covid-19

Oct 14, 2020 by OTC PR

JACKSON CENTER, PA / ACCESSWIRE / October 13, 2020 / Halberd Corporation (HALB) reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike Protein. The performance has exceeded expectations, and Halberd and ASU intend to file for joint patent protection.

Halberd Corporation (HALB)

Development continues toward three major potential utilizations of the antibody against the Coronavirus:

  1. A Preventative;
  2. A Diagnostic, and
  3. A Therapeutic Treatment.

William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, “We are very excited about our progress to date and plan to issue regular progress reports to keep the public aware of our significant developments.”

The details of the Halberd-ASU research contract can be viewed here.

For more information please contact:

William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter: @HalberdC

About Arizona State University.

Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona. It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.

About Halberd Corporation.

Halberd Corporation. (HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus”, and, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

Read more:

Small Cap News:

NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets

Oct 7, 2020 by OTC PR
  • Bintai Kinden Corporation Berhad ( www.bintai.com.my ), an investment holding company headquartered in Malaysia will fund the U.S. Clinical Trials for the Ii-Key-SARS-CoV-2 vaccine against COVID-19
  • NuGenerex Immuno-Oncology has received the upfront licensing fee of $2.625 million
  • Bintai obtains the exclusive license to distribute the Ii-Key-SARS-CoV-2 vaccine in Southeast Asia, including Malaysia, Vietnam, Indonesia, and the Philippines
  • Bintai receives an option with first right of refusal for distribution in Australia and New Zealand
  • Bintai will provide 100% funding for U.S. clinical development, manufacturing and commercial registration of Ii-Key- SARS-CoV-2 prophylactic vaccine against COVID-19 in international markets
  • Price set at $3 per dose for governments and $4.50 on commercial sales
  • Potential $1 billion in GNBT revenues for vaccine sales in Southeast Asia

MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) — NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) is pleased to announce the closing of a Licensing & Distribution Agreement with Bintai Kinden Corporation of Malaysia for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine. Under the terms of the Agreement, Bintai will have an exclusive license to distribute the Ii-Key-SARS-CoV-2 vaccine in Southeast Asia, including Malaysia (pop. 32.4 million), Vietnam (pop. 95.5 million), Indonesia, (pop. 69.4 million) and the Philippines (pop. 106.7 million). Additionally, Bintai has been given an option, with right of first refusal for distribution in Australia (pop. 25.5 million) and New Zealand (pop. 4.8 million) using its extensive connections to secure contracts in the region.

In exchange for the license and distribution exclusivity, Bintai has paid an up-front licensing fee of $2.625 million and has committed to funding 100% of the commercial development costs for the Ii-Key-CoV-2 vaccine including laboratory and pre-clinical work, GMP manufacturing in the U.S., U.S. and global Phase I, Phase II, and Phase III clinical trials, and all clinical and regulatory work required for approval in each of the licensed Australasian countries.

NGIO will earn $3 per dose on sales to governments and $4.50 on commercial sales. Targeting a population of nearly 300 million people, the potential revenues for NGIO exceed $1 billion.

Generex CEO, Joseph Moscato said, “With the closing of this Licensing and Distribution Agreement, we have secured the funding to complete the clinical development and regulatory work we need for approval of the Ii-Key- SARS-CoV-2 vaccine. Under the terms of the final agreement, we will conduct our Ii-Key-SARS-CoV-2 vaccine clinical trials here in the United States, and the U.S. data will support regulatory filings and commercialization in Southeast Asia that includes nearly 300 million people. The agreement allows NGIO to maintain its full, global intellectual property and manufacturing rights, and provides Bintai with exclusive distribution rights in the region thereby leveraging both companies’ strengths for a truly successful partnership that could be worth over $1 billion in licensing and royalty payments to NGIO and Generex, the parent company. Plus, with Bintai’s connections in Australia and New Zealand, we hope to expand our exclusive distribution agreement in these countries, which will bring additional licensing and royalty fees to NGIO and Generex.”

Mr. Moscato continued, “I would like to personally thank the Bintai organization for their belief in Generex and commitment to develop a safe, effective, and universal vaccine against SARS-CoV-2 for the benefit of the world. As we prepare to launch the clinical trial program for our Ii-Key-SARS-CoV-2 with a target date in early 2021, we are happy to announce plans to develop our vaccine for the benefit of the pediatric population – adolescents, children and infants – who have been neglected by other vaccine development efforts. Given the demonstrated safety profile of our other Ii-Key vaccines that has been recognized by the FDA, and upon advice from our KOL advisors, we believe that our Ii-Key peptide vaccine technology can fill the unmet medical need and offer a better approach to developing a COVID-19 vaccine that can be safely and confidently used not only in adults, but also in children. Especially on the safety front, we are confident that our highly specific and targeted Ii-Key-SARS-CoV-2 complete vaccine presents a superior alternative to the RNA and DNA vaccines that are delivered through gene therapy vectors and recombinant vaccine products that utilize the entire spike protein, which may elicit off target immune reactions and adverse antibody responses. We are extremely excited to deliver on the promise of our Ii-Key COVID-19 vaccine.”

Dr. Jonathan Davis, Chief of Newborn Medicine at Tufts Children’s Hospital and a Professor of Pediatrics at Tufts University School of Medicine in Boston who is leading the scientific and clinical advisory board for NuGenerex said, “Once safety is established in adults, it will be important to quickly initiate trials in children and pregnant women. Although children do not become critically ill as frequently as adults, they can still transmit the virus to other children and adults. If we want to fully reopen daycare settings and schools and get parents back to work, immunization of children should be a top priority.”

“Pregnant women who develop COVID-19 can also become quite ill, deliver prematurely, and/or transmit the virus to their newborn,” added Dr. Davis. “Since studies have shown this Ii-Key peptide technology to be safe and effective in adults with cancer, there is optimism that it will also be well tolerated in these vulnerable populations.”

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda ® ) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.

About Bintai Kinden
With over 40 years of specialist engineering and construction experience, Bintai’s unique combination of extensive regional experience and local knowledge has made them the region’s international contractor of choice. Headquartered in Malaysia, Bintai Kinden has expanded operations regionally throughout South-East Asia, China and the Arabian Gulf region.

As multi-disciplined, building and industrial service engineers and specialists, Bintai works in all the major market sectors, from commercial buildings to industrial complexes, designing, installing and commissioning systems that include the full range of engineering services.

Looking beyond today’s frontiers, Bintai Kinden is confident that it has the resources, technical expertise and progressive mindset to consolidate its position globally. The integration of research, management, marketing and sales that transcends organizational borders enables Bintai Kinden to capitalize on synergistic potential and benefits of scale.

References

Perez et al. Cancer Immunol Immunother (2013) 62: 1599-1608
Brown et al Breast Cancer Research and Treatment. 22 April 2020.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Read more:

BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting

Sep 30, 2020 by OTC PR

Presentation outlines design of pivotal Phase 3 trial evaluating NurOwn® as a treatment for ALS

Trial remains on track for topline data in 4Q-2020

NEW YORK , Sept. 30, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, “Advancing NurOwn® for ALS: Phase 3 Clinical Trial Design” at the Annual Northeast ALS (NEALS) Meeting , being held virtually. The poster, which will be presented virtually today by Stacy Lindborg , Ph.D., Executive Vice President and Head of Global Clinical Research at Brainstorm, details the design of the Company’s placebo-controlled, randomized, double-blind, Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for ALS patients.

brainstorm

“This pivotal study has been rigorously designed and powered to detect clinically meaningful effects of NurOwn® in rapidly progressing ALS patients,” said Dr. Lindborg. “Compelling Phase 2 data showed that a single NurOwn® administration slowed disease progression in this patient population, and the current Phase 3 trial aims to confirm this effect in a larger study cohort and show that its duration can be extended through repeated administrations. To test this hypothesis, we are comparing the rate of patient level decline in ALS disease as measured by the ALS Functional Rating Scale between the pre-treatment period to the rate of decline observed after the initiation of treatment. Such an analysis allows us to compare the magnitude of change in disease progression resulting from NurOwn® and placebo treatments while accounting for important variable factors known to influence disease progression. We look forward to sharing the results of this analysis later this year.”

The poster will be discussed by Dr. Lindborg during a live session at NEALS. A copy of the poster will be also be available in the “Investors and Media” section of the BrainStorm website under Events and Presentations .

About the Phase 3 NurOwn® Trial

The Phase 3 NurOwn® trial is a placebo-controlled, randomized, double-blind trial being conducted at six centers of excellence: University of California, Irvine Cedars-Sinai Medical Center California Pacific Medical Center Massachusetts General Hospital University of Massachusetts Medical School and Mayo Clinic . Patient dosing in the trial is complete and topline data is expected in 4Q-2020. The primary endpoint of the trial is a responder analysis of the rate of decline in ALS Functional Rating Scale (ALSFRS-R) score over 28 weeks. Secondary endpoints include safety, the percentage of patients with disease progression halted or improved, ALSFRS-R change from baseline, combined analysis of function and survival, slow vital capacity, tracheostomy-free survival, overall survival and cerebrospinal fluid biomarker measurements. For more information on the trial, visit https://clinicaltrials.gov/ct2/show/NCT03280056 .

About NEALS

The Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium is a multi-function organization that aims to translate scientific advances into new treatments for people with ALS and motor neuron disease (MND) as rapidly as possible. To achieve its goal, NEALS functions as an academic research consortium, a contracted research organization, and a resource tool for the ALS community. NEALS is committed to the principles of open scientific communication, peer review, full and open disclosure of potential conflicts of interest, and democratic governance of its organization and activities. For more information on NEALS, visit https://www.neals.org/ .

About NurOwn®

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a phase 3 pivotal trial in ALS (NCT03280056); this trial is investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for FDA approval of autologous MSC-NTF cells in ALS. BrainStorm is also conducting an FDA-approved phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) is fully enrolled.

For more information, visit the company’s website at www.brainstorm-cell.com .

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov . These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Read more:

Green Stream Holdings Inc. Provides Corporate Update

Sep 30, 2020 by OTC PR

MALIBU, CA / ACCESSWIRE / September 30, 2020 / Green Stream Holdings Inc. (OTC PINK:GSFI) (“Green Stream”), an emerging leader in the renewable energy space, today provided a corporate update to its shareholders and other interested parties.

Green Stream Holdings

Green Stream is a solar utility company engaged in the business of providing renewable energy to transformative markets. Green Stream plans to be a leader in the solar utility business, as well as urban farming in the northeastern US, Southern California, Colorado, and Hawaii. Our primary focus is on states and local cities in the U. S. that have a cost of energy above 8 cents a kilowatt. Targeting areas above 8 cents a kilowatt provides us with a higher Return on Investment (ROI), which allows us to evaluate the efficiency of our investment. We plan to provide profitable renewable power projects, like our urban gardening project using rooftop solar greenhouses. Any surplus power will be back fed into the electrical grid, which generates both utility credits and cash flow.

In the past nine months Green Stream has hit several milestones as we focused on building our corporate infrastructure. We have gone from a dark, defunct company to a fully reporting corporate entity. In 2020 Green Stream filed its first 10-Q and 10-K, and we provided our shareholders with audited financial statements. In addition to filing audited financials, Green Stream management filed a Form 10 with the SEC and started filing our audited financial statements on EDGAR. We also filed a Reg A and look forward to completing it in the near future, along with an S-1 filing.

Our goal is to become a leader in developing resourceful solar energy solutions for our customers, which, in turn, helps them reduce their environmental footprint. Clean energy solutions for businesses are not only improving our environment, they are also profitable. General Electric recently revealed its moving away from new-build coal power and moving toward the renewable energy segment PepsiCo Inc. announced last week it is transitioning its global business operations to source 100% renewable electricity across all of its company-owned and controlled operations by 2030. BP PLC has unveiled the most aggressive overhaul in its 111 year history by calling for a 40% reduction in oil-and-gas production over the coming decade.

According to Allied Market Research, the global renewable energy market was valued at $928.0 billion in 2017, and is expected to reach more than $1.5 trillion by 2025, registering a CAGR of 6.1% from 2018 to 2025.i Renewable energy technologies convert the energy from different natural sources such as sun, tides, wind and others, into its usable forms such as electricity. Allied Market Research also said the global solar energy market was valued at $52.5 billion in 2018 and is projected to reach $223.3 billion by 2026, growing at a CAGR of 20.5% from 2019 to 2026.ii

Green Stream has entered the urban gardening sector with solar greenhouses dedicated primarily to rooftop farming. ResearchAndMarkets.com expects the Global Urban Farming market to grow to $288.71 billion by 2026.iii We are targeting high energy cost urban areas where we utilize empty rooftops, overpasses, and canopies for farming. We provide additional income to the property owners and access to cost effective clean, green energy for the community. Our business plan keeps cars and trucks off of the road and eliminates food desserts.

Madeline Cammarata, CEO and President of Green Stream Holdings Inc. said, “Now that we have completed our corporate infrastructure by becoming a fully reporting company, we are ready to move forward with executing our business plan for the benefit of our shareholders.” Ms. Cammarata continued, “Our entry into the urban gardening sector with solar greenhouses dedicated primarily to rooftop farming is only the beginning. We look forward to capitalizing on many other opportunities to advance our solar utility business.”

About Green Stream Finance, Inc.

Green Stream Finance, Inc., a Wyoming-based corporation with satellite offices in Malibu, CA and New York, NY, is focused on exploiting currently unmet markets in the solar energy space, and is currently licensed in California, Nevada, Arizona, Washington, New York, New Jersey, Massachusetts, New Mexico, Colorado, Hawaii, and Canada. The Company’s next-generation solar greenhouses, constructed and managed by Green Rain Solar, LLC, a Nevada-based division, utilize proprietary greenhouse technology and trademarked design developed by world-renowned architect Mr. Antony Morali. The Company is currently targeting high-growth solar market segments for its advanced solar greenhouse and advanced solar battery products. The Company has a growing footprint in the significantly underserved solar market in New York City where it is targeting 50,000 to 100,000 square feet of rooftop space for the installation of its solar panels. Green Stream is looking to forge key partnership with major investment groups, brokers, and private investors in order to capitalize on a variety of unique investment opportunities in the commercial solar energy markets. The Company is dedicated to becoming a major player in this critical space. Through its innovative solar product offerings and industry partnerships, the Company is well-positioned to become a significant player in the solar space.

Forward-Looking Statements:

This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. That includes the possibility that the business outlined in this press release cannot be concluded for some reason. That could be as a result of technical, installation, permitting or other problems that were not anticipated. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Green Stream Finance, Inc. to be materially different from the statements made herein. Except for any obligation under the U.S. federal securities laws, Green Stream Finance, Inc. undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

For All Inquiries Contact:

TEN ASSOCIATES, LLC
TOM NELSON
480-326-8577

i https://www.alliedmarketresearch.com/press-release/renewable-energy-market.html
ii https://www.alliedmarketresearch.com/solar-energy-market#:~:text=The%20global%20solar%20energy%20market,20.5%25%20from%202019%20to%202026.
iii https://www.businesswire.com/news/home/20190830005210/en/Urban-Farming-Market-Worldwide-Review-Outlook-2017-2026

SOURCE: Green Stream Holdings Inc.

View source version on accesswire.com:
https://www.accesswire.com/608466/Green-Stream-Holdings-Inc-Provides-Corporate-Update

News Provided by ACCESSWIRE via QuoteMedia

Read more:https://otcprgroup.com/who-we-are/

BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory Affairs

Sep 2, 2020 by OTC PR

Company plans to further strengthen its regulatory expertise and capabilities as ALS phase 3 clinical trial nears completion in Q4

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of Anthony P. Waclawski, Ph.D. as Executive Vice President, Global Head of Regulatory Affairs.  Dr. Waclawski is an industry veteran and a recognized leader in regulatory affairs with over 35 years of multinational experience in the FDA regulatory approval process, including Biologics License Applications (BLAs), New Drug Applications (NDAs), and FDA Advisory Committees.

“Tony’s unique regulatory experience within one of the largest global pharmaceuticals, makes him exceptionally well qualified to join the BrainStorm leadership team,” commented Chaim Lebovits, BrainStorm’s Chief Executive Officer.  “He has held leadership roles in many of the key functions of regulatory, including regulatory strategy and operations, establishing a track record of success for many development stage and marketed products.  Dr. Waclawski will enhance our global regulatory strategy, as we work to bring better treatment options to patients afflicted with ALS and other neurodegenerative diseases. We look forward to the strategic contributions and key insights he will bring to BrainStorm.”     

Anthony Waclawski commented, “I’m very excited to join the team at BrainStorm and do all I can to help bring new therapies to patients with ALS and other neurodegenerative diseases.  This is a challenging area for drug development and there is a critical need for effective and safe therapies.“

Prior to his appointment at BrainStorm, Dr. Waclawski spent 35 years of increasing responsibility at Bristol-Myers Squibb, most recently as Vice President and Head, Regulatory and Pharmaceutical Sciences, Cardiovascular, Immunosciences, Fibrosis, and Genetically-defined diseases. In this role, he was responsible for the strategic and operational deliverables of regulatory, biostatistics, clinical pharmacology, and pharmacometrics for the development assets in these areas.  Dr. Waclawski’s experience spans a broad range of regulatory capabilities across multiple therapeutic areas and geographies, guiding successful FDA interactions and establishing and executing successful global regulatory strategies. 

Dr. Waclawski holds a Ph.D. in Pharmaceutical Sciences, a Master of Pharmaceutical Science, and a Bachelor of Science in Pharmacy from Rutgers University. 

About NurOwn®
The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a phase 3 pivotal trial in ALS (NCT03280056); this trial is investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for FDA approval of autologous MSC-NTF cells in ALS. BrainStorm is also conducting an FDA-approved phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019.

For more information, visit the company’s website at www.brainstorm-cell.com.

Safe-Harbor Statement
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

RJD Green Inc. Enters an Acquisition Memorandum of Understanding

Aug 31, 2020 by OTC PR
RJD Green Announces Financial Results

TULSA, OK, Aug. 31, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green Inc. (OTCPK: RJDG) announced today the Company has entered an initial Memorandum of Understanding with a medical billing firm that complements the IOSoft medical payment systems. 

The acquisition target was formed in 2006 and is located in the Southwest United States. Medical billing is the primary revenue, but the company also offers consulting services in telemedicine, IT solutions, and medical marketing. The Company has established long-term relationships within the industry and offers excellent growth potential.

As important, the Company is a synergistic fit with the RJD subsidiary, IOSoft Inc.’s efforts with their Unified Payment Systems software platforms.

Ron Brewer, CEO stated:  “We are pleased to reach the initial stage of establishing acquisition terms with a well-established company that offers immediate growth and excellent profits. As importantly, this company could be the first of multiple acquisitions in this sector that builds an extended client base for the IOSoft software platform.

“Although this agreement gives no assurance of acquisition, our MOU reflects we mutually have agreed to the basic terms of acquisition. RJD Green is continuing an aggressive outreach to possible acquisitions to not only launch our acquisition program, but to procure the best opportunity available to us.”

About IOSoft Inc.

IOSoft provides proprietary software for medical billing, Healthcare claims adjudication, automotive warranty payments, and electronic payments between healthcare Payers and Providers, along with payment software platforms for corporations, government & institutional organizations. Since formation, IOSoft has been a third-party developer of software and provides IT support for the platforms developed. 

The primary focus of IOSoft is in healthcare payment systems where IOSoft can provide unique payment technologies and services or software that can be integrated with legacy or existing systems of healthcare payers and providers, such as major health insurance carriers and third-party administrators.  IOSoft provides targeted product offerings for healthcare providers, provider networks, physicians and hospitals; and clearinghouse companies.

About RJD Green, Inc.

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which owns IOSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers; Earthlinc Environmental Services Division, which provides green environmental services and technologies; and Silex Holdings Division, which is focused in specialty construction and industrial services. The initial operations, Silex Interiors, fills a market niche between the Home Depots and local contractors. Silex manufactures and installs granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and DIY customer. 

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Company Contact: 

RJD Green, Inc. 

Ron Brewer, CEO 

918.551.7883 

ronb@rjdgreen.com

Green Stream Holdings, Inc. Implements Impactful Biosolar Approach with Next-Gen Solar Greenhouses

Aug 11, 2020 by OTC PR

Malibu, California–(Newsfile Corp. – August 11, 2020) – Green Stream Holdings Inc. (OTC PINK: GSFI) (http://www.GreenRainSolar.com ), an emerging leader in the solar utility and finance space, is pleased to announce that it is entering the rapidly growing urban gardening sector with solar greenhouses dedicated primarily to rooftop farming.

Green Stream Holdings


To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61467_d974c5390420c912_001full.jpg

Green Stream Holdings


To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61467_d974c5390420c912_003full.jpg

Roofs with vegetation are widely believed to extend roof life, conserve energy, and reduce stormwater runoff and air pollution; new studies show they can also boost the performance of solar panels. Plants reduce a roof’s contribution to the urban heat-island effect by lowering the surrounding air temperature through evaporation; this cooling can also make photovoltaic panels perform more efficiently. Plants also reduce airborne pollutants and dust particles, allowing the panels to absorb more sunlight.

GSFI CEO Madeline Cammarata comments, “In the last few years, rooftop gardening has been growing exponentially. The opportunity and necessity to grow crops on rooftopsand inside tall building allows for an efficient use of the limited space found in cities and we have the infrastructure in place to begin cultivating these structures alongside and even within a select group of our current projects.”

She continues, “We are confident that a new generation of organic super-sized food products grown locally under strict fully climatized conditions, will provide the next generation of urban cuisine, not to mention a supply source for community minded stores like Whole Foods, Target and local markets.”

Green Stream Holdings


To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61467_d974c5390420c912_004full.jpg

“Now we have the ability to significantly impact the communities we serve with the opportunity for multiple streams of income from each project, from providing electricity for the public utilities, to growing fresh fruits and vegetables for the local restaurants. Growing season is 24 -7/365 in our climate controlled roof top greenhouses powered by solar arrays, and with dual-benefit: storing power during the day for use at night, and utilizing excess power to sell back to communities as an energy source.”

Green Stream has a growing footprint in the significantly underserved solar market in New York City where it is targeting 50,000 to 100,000 square feet of rooftop space for the installation of its solar panels.

Green Stream Holdings


Cannot view this video? Visit:
https://www.youtube.com/watch?v=wdhL_YhoAV8

Cammarata adds, “We are dedicated to becoming a major player in this critical space. Through our innovative solar product offerings and industry partnerships, Green Stream is well-positioned to become a significant player in the solar space.”

Shareholders-visit greenrainsolar.com. where you can view Green Stream’s news, filings and a live Level 2 quote, along with other company information.



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61467_d974c5390420c912_005full.jpg

About Green Stream Finance, Inc.:

Green Stream Finance, Inc., a Wyoming-based corporation with satellite offices in Malibu, CA and New York, NY, is focused on exploiting currently unmet markets in the solar energy space, and is currently licensed in California, Nevada, Arizona, Washington, New York, New Jersey, Massachusetts, New Mexico, Colorado, Hawaii, and Canada. The Company’s next-generation solar greenhouses, constructed and managed by Green Rain Solar, LLC, a Nevada-based division, utilize proprietary greenhouse technology and trademarked design developed by world-renowned architect Mr. Antony Morali. The Company is currently targeting high-growth solar market segments for its advanced solar greenhouse and advanced solar battery products. The Company has a growing footprint in the significantly underserved solar market in New York City where it is targeting 50,000 to 100,000 square feet of rooftop space for the installation of its solar panels. Green Stream is looking to forge key partnership with major investment groups, brokers, and private investors in order to capitalize on a variety of unique investment opportunities in the commercial solar energy markets. The Company is dedicated to becoming a major player in this critical space. Through its innovative solar product offerings and industry partnerships, the Company is well-positioned to become a significant player in the solar space.

Forward-Looking Statements:

This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. That includes the possibility that the business outlined in this press release cannot be concluded for some reason. That could be as a result of technical, installation, permitting or other problems that were not anticipated. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Green Stream Finance, Inc. to be materially different from the statements made herein. Except for any obligation under the U.S. federal securities laws, Green Stream Finance, Inc. undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

For All Inquiries Contact:

TEN ASSOCIATES, LLC/ TOM NELSON AT: 480-326-8577

Green Stream Holdings

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61467

copyright (c) newsfile corp. 2020News Provided by Newsfile via QuoteMedia

Green Stream Holdings, Inc. Profiles CEO Madeline Cammarata: Evolving Solar from Function to Fashion

Aug 6, 2020 by OTC PR

Malibu, California–(Newsfile Corp. – August 6, 2020) – Green Stream Holdings Inc. (OTC PINK: GSFI) (http://www.GreenRainSolar.com ), an emerging leader in the solar utility and finance space, announces today a mission statement from fashion maven turned solar visionary, Madeline Cammarata, Green Stream’s founder and CEO.

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61211_2f3276c424bca86f_002full.jpg

Madeline Cammarata (fka Madeline Harmon) hails from an illustrious background in fashion. Her career began as a fashion model where she was soon discovered by the iconic and provocative fashion photographer Helmet Newton, launching Cammarata to the runways of Europe. Returning the US, Madeline found a powerful niche in the high fashion world of denim, where she was instrumental in providing fabric development for powerful brands like 7 For All Mankind and provided thousands of pieces to celebrity and business elites from Steve Jobs to Morrisey and everywhere in between.

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61211_2f3276c424bca86f_004full.jpg

Madeline Cammarata comments, “My work in high-end vintage fashion continues to be a highlight for me. Working with some of the most powerful people in entertainment and fashion had its perks, but it also left me wanting more. By that, I mean, I wanted to impact people on a larger scale and the last place I thought that would land me is renewable energy; however, I have been greatly inspired by architect Anthony Morali, our design partner, the man responsible for innovations like the first “solar balcony” – early in his career he built what was nicknamed the ‘glass condominium’, featuring broad balconies with photovoltaic glass railings to convert solar energy into electricity. This is where function meets fashion in a highly impactful way. I have always been deeply passionate about how I can make the world a better place and, as an entrepreneur, the opportunity in solar is enormous, and growing exponentially as technology continues to advance. This advancement is key to what we are achieving here with Mr. Morali,” states Cammarata.

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61211_2f3276c424bca86f_005full.jpg

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61211_2f3276c424bca86f_006full.jpg

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61211_2f3276c424bca86f_007full.jpg

“I’ve always been a fan of aesthetics and my career and contacts with some of the most influential people in the world has paved the way for a perfect storm in our agenda here at Green Stream, where function of solar becomes fashionable. In addition to the lucrative utility contracts we are cultivating, the design work is attracting larger conversations with solar production entities realizing that it doesn’t have to be the typical obtrusive, clunky hardware attached to otherwise beautiful buildings-it can be a seamless extension or feature of the beautiful buildings.”

She adds, “Mr. Morali and I, and our whole team at Green Stream are looking to change the way solar is presented to the world. Using my contact base and Morali’s innovative design talents, we have already cultivated a short-list of influencers conducive to this space that we intend on working with. Now that we are positioned in the market with transition to a new transfer agent, ridding the public company of the toxic baggage created by previous management, and squashing nuisance threats from known bad actors in the markets, we are ready to brighten the world in a big way. Positioned with a clean share structure, no toxic debt, a top-tier executive staff and talented market support, Green Stream will lay out our strategic direction in accomplishing this.”

“In the meantime, visit our updated website greenrainsolar.com. where you can view our news, filings and even a live Level 2 stream, along with other company information.”



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/61211_2f3276c424bca86f_008full.jpg

About Green Stream Finance, Inc.:

Green Stream Finance, Inc., a Wyoming-based corporation with satellite offices in Malibu, CA and New York, NY, is focused on exploiting currently unmet markets in the solar energy space, and is currently licensed in California, Nevada, Arizona, Washington, New York, New Jersey, Massachusetts, New Mexico, Colorado, Hawaii, and Canada. The Company’s next-generation solar greenhouses, constructed and managed by Green Rain Solar, LLC, a Nevada-based division, utilize proprietary greenhouse technology and trademarked design developed by world-renowned architect Mr. Antony Morali. The Company is currently targeting high-growth solar market segments for its advanced solar greenhouse and advanced solar battery products. The Company has a growing footprint in the significantly underserved solar market in New York City where it is targeting 50,000 to 100,000 square feet of rooftop space for the installation of its solar panels. Green Stream is looking to forge key partnership with major investment groups, brokers, and private investors in order to capitalize on a variety of unique investment opportunities in the commercial solar energy markets. The Company is dedicated to becoming a major player in this critical space. Through its innovative solar product offerings and industry partnerships, the Company is well-positioned to become a significant player in the solar space.

Forward-Looking Statements:

This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. That includes the possibility that the business outlined in this press release cannot be concluded for some reason. That could be as a result of technical, installation, permitting or other problems that were not anticipated. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Green Stream Finance, Inc. to be materially different from the statements made herein. Except for any obligation under the U.S. federal securities laws, Green Stream Finance, Inc. undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

For All Inquiries Contact:

TEN ASSOCIATES, LLC/ TOM NELSON AT: 480-326-8577

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61211

RJD Green Inc. Updates Acquisition Re-engagement Efforts

Aug 4, 2020 by OTC PR

TULSA, OK, Aug. 04, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green (OTCPK: RJDG),  RJD Green Inc. discusses current company acquisition initiatives and the challenges in creating a win-win acquisition valuation during a period of economic uncertainty.

 Current Acquisition Focus

RJD Green has re-engaged in acquisition search for synergistic opportunities for our company with a primary focus on services to the healthcare sector which complement our current IOSoft payment software platform efforts.

Acquiring a complimentary operation for the Silex Holdings” manufacturing and installation of construction products company will be the secondary focus.

The third tier of acquisition focus is the Earthlinc Environmental Services division, as the industry has more uncertainty in whole than RJDG’s other two divisions.

Merger & Acquisition Efforts

The Company has found relatively strong seller interest in our market focuses. 

In the healthcare focus, RJDG has been able to engage discussions with three entities and is advancing the process with two of the corporations.

The Company has also engaged in initial discussion with three construction products firms and is advancing the acquisition process with two of the entities.

RJDG has come upon an environmental consulting firm, and a national branded remediation services group that have genuine interest in being acquired. These opportunities are being pursued.

RJDG is confident of procuring qualified companies where our management team and other resources bring added value and growth. RJDG feels the major issue of acquisition will be creating a win-win acquisition valuation and structure that meets both buyer and seller needs while facing an uncertain economy. RJDG will maintain its acquisition value of minimizing the EBITDA leveraging ratios to within existing revenues of the acquisition candidate.

RJD Green is making the relaunch of the acquisition program a primary initiative for the remainder of 2020 calendar year.

About RJD Green, Inc. 

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers:Earthlinc Environmental Services Division, which provides green environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. 

Visit http://www.rjdgreen.com

For additional information contact, Ron Brewer, CEO at ronb@rjdgreen.com, or at (918) 551-7883, or Douglass Baker, OTC PR Group at corp@otcprgroup.com or at (561) 807-6350

 Forward-looking Statement:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Company Contact: 

RJD Green, Inc. 

Ron Brewer, CEO 

(918) 551-7883 

ronb@rjdgreen.com

Green Stream Holdings, Inc. Announces New Website Toward Enhanced Shareholder Accessibility

Jul 28, 2020 by OTC PR

Malibu, California–(Newsfile Corp. – July 28, 2020) – Green Stream Holdings Inc. (OTC PINK: GSFI), a holding company of Green Stream Finance, Inc., an emerging leader in the solar utility and finance space, today announces that it has launched its new website at http://www.GreenRainSolar.com with a professional design and content geared toward shareholder accessibility and transparency and featuring a dynamic showcase of the Company’s projects and services.

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/60633_d134b91c04ff0b76_001full.jpg

Green Stream contracted with OTC PR Group (www.otcprgroup.com) for the site. OTC PR Group provides a full suite of Public Relations Small Cap Companies services utilizing the latest technologies coupled with relationship building processes to develop and maintain interest from your shareholder base.

“We have made branding and clarity of model our top priority alongside enhancement of our existing revenue streams. We are also thrilled to be cultivating potential new profit centers as we continue to cultivate additional solar utility projects throughout the U.S.,” states CEO Madeline Cammarata. Updates are forthcoming.

About Green Stream Finance, Inc.:

Green Stream Finance, Inc., a Wyoming-based corporation with satellite offices in Malibu, CA and New York, NY, is focused on exploiting currently unmet markets in the solar energy space, and is currently licensed in California, Nevada, Arizona, Washington, New York, New Jersey, Massachusetts, New Mexico, Colorado, Hawaii, and Canada. The Company’s next-generation solar greenhouses, constructed and managed by Green Rain Solar, LLC, a Nevada-based division, utilize proprietary greenhouse technology and trademarked design developed by world-renowned architect Mr. Antony Morali. The Company is currently targeting high-growth solar market segments for its advanced solar greenhouse and advanced solar battery products. The Company has a growing footprint in the significantly underserved solar market in New York City where it is targeting 50,000 to 100,000 square feet of rooftop space for the installation of its solar panels. Green Stream is looking to forge key partnership with major investment groups, brokers, and private investors in order to capitalize on a variety of unique investment opportunities in the commercial solar energy markets. The Company is dedicated to becoming a major player in this critical space. Through its innovative solar product offerings and industry partnerships, the Company is well-positioned to become a significant player in the solar space.

Forward-Looking Statements:

This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. That includes the possibility that the business outlined in this press release cannot be concluded for some reason. That could be as a result of technical, installation, permitting or other problems that were not anticipated. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Green Stream Finance, Inc. to be materially different from the statements made herein. Except for any obligation under the U.S. federal securities laws, Green Stream Finance, Inc. undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

Company Address

Company Contact/Address
1620 Marquez Avenue Pacific Palisades, CA 90272
Phone: 310-230-0240

For All Inquiries Contact:
info@greenstreamfinance.com

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60633

copyright (c) newsfile corp. 2020News Provided by Newsfile via QuoteMedia

Green Stream Holdings, Inc. Lights Up New York with Multiple MOU’s To Expand Its Reach In Northeastern US

Jul 24, 2020 by OTC PR

Company MOUs exponentially increases revenue streams with Solar Utility Agreements

Malibu, California–(Newsfile Corp. – July 23, 2020) – Green Stream Holdings Inc. (OTC PINK: GSFI), a holding company of Green Stream Finance, Inc., a solar utility and finance company, today announced that it has recently entered into MOU’s in New York.

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/60372_36d4cf73747a9b30_001full.jpg

In line with GSFI’s business model, Morali Architects will design alongside construct and install or retrofitting of various solar structures (rooftops, canopies, parking structures and more) at the designated locations leased by GSFI. The structures produce energy from the sun and GSFI owns the contracts with ability to sell the energy generated to the surrounding communities.

“We are on our way to becoming an industry leader in the renewable energy utility space,” states CEO Madeline Cammarata. “The opportunity in New York is unique in that NY communities offer cash upfront, in addition to above average rates, nationally. We anticipate the projects targeted in New York and surrounding states will generate an average of $265k per year, per project over the 25 year contracts we are able to secure.” 

One of the Company’s new deals, the “Imlay 160 Project” is with Red Hook 160 LLC, a privately‐owned residential developer and owner of residential apartment buildings in New York City, owns 160 Imlay Street, Brooklyn, New York 11231.

Green Stream Holdings

  

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/60372_36d4cf73747a9b30_002full.jpg

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/60372_36d4cf73747a9b30_003full.jpg

The project shall include implementation of a rooftop photovoltaic system providing at a minimum of 300- 450 Kw of electric Photo Voltic Power, utilizing approximately 1000-1440 panels, on approximately 22,000 square foot space on the property.

Green Stream Holdings



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/60372_36d4cf73747a9b30_004full.jpg

Earlier this year the Company had previously disclosed that it had entered into an agreement to construct solar car ports in three separate high traffic locations, owned by a well-known successful regional gas station owner/provider.

“We are thrilled to announce that albeit the prior agreement called for three locations in the North East initially, we expect to expand to all locations post completion,” states Cammarata.

The project calls for Green Stream Holdings to lease the land from the owner for a fixed fee over a twenty-year period. Green Stream Holdings together with Morali Architects as their joint venture partner in this project, will design, erect, construct and install or retrofit the structures at the three locations as well as the locations to be announced. Another result of utilizing Morali’s technology will be that this project will also contribute to the reduction of the location’s carbon footprint.

About Green Stream Finance, Inc.:

Green Stream Finance, Inc., a Wyoming-based corporation with satellite offices in Malibu, CA and New York, NY, is focused on exploiting currently unmet markets in the solar energy space, and is currently licensed in California, Nevada, Arizona, Washington, New York, New Jersey, Massachusetts, New Mexico, Colorado, Hawaii, and Canada. The Company’s next-generation solar greenhouses, constructed and managed by Green Rain Solar, LLC, a Nevada-based division, utilize proprietary greenhouse technology and trademarked design developed by world-renowned architect Mr. Antony Morali. The Company is currently targeting high-growth solar market segments for its advanced solar greenhouse and advanced solar battery products. The Company has a growing footprint in the significantly underserved solar market in New York City where it is targeting 50,000 to 100,000 square feet of rooftop space for the installation of its solar panels. Green Stream is looking to forge key partnership with major investment groups, brokers, and private investors in order to capitalize on a variety of unique investment opportunities in the commercial solar energy markets. The Company is dedicated to becoming a major player in this critical space. Through its innovative solar product offerings and industry partnerships, the Company is well-positioned to become a significant player in the solar space.

Forward-Looking Statements:

This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. That includes the possibility that the business outlined in this press release cannot be concluded for some reason. That could be as a result of technical, installation, permitting or other problems that were not anticipated. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Green Stream Finance, Inc. to be materially different from the statements made herein. Except for any obligation under the U.S. federal securities laws, Green Stream Finance, Inc. undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

Company Address

Company Contact/Address
1620 Marquez Avenue Pacific Palisades, CA 90272

Phone: 310-230-0240

For All Inquiries Contact:
info@greenstreamfinance.com

RJD Green Announces Financial Results for the Three Months Quarter 3 Ended May 31, 2020

Jul 20, 2020 by OTC PR

RJD Green Announces Financial Results

RJD Green Announces Financial Results

Tulsa, OK, July 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green, Inc. (RJDG) announced results for the three months ended May 31, 2020, and updates shareholders.

Dear Valued RJD Green Shareholders,

As we have announced our financial results for the three months ended May 31, 2020, RJD Green’s management team would like to take the opportunity to update all existing and potential shareholders with the latest information on developments with the company. Please be advised – this letter is not a substitute for reviewing our press releases and SEC filings. Some of this update is opinion – so be sure to note the forward-looking statements disclosure. We wanted to simplify the complexity and put our latest news items in context and keep you updated on our activities and events that may not rise to the level of a press release or SEC filing.

We continue to work diligently to execute our business model to create a substantive holding company with a focus of acquiring and managing assets and companies.  In the current economic climate, we remain very diligent in conserving our liquid assets. The Company currently has reengaged in acquisition discussions searching for companies that symmetrically meet our program, and that are flexible in creating a win-win acquisition structure during these volatile economic times. RJD Green operates in three divisions.

RJD Green Announces Financial Results

Financial Results for the Three Months Ended May 31, 2020

§  The Company has nine months revenue of $3,227,224 and cash of $352,749 held in a bank and cash equivalents of $48,298 as of May 31, 2020.

  •  The Company has monthly recurring revenues $358,580 with $401,104 of working capital and shareholder equity of $1,128,320 as of May 31, 2020.
  •  All items of financial performance are higher than May 31, 2019 despite working in a pandemic economic environment.

Recent Corporate Highlights:

Silex Holdings Inc.

 RJD Green subsidiary, Silex Holdings Inc., has continued to establish its long-term revenue growth through three additional focuses:

  •  Commercial and multi-family projects awarded within a four-state region are maintaining a $1,000,000 backlog to date.
  •  High-end custom home market in both of their metropolitan regions continue to increase offering a more significant revenue and gross profits from the home builder sector
  •  Continuing creating an additional revenue stream in both residential and multi-family cabinet sales that will grow annually within a four-state regional market
  •  Current 4th quarter backlog, if completed will give the Company is largest annual revenue.

Healthcare Industry Services

IOSoft Inc. continues creating inroads into the third-party administrator payment companies and establishing a larger sales representation network. IOSosft continues to draw closer to offering an additional rapid payment process for corporate usage. The Company feels there are synergistic acquisitions available in this sector.

Earthlinc Environmental Division

RJD Green has accrued three very relevant patented technologies. Earthlinc continues to acquire short-term consulting contracts allowing RJD to remain active in acquisition search. The Company is focused on acquiring an established environmental consulting group to manage corporate waste programs and oversee the development of our patented technologies.

Acquisitions

RJD Green has again engaged in acquisition search for an appropriate acquisition for each of our three divisions. We maintain strict acquisition guidelines that offer best opportunity for positive results in revenue, profits, and creating synergy within each of the division.

We will continue to update our investors with any and all progress in the coming months as newsworthy occurrences happen.

Sincerely,

Ron Brewer
CEO, RJD Green, Inc.

About RJD Green, Inc. 

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IOSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. Visit http://www.rjdgreen.com

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Company Contact: 

RJD Green, Inc. 

Ron Brewer, CEO 

(918) 551-7883 

ronb@rjdgreen.com

Investor Relations:

OTC PR Group

Douglas Baker

(561) 807-6350

corp@otcprgroup.com

RJD Green Announces Financial Results Read More:

What did we learn from SEO and COVID-19?

Jul 15, 2020 by OTC PR

A behavioral analysis of search shifts using real GSC data for SEO and COVID-19

SEO and COVID-19

We analyzed how searcher behavior shifts during the COVID-19 crisis has impacted different industries. Using our extensive pool of Google Search Console data, we analyzed the clicks, impressions, CTR, and position of keywords from 4800 domains to get valuable insights into which industries have profited, and which have lost out. 

The COVID-19, a global pandemic, is unlike anything that most of us have experienced. Lives are threatened, but the very way we work and exist has changed rapidly, and average daily life has reached a whole new level of strangeness.

As many of us adjust to working and functioning fully from home, most of our wants and needs can only be satisfied via digital channels and virtual spaces. We are all seeking outlets of entertainment, social interaction, fitness, grocery shopping, and education quickly and reliably without having to leave our homes.

The home office is not my natural environment, nor is it my preferred one, but obviously, those preferences don’t matter anymore when others’ health hangs in the balance. 

SEO and COVID-19

Working in the digital marketing or SEO industry should be a massive advantage as we witness the world to move offline to online exclusively. However, knowing to uplift online traffic means little if that business can’t operate anymore. 

This ongoing uncertainty and turbulence are evident with the enormous changes in searcher behavior and consumer demands we witness right now. We must understand and adhere to these shifts as we move forward and rapidly adopt digital strategies for our businesses to survive.

Due to the increased online-activity and dependency on reliable search results, SEO and website optimization are now an important marketing channel. Still, it can also ultimately become a defining factor in whether a business survives. Proper SEO helps assure our information is factual, well-represented, and that websites are technically capable of search engines and users. In doing so, we can ensure that we are prominently ranked for search queries.

Takeaways and advice for positively impacted industries

COVID-19 and SEO Steps:

Use increase impression data as an interpretive sign for which products to restock online as a priority.

Keep a close eye on the new keywords rising in impressions and clicks, as these are clear indicators of trending topics that your domain may already be ranking. Even if it’s a low position yet relevant placement, you can pipeline these to editorial teams and work to rank highly for those keywords as fast as possible.

Invest time analyzing your search snippets and seeing how you can best stand out to drive more clicks. There aren’t many industries that have been positively impacted, so the competition is fierce, and standing out more in the SERPs is a must. To improve your search snippets, you can test providing better copy, apply Structured Data for rich snippets, and structured content for Featured Snippets to secure traffic for your rankings.

Create fantastic online services and resources that keep people active, productive, and happy!

Final thoughts

SEO and COVID-19 analysis of organic search impressions provides an in-depth and reliable understanding of what is taking place in search during the current crisis. People rely on search to discover information and facts about the crisis, but more importantly, search helps people fulfill the needs they can no longer meet offline and in person.

Whether your business stands to be positively impacted by the crisis or scaled-down due to lack of ability to operate, we digital marketers and SEO practitioners have to ensure our website and content make a positive contribution to the current situation. By building enriched online experiences, resolving worries and uncertainties with informational content, targeting and solving upcoming topics, creating happy distractions, and adapting our services and products for the stay-at-home period, we can help make dealing with this crisis a little easier.

At OTC PR Group, we provide a full suite of investor relations services utilizing the latest web and SEO solutions coupled with relationship building processes to develop and maintain interest from your shareholder base. We work to build shareholder value by engaging with key-stakeholders and effectively following up and communicating your message, investment potential, and corporate vision.

Investor relations is all about grabbing attention and creating an audience.  OTC PR Group networks with only the “Top Rated” service providers and advertising partners, including our In house and external newsletter publishers, social media specialist, editors, analysts, research writers, and video talk show producers, are utilized in our corporate outreach visibility programs.

Working closely with our clients and professional network partners in conjunction with our newsletter publishing sites, we can create and implement marketing and advertising programs that deliver high impact exposure campaigns.

ProtoKinetix AAGP® Dry Eye Program Advancing

Jul 9, 2020 by OTC PR

MARIETTA, Ohio

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.

Protokinetix

Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will test AAGP® for treatments related to Dry Eye Disease. Proof of concept work and basic formulation have been completed.

Current project updates are expected from the following:

  • EyeCRO has been contracted to conduct confirmatory testing and dose ranging. Early progress reports from EyeCRO will be received over the next two weeks.
  • Charles River have been contracted to conduct pilot toxicology studies, to start at the end of July 2020. Early stage indications are expected by mid-August 2020.
  • Stability tests have been completed by Ambiopharm. The tests were conducted at room temperature, in a provisional formulation, under non-sterile conditions. These preliminary results are extremely encouraging.

“We are pleased with the progress made with respect to the expansion of ProtoKinetix’s Dry Eye Disease program.” – said Clarence E. Smith, President and Chief Executive Officer of ProtoKinetix.

Dry Eye Disease Market Overview

According to market research published by Mordor Intelligence LLP, studies of the Dry Eye Disease market indicated a value of approximately USD 4.5 billion in 2018, and the market is expected to reach up to USD 6.2 billion by 2024, with an anticipated CAGR of 5.23%, during the forecast period (2019-2024). The growth of dry eye related diseases may include several factors, such as aging, a decrease in the supportive hormones, systemic inflammatory diseases, ocular surfaces diseases or surgeries affecting the cholinergic nerves, which stimulate tear secretion.

Please visit our new website at ProtoKinetix.com for more information and to join our email list.

About ProtoKinetix, Incorporated

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells, tissues and organs used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, and retinal degeneration for example.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Among these risks are those set forth in a Form 10-K filed on February 19, 2020. It is important that each person reviewing this release understand the significant risks attendant to the operations of ProtoKinetix. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act.

Read more:

BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS

Jul 2, 2020 by OTC PR

NEW YORK, July 2, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that final participant dosing has been administered in the Phase 3 pivotal trial of NurOwn® (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS).  The trial enrolled approximately 200 participants, randomized 1:1 to receive three doses of MSC-NTF cells or placebo, administered over four months.  As previously reported, the Company expects top-line data from the trial to be available in the fourth quarter of 2020, consistent with the timeline established upon trial enrollment.

BrainStorm Phase 3 Clinical Trial in ALS

“Completion of participant dosing in this clinical trial is an important milestone and brings us a step closer to potentially filing a Biologics License Application to make MSC-NTF cells available to people with ALS,” Chaim Lebovits, CEO of BrainStorm stated. “I would like to thank the investigators and their staff at the participating sites for their clinical excellence, especially for enabling this trial to complete on time in the middle of the ongoing COVID-19 pandemic. I must also express my complete gratitude to the trial participants and their loved ones who fully devoted themselves to the challenges of bringing an investigational therapeutic forward. We look forward to the data readout later in 2020.”

The Phase 3 NurOwn trial is being conducted at six centers of excellence: University of California, IrvineCedars-Sinai Medical CenterCalifornia Pacific Medical CenterMassachusetts General HospitalUniversity of Massachusetts Medical School and Mayo Clinic.

About NurOwn®       

The NurOwn technology platform (autologous Mesenchymal stem cells, MSC-NTF cells) represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. With this press release, BrainStorm has now fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and initiated enrollment in March 2019.

About BrainStorm Cell Therapeutics Inc.   

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company’s website at www.brainstorm-cell.com

Safe-Harbor Statement       

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

BrainStorm Phase 3 Clinical Trial in ALS read more:

BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer’s Disease

Jun 26, 2020 by OTC PR

Protocol for the proposed multi-national trial has been submitted for EU regulatory approval Company will host a Key Opinion Leader call and webcast to discuss the newly announced Alzheimer’s Disease program on July 8, 2020 at 8:15 AM ET

NEW YORK, June 24, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new clinical program focused on the development of NurOwn® as a treatment for Alzheimer’s disease. As part of the newly announced program, the Company is planning a multi-national Phase 2 clinical trial to evaluate the safety and efficacy of NurOwn treatment in patients with prodromal to mild Alzheimer’s disease.

BrainStorm Expands Clinical Pipeline

“Our newly announced Alzheimer’s program is an important strategic expansion of BrainStorm’s clinical pipeline,” said Chaim Lebovits, Chief Executive Officer of BrainStorm. “We see this as an ideal complement to our lead amyotrophic lateral sclerosis (ALS) program, as there are compelling data suggesting that the benefits observed with NurOwn in ALS patients may extend to other neurological conditions, including Alzheimer’s disease. As we move towards completion of our pivotal Phase 3 ALS study, the newly announced Alzheimer’s program, combined with our ongoing progressive multiple sclerosis (MS) program, will continue to drive the advancement of the NurOwn platform. Through the completion of our clinical trial programs, BrainStorm hopes to advance NurOwn to address unmet needs across a broad population of patients with neurodegenerative disease.”

The lead investigators of the trial are two world renowned clinical experts in Alzheimer’s disease, Philip Scheltens, M.D., Ph.D., and Bruno Dubois, M.D., Ph.D. Prof. Scheltens, the principal investigator (PI) of the study, is Professor of Cognitive Neurology and Director of the Alzheimer Centre at Amsterdam University Medical Centers. He has extensive experience as PI of many international clinical trials in this field. Prof. Dubois, the French national coordinator of the study, is Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer’s Disease) as well as a member of the European Alzheimer Disease Consortium (EADC). Profs. Scheltens and Dubois will discuss the proposed clinical trial during an upcoming Key Opinion Leader (KOL) webinar and call hosted by BrainStorm on July 8, 2020 at 8:15 AM ET.

Speaking on the trial Prof. Scheltens stated, “We are very eager to evaluate the efficacy of NurOwn in the treatment of Alzheimer’s disease, because of its unique mechanism of action. While many previous Alzheimer’s therapies have focused on a single target such as tau or beta-amyloid, NurOwn has the capability to simultaneously target multiple relevant biological pathways and bring a comprehensive approach to this multifactorial disease. Importantly, NurOwn’s mechanism of action may also allow the therapy to enable synergistic combinations with anti-tau or anti-beta-amyloid treatments, further underscoring its potential to address critical unmet needs in Alzheimer’s disease.”

Prof. Dubois added, “In such a complex disease, addressing inflammation and neuro-protection is an innovative and very interesting approach. It is a first in the world for this technology and Brainstorm is leveraging encouraging results from the Phase 2 study in ALS.”

Ralph Kern, M.D., MHSc., President and Chief Medical Officer of BrainStorm, noted, “In the proposed Phase 2 clinical trial, our goal is to confirm that the potential shown by NurOwn in our lead ALS program may be extended to patients with Alzheimer’s disease. We now have a compelling set of biomarker data supporting NurOwn’s mechanism of action, including important pharmacodynamic changes in cerebrospinal fluid (CSF) inflammatory mediators. Additionally, our innovative biomarker-driven precision medicine approach, which will focus on patients with early-stage disease and pre-defined levels of CSF tau and beta-amyloid proteins, may greatly facilitate Phase 2 clinical trial success.”

Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research at BrainStorm, said, “We are excited to introduce a novel approach to Alzheimer’s disease that targets both inflammation as well as neurotrophic factors. Given the acute need for vastly different treatment methodologies, we believe our broad targeting approach, combined with robust effects on CSF measures and a favorable safety profile, allows us to go forward with confidence. Additionally, compiling NurOwn safety data across diseases will allow us to enhance patient safety for each trial.” 

Phase 2 Trial to be Conducted at Leading Alzheimer’s disease Centers in Europe

BrainStorm plans to conduct a 52-week, Phase 2 open-label, proof-of-concept clinical trial to evaluate NurOwn in 40 participants with prodromal to mild Alzheimer’s disease. Study participants will receive three intrathecal NurOwn doses 8 weeks apart. In addition to meeting well-defined clinical criteria for prodromal to mild Alzheimer’s disease, participants must also meet biomarker defined criteria for Alzheimer’s disease. The clinical trial will evaluate safety and pharmacodynamics of NurOwn, including effects on inflammatory, Alzheimer’s-specific, neurodegenerative, and synaptic biomarkers, as well as a range of key clinical measures of cognition and function. The clinical trial will be conducted at the Brain research Center affiliated with the Alzheimer Center Amsterdam, Pitié-Salpêtrière Hospital (Paris), and several other clinical trial sites in the Netherlands and France.

NurOwn is protected by patents granted in the United States, Europe, Israel, and elsewhere covering treatments of neurodegenerative diseases, including Alzheimer’s disease.  These include European patent no. EP2620493B1 (Mesenchymal stem cells for the treatment of CNS diseases).

Key Opinion Leader Call and Webcast

BrainStorm will host a call and webinar featuring Philip Scheltens, M.D., Ph.D., and Bruno Dubois, M.D., Ph.D., on July 8, 2020 at 8:15 AM ET. The webinar will be followed by a question-and-answer session with Professors Scheltens and Dubois.

Dial-in and Webcast Information

Register for Call/Webinar Here

About NurOwn®

NurOwn (autologous MSC-NTF cells) represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and initiated enrollment in March 2019.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company’s website at www.brainstorm-cell.com

Safe-Harbor Statement 

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

BrainStorm Expands Clinical Pipeline alzheimer’s disease read more

Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients

Jun 19, 2020 by OTC PR
Aethlon Medical

Allows for enrollment of up to 40 subjects in up to 20 centers

SAN DIEGO, June 18, 2020 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Company’s existing Investigational Device Exemption (IDE) for the Company’s Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.

The feasibility study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S.  Subjects will have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit (ICU) and will have acute lung injury and/or severe or life threatening disease among other criteria.

The Hemopurifier has previously been tested in patients with hepatitis C virus (HCV) infection and in one patient with Ebola virus infection.  A laboratory version of the Hemopurifier has also been shown to clear multiple other viruses in vitro including a model version of the Middle Eastern Respiratory Syndrome (MERS) virus which is a coronavirus from the same family as the SARS-CoV-2 virus that causes COVID-19.

Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon, stated, “We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19.  We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease.”

The Hemopurifier is an FDA designated “Breakthrough Device” for the treatment of life-threatening viruses that are not addressed with approved therapies. The Hemopurifier also holds a Breakthrough Device designation for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.

About Aethlon Medical, Inc.
Aethlon Medical, Inc. is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections.

Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” “potentially,” “appear” or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, Aethlon Medical, Inc.’s (the Company) ability to enroll patients and to successfully complete the Early Feasibility Studies in viral diseases and cancer and achieve the endpoints for the study or any future studies with its Hemopurifier or to successfully develop and commercialize the Hemopurifier. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company’s other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Read more

Ecoark Holdings, Inc. Completes Acquisition of Energy Assets

Jun 16, 2020 by OTC PR
Ecoark

Acquired assets expected to deliver attractive payback and achieve a production rate of 1,000 barrels of oil per day by the end of the third quarter of 2020

Reiterating commitment to value creation and growing via multi-industry holding company strategy

Exploring a potential near-term uplist to a national exchange

FRISCO, Texas, June 11, 2020 (GLOBE NEWSWIRE) — Ecoark Holdings, Inc. (“Ecoark”) (OTC: ZEST), announced that it has completed an acquisition of certain energy assets from an energy company, whose identity will be released in the future, in the process of bankruptcy reorganization.  The all-cash transaction, with a projected short-term payback, includes the transfer of 262 total wells in Mississippi and Louisiana, approximately 9,000 acres of active mineral leases, and significant drilling and production materials and equipment.  The 262 total wells include 57 active producing wells, 19 active disposal wells, 136 shut-in with future utility wells, and 50 shut-in pending plugging wells.  Included in the assignment are four wells in the Tuscaloosa Marine Shale (“TMS”) formation.  The acquired assets are expected to achieve a production rate of 1,000 barrels of oil per day (“BOPD”) by the end of the third quarter of 2020 when considering the acquired asset’s current production, planned production, and planned re-entry projects.

“We are excited to complete this highly opportunistic transaction as we grow our asset portfolio and extend our industry diversification strategy while maintaining a consistent and intense focus on value creation,” said Randy May, Chairman Chief Executive of Ecoark. “This transaction is a continuation of our recent acquisition of the energy assets of Banner Midstream and our ongoing focus on growing through select energy investments to further strengthen our position as a holding company and support our long-term success. The current energy landscape is providing resourceful companies like Ecoark with access to deal flow and unique prospects to selectively invest in the long-term success of domestic energy markets at a highly opportunistic time. We remain committed to expanding Ecoark’s energy portfolio and are currently evaluating the potential acquisition of other high-quality assets under bank or credit ownership.” 

“To maximize the value of our latest acquisition, we plan to immediately deploy our existing workover rigs to re-enter some of the shut-in with future utility wells with the most immediate expected production impact and highest economic returns,” said Brad Hoagland, CFA, Principal Financial Officer of Ecoark. “We expect that these actions focused on advancing our production profile, combined with modest additional investments, will generate approximately six-month payback on the growth capital deployed. The current positive free cash flow generated from the acquired active producing wells and the minimal capital expenditure estimated to bring additional production wells back online is expected to drive further improvement in Ecoark’s overall profitability.  As commodity price volatility subsides and we establish a reliable production baseline, we will explore implementing hedging instruments to efficiently manage risk and consider initiating earnings guidance for our energy operations.” 

“With the actions we have taken to date, Ecoark has advanced its position as a growth-oriented, opportunistic holding company,” continued Mr. May. “Today, we maintain a portfolio of three active, wholly-owned operating subsidiaries spanning a range of sectors including technology, financial services, and energy. We remain fully committed to each of our operating businesses and believe that each business will drive value creation through our diversified industry strategy.”

“We have analyzed the various standards to uplist to a national exchange and feel that the company currently unequivocally exceeds, or can exceed, all minimum criteria,” continued Mr. Hoagland.  “We are working diligently to complete the filing of our March 31, 2020 Form 10-K and will immediately initiate the various steps to uplist upon the completion of that filing.”

About Ecoark Holdings, Inc.
Founded in 2011, Ecoark is a diversified holding company.  The company has three wholly owned subsidiaries: Zest Labs, Inc. (“Zest Labs”), Banner Midstream Corp (“Banner Midstream”) and Trend Discovery Holdings (“Trend Discovery”).  Zest Labs, offers the Zest FreshTM solution, a breakthrough approach to quality management of fresh food, is specifically designed to help substantially reduce the $161 billion amount of food loss the U.S. experiences each year. Banner Midstream is engaged in oil and gas exploration, production, and drilling operations on over 20,000 cumulative acres of active mineral leases in Texas, Louisiana, and Mississippi. Banner Midstream also provides transportation and logistics services and procures and finances equipment to oilfield transportation services contractors.  Trend Discovery invests in a select number of early stage startups each year as part of the fund’s Venture Capital strategy; we are open-minded investors with a founder-first mentality.  Trend Discovery LP has an audited track record of uncorrelated outperformance of the S&P 500 since inception.

Forward Looking Statements
In addition to historical information, this release may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this release that address activities, events or developments that are expected or anticipated to occur in the future are forward-looking statements and are identified with, but not limited to, words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions (or the negative versions of such words or expressions). Forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including all statements regarding financial guidance, anticipated future growth, business strategies, competitive position, industry environment, potential growth opportunities and the effectiveness of the technology discussed in this release and the effects of regulation. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside management’s control that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks include, without limitation, the risk of increased competition; the potential inability to grow and manage growth profitably, including that the collaboration between AgroFresh and Zest may not yield the results expected, the technology described herein may not perform as intended, risks associated with acquisitions and investments, changes in applicable laws or regulations, commodities prices, and the possibility of adverse economic, business, and/or competitive factors. Additional risks and uncertainties are identified and discussed in each company’s filings with the SEC, which are available at the SEC’s website at www.sec.gov.

ZEST FRESH™ and Zest Labs™ are trademarks of Zest Labs, Inc.

BrainStorm Granted SME Status by the European Medicines Agency

Jun 15, 2020 by OTC PR
brainstorm

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has been granted Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency’s (EMA) Micro, Small and Medium-Sized Enterprise (SME) office.

The newly granted SME status allows BrainStorm to participate in significant financial incentives that include a 90% to 100% EMA fee reduction for scientific advice, clinical study protocol design, endpoints and statistical considerations, quality inspections of facilities as well as fee waivers for selective EMA pre and post-authorization regulatory filings, including Orphan Drug and PRIME designations.

Brainstorm is also eligible to obtain EMA certification of quality and manufacturing data prior to review of clinical data. Other incentives include EMA-provided translational services of all regulatory documents required for market authorization, further reducing the financial burden of the market authorization process.

“This is an additional and timely step in our global strategy as we continue to engage with the EMEA,” said David Setboun, Pharm.D, MBA, Chief Operating Officer of BrainStorm. “Our ALS investigational product received orphan drug status in Europe in July 2013 and we will benefit from the enhanced interaction and early dialogue allowing us to optimize development plans and speed up evaluation in Europe. EMA is facilitating pathways such as PRIME designation that enables critical medicines for major unmet medical need like NurOwn®  to reach patients earlier.”

The EMA plays a central role in facilitating the development and authorization of medicines across Europe. The SME initiative promotes innovation from smaller companies such as BrainStorm to ensure Europe continues to be a favorable environment for preclinical and clinical development of promising new therapeutic options like NurOwn.                                     

About NurOwn®
NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019.

Safe-Harbor Statement 
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Profiles

RJD Green Inc. Posts Update of Quarterly Revenues and Focus for the Remainder of Fiscal Year 2020

Jun 10, 2020 by OTC PR
RJD Green Inc.

TULSA, OK, June 10, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green (OTCPK: RJDG) announced today, a 9.2% increase in revenue for the ending quarter over 2019 and a 9.3% increase in revenue for the year to date revenue ending May 31, 2020.

Current Revenues

Quarter 3 ending May 31, 2020

  • $1,129,817                                                                   
  • +9.2% from Quarter 3 2019                            

Year to Date ending May 31, 2020

  •  $3,125,760
  • +9.3% from Year to Date ending May 31, 2020 

Focus in Quarter 4

Ron Brewer, CEO, stated; 

“We feel very blessed to have completed growth in revenue while dealing with an uncertain and recessive economy and an intimidating health crisis.

“Our primary focus has been and will be the safety of our employees, and retention of capital to preserve existing operations.

“However, as we watch the economic and health issues progression in 2020, we plan to address potential acquisition opportunities with our equity partners, as the market allows.

“RJD Green’s ability to complete planned acquisitions meeting the growth needs of 2020 has obviously been sidelined by the world health crisis and dramatic effect on the economy.

“RJD Green remains diligent to the serious and volatile issues that we face in today’s current business environment, but remain positive in our outlook for our long-term future business opportunities.”

About RJD Green, Inc. 

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers:Earthlinc Environmental Services Division, which provides green environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. 

Visit http://www.rjdgreen.com

For additional information contact, Ron Brewer, CEO at ronb@rjdgreen.com, or at (918) 551-7883, or Douglass Baker, OTC PR Group at corp@otcprgroup.com or at (561) 807-6350

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.News Provided by GlobeNewswire via QuoteMedia

The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study

Jun 9, 2020 by OTC PR

Research Study to Use Data and Samples from NurOwn® Phase 3 Clinical Trial

WASHINGTON, June 9, 2020 /PRNewswire/ — The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI), a biotechnology company, to support an amyotrophic lateral sclerosis (ALS) biomarker research study. The grant will be used to draw insights from data and samples collected from patients enrolled in BrainStorm’s ongoing phase 3 clinical trial of its NurOwn® treatment, to further understanding of critical biomarkers associated with treatment response for people with ALS.

BrainStorm_Logo

The study is designed to evaluate how NurOwn interacts with its targets in the brain and spinal cord and to explore the changes in the biomarkers that may correlate with response to the drug treatment. Biomarkers are any measurable substance in the body that change over time (such as cholesterol or blood pressure) and that correlate with disease processes or treatment response. If successful, this study will help confirm that the ALS treatment NurOwn works in the way it is intended and will help inform our larger understanding of ALS biomarkers. 

“This grant to BrainStorm marks an important step forward in establishing how exactly NurOwn works in the body,” said Calaneet Balas, President and CEO of The ALS Association. “This research is also important to our overall pursuit of identification and validation of ALS biomarkers. We hope NurOwn is ultimately proven effective in treating ALS and we stand ready to support BrainStorm in its plan to apply for a biologics license for NurOwn.”

Danielle Carnival, CEO of I AM ALS commented, “We need to move with urgency in all of our efforts to deliver treatments and cures for ALS. This biomarker research will help us more expeditiously understand the effectiveness of NurOwn, while possibly unlocking discoveries that provide clues for other promising treatments. We are at a pivotal time for ALS research in pursuit of treatment solutions and will do whatever we can, together, to drive new answers and new hope for patients.”

The joint award to BrainStorm consists of a $400,000 grant from The ALS Association and a $100,000 grant from I AM ALS. As part of this agreement, BrainStorm has agreed to share data and samples with the ALS community so that the results can be independently validated and to advance other ALS research.

Chaim Lebovits, CEO of BrainStorm stated, “We sincerely appreciate the scientific recognition and generous support from The ALS Association and I AM ALS and we are excited through this study to further an already strong partnership between The ALS Association, I AM ALS and Brainstorm. This critical research study involves one of the largest and most robust clinical trial collections of CSF biomarkers. Data generated from this study will increase our understanding of how NurOwn® therapy impacts ALS disease progression and may identify patients who benefit the most from this form of therapy. We also hope that this research study will benefit the broader ALS scientific community as we collectively advance towards our shared goal of delivering much needed treatments.”

 About NurOwn®            

NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About The ALS Association

The ALS Association is the largest private funder of ALS research in the world. The Association funds global research collaborations, provides assistance for people with ALS and their families through our nationwide network of chapters and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association builds hope and enhances quality of life while urgently searching for new treatments and a cure. For more information about The ALS Association, visit our website at www.als.org.

About I AM ALS

Founded in 2019 by husband-wife team Brian Wallach and Sandra Abrevaya, I AM ALS was born out of their desire to change the future for Brian and the thousands of other ALS patients in the world. I AM ALS brings together patients, advocates, organizations and scientists to deliver critical and innovative resources for patients, empower and mobilize patients and their networks to lead the fight for cures, and transform the public understanding of ALS with a goal of flooding the research pipeline with new, lifesaving drugs. A cure is possible … if we work together to re-imagine the fight against ALS. Learn more here: www.iamals.org.

About BrainStorm Cell Therapeutics Inc.             

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company’s website at www.brainstorm-cell.com

About ALS

ALS is a disease that attacks cells in the body that control movement. It makes the brain stop talking to the muscles, causing increased paralysis over time. Ultimately, ALS patients become prisoners within their own bodies, unable to eat, breathe, or move on their own. Their mind, however, often remains sharp so they are aware of what’s happening to them.

BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020

Jun 2, 2020 by OTC PR

The fully enrolled placebo-controlled Phase 3 trial is evaluating NurOwn® investigational treatment in ALS patients All patients have received at least 2 doses of NurOwn® Completion of all dosing is expected by July 2020

NEW YORK, June 2, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an update on the Company’s Phase 3 pivotal trial investigating NurOwn® in ALS. The Company continues to expect that top-line data from the trial will be announced by Q4-2020, despite the ongoing COVID-19 pandemic that has delayed hundreds of other clinical trials around the world.

BrainStorm Logo

Due to the importance of the clinical trial and the recognized high unmet need in ALS, Brainstorm and the 6 prestigious U.S. clinical sites have been able to continue treatment visits throughout the COVID-19 pandemic with only occasional scheduling changes to treatments. The decision to continue the trial is also shared by the ALS community and the FDA. The clinical trial sites are at University of California, IrvineCedars-Sinai Medical CenterCalifornia Pacific Medical CenterMassachusetts General HospitalUniversity of Massachusetts Medical School and Mayo Clinic. Importantly, the trial’s primary outcome measurement (the ALSFRS-R rating scale) is fully validated for telephonic administration, which allowed non-treatment visits to be conducted remotely and to be aligned with protocol assessment timelines. This allows for ongoing high-quality data collection while prioritizing safety of patients and clinical trial site staff.

“Despite the challenges presented by COVID-19, patient dosing remains on track with all participants having received at least 2 treatments of NurOwn®,” said Dr. Merit Cudkowicz, the Julieanne Dorn Professor of Neurology at Harvard Medical School and the Director of the Healey Center for ALS and Chair of Neurology at Mass General Hospital. “Moving forward, only 20 patients are still to be dosed for the third and final time, and these final treatments remain on schedule.”

Chaim Lebovits, CEO of BrainStorm stated, “BrainStorm made the decision to continue our Phase 3 trial and we have been strongly supported by our partners in the clinical community.  Quick planning and coordination across our clinical sites and the support and direction of the U.S. FDA enabled our Phase 3 investigational trial for NurOwn to advance, with final dosing by July 2020. While numerous clinical trials in the U.S. have been interrupted or completely shut down by the COVID-19 pandemic, trial participants, their families, and the investigational teams remain committed to the trial’s advancement. I am extremely proud and grateful for the outstanding work and commitment of so many, and particularly by these trial participants and their caregivers. We hope to soon reward their commitment by bringing forward a much-needed treatment for ALS.”

Ralph Kern, MD, MHSc, BrainStorm’s President and Chief Medical Officer said, “We are very fortunate to have developed an outstanding team of partners who are committed to BrainStorm’s investigational therapy NurOwn and share its promise in ALS research. Our primary concerns will always be the overall health and safety of trial participants and the scientific integrity of the trial. Fortunately, ALSFRS-R, the primary outcome measurement of the Phase 3 trial, is validated by phone and allows for the collection of quality data with minimal risk of COVID-19 exposure. This, along with the collective efforts of so many of our employees, partners, and patients, has enabled us to remain on track for study completion as planned in the fourth quarter of this year.” 

About NurOwn®

NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company’s website at www.brainstorm-cell.com

Safe-Harbor Statement 

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CBD Global Sciences Commences Its 6th Year of Planting at Its Strasburg Pharms Subsidiary

Jun 1, 2020 by OTC PR

Denver, Colorado, May 19, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — CBD Global Sciences Inc. (CSE: CBDNOTC: CBDNFFrankfurt: GS3), (“CBD Global” or the “Company”), is pleased to announce the start of the 2020 hemp planting season, at our wholly-owned Colorado subsidiary Strasburg Pharms, has begun. This is the Company’s 6th straight year of Hemp production at our 179-acre site. The Company has brought in additional farming expertise this season and, along with our first year of implementing expanded use of feminized seed, we will also be employing some additional techniques that we believe will greatly expand our yields while at the same time significantly reduce our costs per pound of produced biomass.

“The 2020 growing season has arrived at Strasburg Pharms, Colorado, and we look forward to building on the progress we made with the previous year’s harvests,” commented Brad Wyatt, President and CEO. “We look forward to working with our team to optimize all aspects of cultivation and to deliver on a larger mission of bringing wellness to people so they can live happier and healthier lives.”

In order to meet the growing demand for quality CBD products throughout the US, the Company will be planting in excess of 1.7 million feminized seeds which have been derived from our previous high yielding CBD strains. Hemp with higher potency CBD content reduces the amount of biomass required for CBD extracts allowing the maximum benefit in the production of cannabinoids, terpenes and other beneficial compounds. The biomass will be used to create our CBD products sold under our own brands, Aethics and CannaOil, and also for fulfilling orders for our select white label partners throughout the US and other parts of the world.

Our hemp is 100% Colorado grown with all-natural Colorado water, soil, sun and nutrients and NEVER sprayed with pesticides or chemicals. The hot summer days and cool Colorado nights creates the perfect environment for hemp cultivation. On top of that, at 5280 feet above sea level, the farm enables more potent UV rays presenting the perfect state for the plants’ natural photosynthesis reactions to facilitate maximum plant potency and growth.

In addition to the foregoing, CBD Global also announces the grant of an aggregate of 6,000,000 options to acquire common shares of the Company to officers, directors, employees and consultants of the Company, each such options being exercisable at a price of CDN$0.20 per common share for a three-year term expiring on May 19, 2023. These stock options all vest over a 2-year period with one-third vested immediately upon the date of grant and further one-third vesting on each of the first and second anniversaries of the date of grant.

ABOUT CBD GLOBAL SCIENCES INC.

CBD Global Sciences Inc., is a vertically integrated hemp-based CBD producer, extractor, and branding investment vehicle which currently owns two product categories, branded under the name AETHICS (www.aethics.com) and CANNAOIL (www.cannaoilshop.com), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals and CBD hydration products.  CBD Global’s hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.

CBD Global Sciences, through its wholly owned subsidiary, Strasburg Pharms, grows and operates irrigated land in Colorado that grows hemp with only all-natural Colorado water, soil, sun and nutrients that is NEVER sprayed with pesticides or chemicals.  Our genetics are hand selected and maintained to present the best cannabinoid profile with extremely high CBD.  The extraction/processing facility, operated by CBD Global, is located approximately 40 minutes from the farm.

For further information, please contact Bruce Nurse, Investor Relations, (303) 919-2913, info@cbdglobalsciences.com.

https://www.cbdglobalsciences.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to future developments and the business and operations of the Corporation after the CSE listing.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals.  Readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CBD Global Sciences

BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research

May 27, 2020 by OTC PR

Experience Developing, Seeking Regulatory Approval of and Commercializing Multi-Billion Dollar Neurology Therapies

NEW YORK, May 27, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Stacy R. Lindborg, Ph.D. has been appointed Executive Vice President Head of Global Clinical Research effective June 1, 2020. Dr. Lindborg is an experienced healthcare professional and globally recognized medical statistician with over 24 years of multinational experience in R&D, regulatory, strategy development, analytics and big data.   

BrainStorm Logo

Prior to her appointment at BrainStorm, Dr. Lindborg spent 8 years at Biogen Inc. the global biotech that discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. She held several senior leadership positions, most recently Vice President, Analytics and Data Science, where she built a world class Analytics and Data Sciences team, responsible for global data as well as statistical and epidemiological support for R&D and marketed products. She served on R&D governance during a time of significant growth for Biogen, and was active in guiding the firm’s long-term vision for growth through analytics and by stimulating innovative development platforms to increase productivity. As the portfolio grew to tackle a diverse set of neurological diseases, Dr. Lindborg motivated novel analytic and development approaches, shaving time off novel drug approvals to globally address chronic diseases.  Her accomplishments at Biogen included a leadership role in seeking, receiving and maintaining global marketing approvals for Zinbryta®, Plegridy® and Spinraza®, all of which included novel data analytical elements.  The Phase 3 Spinraza program was recognized with the prestigious 2017 Prix Galien Award Winner for Best Biotechnology Product (the biomedical industry’s highest accolade).  She also played a key role in the Phase 3 development program for Aducanumab in Alzheimer’s Disease. 

“The investigational NurOwn® technology platform currently in Phase 3 and Phase 2 for ALS and  progressive MS, respectively, have life changing potential. This has been the most significant factor in my decision to join Brainstorm,” said Dr. Stacy R Lindborg. “I have been impressed by the leadership, depth of talent and aspiration of goals at BrainStorm. I look forward to seeing NurOwn and the Company’s pipeline advance across all stages of clinical development.”

Chaim Lebovits, Chief Executive Officer of BrainStorm, commented, “Stacy’s experience in launching and commercializing highly visible top selling neuroscience- based pharmaceutical products and her expertise in product launches from NDA to post-approval marketing studies make her exceptionally well qualified to join the BrainStorm leadership team at this pivotal time in the Company’s history. She has played leadership roles in clinical trial design and regulatory interactions for development stage and marketed products in neuroscience, immunology and orphan diseases.  Her experience includes global organization design and development at two of the world’s leading neurology companies, including substantial corporate builds. Without question Dr. Lindborg, will significantly enhance our global commercialization and regulatory strategy, as we work to bring better treatment options to patients afflicted with neurodegenerative diseases. We look forward to the strategic contributions and insights she will being to BrainStorm.”

Prior to her roles in Biogen, from 1996 to 2012, Dr. Lindborg held positions of increasing responsibility at Eli Lilly and Company. As Head of R&D strategy, she was responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan.  In this role, she created seminal insights into R&D productivity by connecting individual drug program-based development decisions to portfolio risk practices, driving fundamental R&D decisions to increase number of drug launches. Additionally, she was Leader of Zyprexa Product Management in which she was responsible for R&D, Commercial and Manufacturing plans. She was accountable for driving market share through product differentiation, global registration and launching of an injectable form of Zyprexa, working through regulatory manufacturing inspections and 483 citations. Zyprexa had peak sales of $4.7 billion.

Dr. Lindborg holds a Ph.D. in statistics from Baylor University. She has been active in professional organizations across her career, holding numerous positions within the American Statistical Association and International Biometric Society, having been elected Fellow of the association in 2008. She serves on the Scientific Advisory Board of biotechnology and technology companies and on the board of directors of the Massachusetts Down Syndrome Congress. She was a Board Member to the Strategic Initiative: Women in Statistics. Dr. Lindborg was also profiled in the book “STEM Gems” (2017) as the only women from the pharmaceutical industry highlighted as a leader in science, technology, engineering and mathematics.

About NurOwn

NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company’s website at www.brainstorm-cell.com

Safe-Harbor Statement 

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Ecoark Holdings, Inc. Announces Conversion of Trend Discovery SPV I Credit Facility Into Common Stock at $0.73 per Share

May 7, 2020 by OTC PR
Ecoark

FRISCO, Texas, April 06, 2020 (GLOBE NEWSWIRE) — Ecoark Holdings, Inc. (“Ecoark”) (OTC: ZEST), announced that it has converted all principal and interest within the Trend Discovery SPV I, LLC (“TD SPV”) credit facility, into Ecoark common stock on Tuesday, March 31, 2020.  The conversion includes the issuance of approximately 3.9 million shares at $0.73 per share to convert approximately $2.5 million of principal and $0.3 million of accrued interest into Ecoark common stock. The conversion price of $0.73/share represents a 24% premium to Ecoark’s closing share price of $0.59/share on the date of the conversion. 

“The willingness of the TD SPV debt holders, which include company insiders, to convert to Ecoark common stock at an above-market rate is a reflection of their confidence in both our business model and future prospects” said Randy May, Chairman and CEO of Ecoark.  “Completing this conversion on Ecoark’s March 31st fiscal year-end will continue to strengthen the company’s stockholders’ equity, balance sheet and its prospects to up list to a national securities exchange”, said Brad Hoagland, CFA, Principal Financial Officer of Ecoark.

About Ecoark Holdings, Inc. and Zest Labs

Founded in 2011, Ecoark is a diversified holding company.  The company has three wholly-owned subsidiaries: Zest Labs, Inc. (“Zest Labs”), Banner Midstream Corp (“Banner Midstream”) and Trend Discovery Holdings (“Trend Discovery”).  Zest Labs, offers the Zest FreshTM solution, a breakthrough approach to quality management of fresh food, is specifically designed to help substantially reduce the $161 billion amount of food loss the U.S. experiences each year. Banner Midstream provides transportation and logistics services, and procures and finances equipment to oilfield transportation services contractors.  Banner Midstream is also engaged in oil and gas exploration, production, and drilling operations on over 10,000 cumulative acres of active mineral leases in Texas, Louisiana, and Mississippi. Trend Discovery invests in a select number of early stage startups each year as part of the fund’s Venture Capital strategy. We are open-minded investors with a founder first mentality.

Forward Looking Statements
In addition to historical information, this release may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this release that address activities, events or developments that are expected or anticipated to occur in the future are forward-looking statements and are identified with, but not limited to, words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions (or the negative versions of such words or expressions). Forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including all statements regarding financial guidance, anticipated future growth, business strategies, competitive position, industry environment, potential growth opportunities and the effectiveness of the technology discussed in this release and the effects of regulation. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside management’s control that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks include, without limitation, the risk of increased competition; the potential inability to grow and manage growth profitably, including that the collaboration between AgroFresh and Zest may not yield the results expected, the technology described herein may not perform as intended, risks associated with acquisitions and investments, changes in applicable laws or regulations, and the possibility of adverse economic, business, and/or competitive factors. Additional risks and uncertainties are identified and discussed in each company’s filings with the SEC, which are available at the SEC’s website at www.sec.gov.

ZEST FRESH™ and Zest Labs™ are trademarks of Zest Labs, Inc.

BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union

May 7, 2020 by OTC PR

brainstorm

NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today a lease agreement with the Tel Aviv Sourasky Medical Center (“Sourasky) in Tel Aviv, Israel, to produce NurOwn® in three state-of-the-art cleanrooms. The new facility will significantly increase the Company’s capacity to manufacture and ship its product into the European Union and the local Israeli market. The cleanroom facility is part of Sourasky’s Institute for Advanced Cellular Therapies.

“Sourasky Hospital is a leader in the advancement and manufacturing of cell and gene therapy products and is well-equipped to rapidly scale up and produce NurOwn,” stated Prof. Ronni Gamzu, CEO of Tel Aviv Sourasky Medical Center. “We look forward to continuing our work with BrainStorm to bring NurOwn to ALS patients and help fulfill the clinical therapy demands for the Company’s pipeline programs.”

“Sourasky Hospital, known for introducing pioneering solutions into clinical practice and advancing patient care, has a first rate team with the proven experience to produce regenerative products in accordance to the highest standard of cGMP manufacturing,” said Chaim Lebovits, CEO of BrainStorm.  “This agreement will ensure that we can provide NurOwn to patients after regulatory approval, not only in Israel but we have secured capacity to rapidly scale up production as we advance our investigational treatment across the European Union. We are very pleased to be able to expand our ongoing collaboration with Sourasky Hospital, one of the world’s most innovative and respected medical centers.”

About NurOwn® 
NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company’s website at www.brainstorm-cell.com

Safe-Harbor Statement       
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Generex Biotechnology Initiates Peptide Manufacturing for Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic

May 5, 2020 by OTC PR
  • Submitted proposal to BARDA for start-to-finish funding to develop an approved, commercial Ii-Key peptide vaccine against the SARS-CoV-2 coronavirus
  • SARS-CoV-2 epitope identification and selection completed
  • Initiated GLP manufacturing of synthetic Ii-Key-SARS-CoV-2 peptides for screening in “Ex-vivo” human trial in blood samples from COVID-19 convalescent (recovered) patients
  • Obtained letters of support for BARDA Application from scientific partners, prestigious universities, major contract manufacturers, and a prominent CRO that will manage the international regulatory effort and the proposed end-to-end clinical program

MIRAMAR, Fla., May 04, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has submitted a contract proposal to BARDA to develop a vaccine against the SARS-CoV-2 coronavirus using the patented Ii-Key vaccine technology. Following the BARDA application, and in an effort to rapidly respond to this pandemic emergency, Generex has now initiated the manufacturing of synthetic peptides with Ii-Key linked to SARS-CoV-2 epitopes predicted by computational vaccinology algorithms.  These Ii-Key-SARS-CoV-2 peptide epitopes, which contain target amino acid sequences from the virus, will be screened against blood samples collected from COVID-19 convalescent (recovered) patients to select those Ii-Key peptides that activate the immune system to fight the coronavirus infection. The blood screening program, which is scheduled to begin to begin shortly, incorporates T Cell Assays, B Cell Assays, Antibody and Virus Neutralization tests, and a novel in-vitro “cytokine storm” cellular assay to identify the Ii-Key-SARS-CoV-2 peptides vaccines most likely to stimulate the T-Cell (CD4 and CD8) response, modulate appropriate immune system responses to minimize potential for dysregulated cytokine-related inflammation, stimulate a neutralizing antibody response, and provide a broad-spectrum coverage for the vast majority of people. This strategy leverages Ii-Key technology to develop a “Complete Vaccine” that has the potential to induce the likelihood of protective immunity with long-lasting immunologic memory against SARS-COV-2 in a highly specific manner to ensure safety. The most important aspect of this ex-vivo human trial approach is that we can select the right peptides for Ii-Key vaccine peptides that will limit the risk of off-target immune responses that may lead to a cytokine storm, and we find the answers very early in the development process before we vaccinate any human volunteers.

Generex CEO, Joseph Moscato said, “We have been working diligently over the last two months to rapidly respond to the coronavirus pandemic, because our Ii-Key peptide technology offers true promise for an effective and safe COVID-19 vaccine. Highlighting the potential for our Ii-Key-SARS-CoV-2 “Complete Vaccine”, Generex has obtained letters of support from key, industry leading partners to provide their expertise, experience, facilities and infrastructure for the development and manufacturing of an Ii-Key-SARS-COV-2 vaccine.  We have contracted PPD, a recognized leading CRO to provide comprehensive, turnkey clinical and regulatory services, including regulatory submissions, site preparation, clinical testing, data management, protocols and reports required to maximize the speed and path to licensure. Additionally, we are planning GMP vaccine production with industry leaders in GMP peptide synthesis, including Polypeptide Laboratories (the manufacturers of our AE37 Ii-Key-HER2 immuno-oncology product), Bachem, and Corden Pharma who are on board to provide clinical trial material and kilogram scale commercial manufacturing.  We also have support from international leaders, Ajinomoto and Thermo-Fisher for fill/finish and quality control, ensuring both capacity and redundancy to deliver on large scale vaccination requirements. Further, we have obtained a letter of support from 3M to evaluate the use of their new vaccine adjuvant in the formulation of the Ii-Key peptide vaccines for the comprehensive clinical program that was outlined in our proposal.”

Mr. Moscato continued, “Because Generex’ subsidiary NuGenerex Immuno-Oncology has a long history of developing the Ii-Key peptide vaccine technology to rapidly respond to potential pandemic threats, we have been able to rapidly mobilize our efforts to help respond to the COVID-19 global pandemic.  And, as shown in the recently published positive results from our Phase II trial of AE37 in the prevention of breast cancer recurrence in hard to treat patients, the Ii-Key activates the T-Cell response against the HER2 antigenic epitope to which it is attached. The authors point out the benefit of such a complete immune response combining CD8+ and CD4+ activation may not only induce an immediate cell mediated cytolytic response versus tumor antigens but may also induce T-Helper cell mediated long-term immunity to protect against tumor recurrence. The activation of a complete immune response against coronavirus antigens modulated by the Ii-Key is what sets us apart from others in the field and makes us confident in our plans to deliver a COVID-19 vaccine with our Ii-Key-SARS-CoV-2 peptide vaccine development program. We will keep our investors informed as the development progresses.”

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

NuGenerex Immuno-Oncology (formerly Antigen Express), a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD-4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) is being spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Primary Logo

BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology

May 4, 2020 by OTC PR

NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that new data highlighting the immunomodulatory effects of NurOwn® on B and T regulatory function appeared in an online supplement to Neurology.

The abstract was originally planned for presentation at the recently cancelled 2020 American Academy of Neurology (AAN) annual meeting. In addition to the online supplement, the abstract is also available through the AAN online abstracts website.

“Neuroinflammation is a prominent pathological feature of ALS and progressive MS. Reduced T and B regulatory function may contribute to disease progression, and lower IL-10 levels may be associated with reduced ALS function and with higher disability and MRI lesion load in secondary progressive MS,” said Ralph Kern MD, MHSc, President and Chief Medical Officer of Brainstorm, “The immunomodulatory properties of MSC-NTF cells, including their effects on T and B regulatory cells, and the observed increase in IL-10 secretion, may be an important contributor to the potential therapeutic benefits of NurOwn in ALS and progressive MS.”

“Brainstorm is committed to fully developing NurOwn technology while continuing to expand our understanding of potential biological mechanisms of action that may contribute to its therapeutic effects in neurodegenerative diseases,” said Chaim Lebovits, Brainstorm CEO, “We look forward to advance our technology platform across several neurodegenerative disease indications and bring much-needed solutions to patients.”

Brainstorm AAN 2020 abstract:
MSC-NTF Cell Immunomodulation: Effects on T and B Regulatory Cells
Revital Aricha, Natalie Abramov, Jonathan Semo, Haggai Kaspi, Chaim Lebovits, Ralph Kern.

About NurOwn®
NurOwn® (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn® is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.  
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company’s website.

Safe-Harbor Statement      
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Primary Logo

BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update

Apr 29, 2020 by OTC PR

Thursday, May 7, 2020, 8:30 a.m. EDT

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) — BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, on Thursday, May 7, 2020. 

BrainStorm’s CEO, Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer and Preetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. EDT, Tuesday, May 5, 2020. 

Teleconference Details – BRAINSTORM CELL THERAPEUTICS 1Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:Toll Free: 877-407-9205
International: 201-689-8054

Those interested in listening to the conference call live via the internet may do so by visiting the “Investors & Media” page of BrainStorm’s website at www.ir.brainstorm-cell.com and clicking on the conference call link.

Event Link:Webcast URL:
https://www.webcaster4.com/Webcast/Page/2354/34588
Webcast Replay Expiration:Friday, August 07, 2020

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Number:Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 34588
Teleconference Replay Expiration:Thursday, May 21, 2020

ABOUT NUROWN®
NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn® is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

ABOUT BRAINSTORM CELL THERAPEUTICS INC.:
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company’s website.

SAFE HARBOR STATEMENT:
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn® treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

3 Ways To Fund Your Business

Jul 30, 2019 by OTC PR
Ways to Fund your business

A well-organized, professional Investor Relations and Broker Network Program can help provide ways to fund your business, build the familiarity your company needs in order to get its share of attention and increase the liquidity in your company stock.

Finding ways to fund your business still remains a difficult task even though in recent years a number of platforms have been developed to help new entrepreneurs.

New technological advancements have opened up many new avenues to launch and fund budding enterprises. To succeed in this process, you have to find ways to fund your business and get noticed by those who want to provide financing in exchange for a stake in your new company.

Online Fundraising Platforms

The past few years have given birth to virtually countless online fundraising platforms. They have become highly popular with sophisticated and accredited individual investors, angels, and even banks and funds looking for new ways to deploy capital.

The major platforms run from peer-to-peer lending sites that offer business loans to donation-based, debt and equity crowdfunding portals.

For donations, you can try Kickstarter or Indiegogo. For equity crowdfunding platforms the most popular platforms are the following:

•AngelList

•Seedinvest

•StartEngine

•CircleUp

•Wefunder

Even if you don’t use online platforms to raise all the money you want, they can be extremely effective for getting noticed. The key is finding the right match in a platform for your venture and needs, as well as being realistic about what it will take to make a campaign work.

Social Media

Social media can be your best friend when looking for ways to fund your business. Whether engaging in it or not: social media isn’t going anywhere any time soon. Implementing the right social media solutions is paramount for any successful marketing program. It’s a digital world out there, and with hyper-connectivity comes new technological ways to keep us socially linked. As a lean startup or solo entrepreneur looking to test the market, gain traction, and attract investors, social media makes it easy to be discovered and is still one of the most cost-effective methods of reaching others.

You can take an inbound approach with your own posts and updates, or take a more active approach with collaborations and leveraging sponsored posts or influencers.

Direct messaging can be a powerful tool when searching for ways to fund your business. If you can get the social profile handles of well-fitting investors, it might only take one great message to connect with the capital your startup needs. If this sounds like a fit for you, check out LinkedIn contact information for the top 50 angel investors based on investment volume.

In the event you need VCs you can always go to Crunchbase and research for those investors that are actively investing in your industry.

When it comes to social media, here are the most popular channels and how to use them:

•LinkedIn for cold messages or to seek quality introductions to pass the social proof with guarded investors such as Venture Capital investors. LinkedIn Premium is totally worth for unlocking certain features.

•Facebook for meaningful relationships after you have been able to meet with an investor once or twice. It is critical to building a relationship to generate trust.

•Twitter for thoughtful conversations and engagement with relevant information shared by the investor

Ways To Fund Your Business try Attending Events

Success in business and fundraising is all about visibility, getting noticed by the right investors, who you know, and who knows you. Attending events is a great way to achieve this. Try to find out who is attending the event ahead of time and schedule meetings to be productive.

This can be pitch nights for presenting your own opportunity and meeting active investors who are there, engaging in coding marathons, or simply getting out to organized networking functions and industry trade shows.

If you are operating an early-stage company, you may want to consider attending any of the following events:

•WebSummit

•Money2020

•TechCrunch Disrupt

•SXSW

•Collision

To get ahead of the competition and take a more passive route, consider attending other events where your investors are likely to be. Think sporting events, charity fundraisers, film festival and yacht shows.

Our experience has shown that a properly coordinated outreach program can attract venture capital and increase awareness. At OTC PR Group we’re experts in investor relations and figuring out what message you want to convey, who you want it to reach, and then executing a successful program to effectively relay that information.

Find Investors To Launch Your Business!

Jun 13, 2019 by OTC PR

Find Investors & Raise Capital for your business.

Find Investors

Part-1

There’s more than one way to find investors, raise capital and to get on the radar of those with the capital and knowledge you need to grow your budding enterprise.

It’s hard to believe, but finding investors is not the hard part in fact, through the process of trying to raise capital, an entrepreneur might have opportunities to talk to many investors, depending on their business model and unique idea.

However, just as it takes a great idea and presentation to find success, it also requires a motivated investor. An investor who works in the same field as your company, one who is able to provide assistance and knowledge throughout the development of the company and most of all, an investor who can come to a reasonable financial agreement that suits all parties involved.

Even the best funded and successful million dollar start-ups have been engaging in more fund-raising rounds than ever before.

No matter how good your product or business concept is, you will still need to find investors to gain the necessary financial leverage to grow your business.

Thankfully, for today’s entrepreneurs, we have seen increasing new ways start-ups are getting noticed, found and connected with potential investors.

1) Raise Capital with Blogging

Blogging to find investors is one of the most underestimated methods of raising capital. Blogging about your business, progressing potential investors through the learning process of wanting to invest in you, and remaining on their radar through each series of fund-raising.

Creating a basic corporate website using the many WordPress themes as a website builder, along with good SEO practices, can launch your business idea into the laps of many quality investors.

Even without a corporate website or blog of your own yet, you can publish via LinkedIn or Medium.

Moreover, another good option is to go to the blogs of the investors that you are looking to target. They all read their comments and often engage with responses. Leave a thoughtful comment to get noticed and start building the relationship from there.

A simple search in Google can provide many well funded individuals who are looking for new ideas to place their money.

Investors that are probably the most active right now on blogs include:

•Bill Gurley

•Fred Destin

•Brad Feld

•Matt Turck

•Seth Levine

•Jalak Jobanputra

•Tomas Tunguz

2) Raise Capital with Email

Simple emails have proven to be able to get the attention of notable angel investors and VCs. They have been responsible for the launch of some very important and notable start-ups.

Building or acquiring lists of Angel/VC investors can be done with a basic search on the internet. Or working with an experienced OTC PR Firm you can tap extensive databases and networks without the need of building your own.

3) Raise Capital & Apply to Accelerators

Accelerators offer entrepreneurs good opportunities early on. Founders get help to quickly grow their business and they often better their chances of attracting a top venture capital (VC) firm to invest in their startup at a later point. Still, the programs are different frameworks for startup success.

Popular start up accelerator programs always have an open invitation for applications from serious entrepreneurs. If accepted, you’ll likely get a modest amount of funding to keep developing your work, as well as introductions to other investors, business advice and help in staging future fund-raising rounds.

Typically Accelerator programs include a demo day. This is when the start-ups attending the program pitch to a crowd of investors.

Startup accelerators and incubators can get involved at all stages of a startup’s development, from idea stage to revenue-generating, late stage.

Startups are usually admitted in batches, with many incubators and accelerators offering 1-3 batches per year. Some focus on a specific industry, market, technology, stage, or other thesis, whereas others are more generalists.

Accelerators and incubators have been very successful in helping startups attain success, being admitted to a startup accelerator or incubator is not a guarantee for success to a startup founder, and not a guarantee of a sound investment for a startup investment.

I would highly recommend to do extensive research to verify the type of success stories and the track record from such programs. You may be better off using that equity that you intended to allocate to the Accelerator to create instead a very active board of advisers and incentivize them to help with making investor introductions.

4) Raise Capital Buy Sharing Your Product

Fund-raising and growth needs to be strategic to be successful. Yet, far too many entrepreneurs and start-ups aren’t focusing enough on just getting their product or service out there in the hands of customers, influencers, and in turn, in front of investors.

If you can acquire real customers, you will be under less pressure to seek outside money. When you do, you can achieve better terms, from better investors.

At OTC PR Group we use our publishing sites and knowledge of the markets and industry to provide our clients with a better understanding on how to approach their marketing decisions. Your goals are our goals, which is why OTC PR engages in a true partnership with our clients. OTC PR has worked with a diverse group of talented and respected professionals whom have joined forces with us in order to create a cost effective advertising network dedicated to publicly traded Companies.

OTC PR Group founders utilize over 20 years of experience in managing awareness campaigns. We understand that increasing brand and investor recognition, as well as broker awareness through network marketing, can be an extremely daunting task. 

OTC PR Group excels in providing you with the proper network media outlets because of the screening process we put list network owners through. This allows us to avoid the mistakes many people make and be sure that your news and story sends the right message to the right people at the right time.

RJD Green Inc. Specialty Contracting Division, Silex Holdings, Announced their Commercial Sector Contract Growth for 2019

May 14, 2019 by OTC PR
RJD Green Inc

TULSA, OK, May 14, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green (OTCPK: RJDG), Silex Holdings announced their commercial contracts awarded for 2019 total over $750,000 to date, creating an additional reoccurring profit center for the Company.

RJD Green Inc. subsidiary Silex Holdings announced their current contracts for the commercial contracting division total over $750,000 for the manufacturing and installation of natural stone countertops and related products, creating a solid market base to sustain an ongoing additional revenue stream.

The compilation of various permit reporting outlets indicates the new home permits will sustain a 10% growth into 2020 barring serious economic upheaval, which gives Silex complimentary profits from their major revenue stream. Commercial projects planned in the regional market project indicate a continued growth in 2020.

Ron Brewer, CEO of RJD Green Inc. states, “Silex continues its progression in solidifying long-term relationships with valued clients in the construction industry by providing custom quality product with fast turnaround times on our clients’ orders. The establishment of the commercial market allows Silex Holdings to continue regional expansion creating ongoing profitable revenue while exploring appropriate acquisitions that would consolidate a larger six state regional position.”

About RJD Green, Inc. 

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers:Earthlinc Environmental Services Division, which provides green environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. Visit http://www.rjdgreen.com

For additional information contact, Ron Brewer, CEO at ronb@rjdgreen.com, or at (918) 551-7883, or Douglass Baker, OTC PR Group at corp@otcprgroup.com or at (561) 807-6350.

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

RJD Green Announces Financial Results for the Three Months Ended February 2019

Apr 30, 2019 by OTC PR

RJD Green Net Operating Profit for 2019 Q2 Increasing by 34.4% Over Q2 2018

RJD Green Inc

Tulsa, OK, April 30, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green, Inc. (RJDG):

Dear Valued RJD Green Shareholders,

As we have announced our financial results for the three months ended February 28, 2019, RJD Green’s management team would like to take the opportunity to update all existing and potential shareholders with the latest information on developments with the company. Please be advised – this letter is not a substitute for reviewing our press releases and SEC filings. Some of this update is opinion – so be sure to note the forward-looking statements disclosure. We wanted to simplify the complexity and put our latest news items in context and keep you updated on our activities and events that may not rise to the level of a press release or SEC filing.

We continue to work diligently to execute our business model to create a substantive holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions.

Recent Corporate Highlights:

  • The Earthlinc Environmental Division of the Company has entered into an initial eighteen-month product development program utilizing Agrico’s forestation program in relation to animal waste. The initial contract is primarily focused on creating services that are proprietary to Agrico. The two companies have agreed to create joint-venture efforts in utilization of proprietary intellectual properties or services created.
  • RJD Green Inc. announced the hiring of Kyle Schmidt to assist in the growth and expansion program of Silex Holdings. Mr. Schmidt has a success record in both the commercial and homebuilder markets in the kitchen and bath product sales. As well he has served in the roles of National Sales Manager and National Marketing Director within Silex Holding’s target markets.
  • On March 5, 2019, RJD Green Inc. announced the awarding of a regional homebuilder purchase order for natural stone countertops and related products. The contract is projected to be $550,000 in 2019 revenue with an expectation of an ongoing multi-year relationship. The compilation of various permit reporting outlets indicates the new home permits will reflect an increase as much as 5% – 10% in Oklahoma in 2019, Silex’s primary market. Commercial projects, other than multi-family, are projected to increase by over 10% for the same time periods.
  • On February 19, 2019 RJD Green Inc. announced Earthlinc Environmental has entered into a Memorandum of Understanding with a ten-year-old environmental consulting and engineering firm located in the Southern United States market. Completion of the definitive agreement is pending funding approval and final diligence.

Financial Results for the Three Months Ended February 28, 2019

  • The Net Operating Profit for 2019 Q2 increased by 34.4% over Q2 2018
  • The Net Operating Profit for 2019 Q2 increased by 34.9% over Q1 2019
  • The Company has recurring revenues of $974,411, working capital of $161,447 and shareholder equity of $980,064 as of February 28, 2019.
  • The Company has six months revenue of $1,995,943 and cash of $161,447 held in a bank and cash equivalents of $65,005 as of February 28, 2019.

We will continue to update our investors with any and all progress in the coming months as newsworthy occurrences happen.

Sincerely,

Ron Brewer
CEO, RJD Green, Inc.

About RJD Green, Inc. 

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. Visit http://www.rjdgreen.com

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Company Contact: 

RJD Green, Inc. 

Ron Brewer, CEO 

(918) 551-7883 

ronb@rjdgreen.com

AppSwarm Announces the Launch of SwiftCrypto Website for its Secure Crypto Wallet ‘SwiftCoin’

Apr 24, 2019 by OTC PR

TULSA, OK, April 24, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AppSwarm, Corp. (OTC: SWRM) announces the launch of its secure crypto wallet ‘SwiftCoin’ website SwiftCrypto.

AppSwarm

SwiftCrypto (http://www.swiftcrypto.io/) offers all of the details of just what the wallet can do. The company expects the app to be in the Google Play and the Apple Store very soon. The company will make announcements when the apps are available for download.

SwiftCoin is an easy to use and secure crypto wallet. You can store, send, and receive Bitcoins and Ethereum.

SwiftCoin

– De-mystifies the process of storing digital currency.

– Provides an easy-to-use digital wallet with guided instructions on setup and configuration.

– Uses paper key backup which is more secure as no data is stored online.

– Currently, you can store, send and receive both Bitcoin and Ethereum in the wallet. 

The Crypto and cannabis markets are in need of technology solutions that can advance productivity and do it safely. AppSwarm intends to develop mobile applications that address these needs by creating a system that allows a business to see what is going on in the market around them. The mobile app and tech created will also attempt to modernize the consumer experience by adding in SwiftCoin’s payment features, as well as a multitude of other functions that are currently proprietary to AppSwarm.

About APPSWARM

AppSwarm is a technology company specializing in the accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.

For more information, visit us at www.app-swarm.com or follow us on www.facebook.com/AppSwarm Twitter https://twitter.com/AppSwarm or Instagram https://www.instagram.com/appswarm/

Request More Information

To receive status updates on our company we invite you to register to our investor mailing list at http://www.app-swarm.com/investors/

Forward-Looking Statements:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

AppSwarm, Corp.
888-886-8583
info@app-swarm.com

RJD Green Inc. Earthlinc Division Executes an Initial Environmental Product Development Agreement with Agrico LLC

Apr 16, 2019 by OTC PR

TULSA, OK, April 16, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green (OTCPK: RJDG) CEO, Ron Brewer, announced today the Earthlinc Environmental Division of the Company has entered into an initial eighteen-month product development program utilizing Agrico’s forestation program in relation to animal waste. 

RJD Green Inc

Ron Brewer, RJDG Green Inc. CEO, states: “Through our Earthlinc Environmental Division, RJD Green has received a contract for development services with Agrico that encompasses developing environmental products and services focused on animal waste. The initial contract is primarily focused on creating services that are proprietary to Agrico. The two companies have agreed to create joint-venture efforts in utilization of proprietary intellectual properties or services created.”

About Agrico LLC

Agrico LLC is an Oklahoma based enterprise that is involved in forestation and natural resource conservation internationally focused in efforts with developing countries.

About RJD Green, Inc. 

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. Visit http://www.rjdgreen.com

Company Contact: RJD Green, Inc. Ron Brewer, CEO ,(918) 551-7883

ronb@rjdgreen.com

Investor Relations:OTCPR Group,Douglas Baker (561) 807-6350

corp@otcprgroup.com

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

AppSwarm Announces the Imminent Release of its Secure Crypto Wallet “SwiftCoin”

Apr 11, 2019 by OTC PR

TULSA, OK, April 11, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AppSwarm, Inc. (OTC: SWRM) announces the imminent release of its secure crypto wallet “SwiftCoin.”

AppSwarm

SwiftCoin is an easy to use and secure crypto wallet. You can store, send, and receive Bitcoins and Ethereum.

SwiftCoin

  •  De-mystifies the process of storing digital currency
  •  Provides an easy-to-use digital wallet with guided instructions on setup and configuration
  •  Uses paper key backup, which is more secure as no data is stored online.
  •  Currently, you can store, send and receive both Bitcoin and Ethereum in the wallet.  

The Crypto and cannabis markets are in need of technology solutions that can advance productivity and do it safely. AppSwarm intends to develop mobile applications that address these needs by creating a system that allows a business to see what is going on in the market around them. The mobile app and tech created will also attempt to modernize the consumer experience by adding in SwiftCoin’s payment features, as well as a multitude of other functionalities that are currently proprietary to AppSwarm.

About APPSWARM

AppSwarm is a technology company specializing in the accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.

For more information, visit us at www.app-swarm.com, or follow us on www.facebook.com/AppSwarm Twitter https://twitter.com/AppSwarm or Instagram https://www.instagram.com/appswarm/

Request More Information

To receive status updates on our company we invite you to register to our investor mailing list at http://www.app-swarm.com/investors/

Forward-Looking Statements:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

AppSwarm, Inc.
888-886-8583
info@app-swarm.com

Primary Logo

DeliverySwift Signs Agreement with ‘M² Farms,’ a Licensed Cannabis Cultivator, Dispensary and Delivery Company in Sacramento California

Apr 2, 2019 by OTC PR

TULSA, OK, April 02, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AppSwarm, Corp. (OTC: SWRM) announces it has executed a license agreement with M² Farms to utilize the DeliverySwift platform for their cannabis delivery service in Northern California.

AppSwarm

Under the agreement, DeliverySwift will provide all of the backend support via its DeliverySwift technology to help M² Farms grow their business model as well as comply with all track and trace laws. 

About  Farms

M² Farms cultivates and sells marijuana to benefit the health and wellness of their clients. M² takes pride in providing CBD products that have various medical benefits including, but not limited to, actively relieving pain, stress, anxiety, seizures, and inflammation. https://m2farms.com/https://twitter.com/m2farms_ca https://www.instagram.com/m2_thegreenery/ https://www.facebook.com/thegreenerey/

California’s Marijuana Enforcement Tracking Reporting Compliance (METRC) requires technical expertise for growers to provide for a real-time tracking system for their cannabis inventory to comply with state law requirements. The Track-and-Trace system, or something known as “seed to sale,” is designed to track the movement of cannabis and cannabis products from the cultivator all the way to the retailer and on to the consumer. 

DeliverySwift’s technology offers the ability for delivery companies, dispensaries and growers to track their shipments in real-time and with specific ID numbers, or QR codes to any location utilizing the GPS function of the DeliverySwift platform.

M² Farms President Mario Martin stated, “We are extremely pleased to have found a single solution in DeliverySwift that keeps us compliant with all facets of California’s stringent track and trace laws. We can now confidently deliver our high-quality products knowing DeliverySwift has our back.” 

About DeliverySwift

DeliverySwift is an On-Demand logistics last mile delivery platform that acts as an intermediary between merchants and prospective buyers who wish to get products from local merchants delivered to their doorstep. DeliverySwift’s focus is direct to consumer deliveries for such products as groceries, furniture, pharmacies, Cannabis dispensaries and small bulk job site materials based on local driver transport capacities. www.deliveryswift.io

About APPSWARM

AppSwarm is a technology company specializing in the accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.

For more information, visit us at www.app-swarm.com, or follow us on www.facebook.com/AppSwarm Twitter https://twitter.com/AppSwarm and Instagram https://www.instagram.com/appswarm/

Request More Information

To receive status updates on our company we invite you to register to our investor mailing list at http://www.app-swarm.com/investors/

Forward-Looking Statements:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

AppSwarm, Inc.
888-886-8583
info@app-swarm.com

DeliverySwift Announces Beta Trials to Start Immediately With HerbSwift for Last Mile Delivery Technology

Mar 27, 2019 by OTC PR

TULSA, OK, March 27, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AppSwarm, Corp. (OTC: SWRM) is pleased to announce that it is now starting to roll out its DeliverySwift product with HerbSwift (www.herbswift.com), a new CBD delivery service in Phoenix, AZ. BETA Trials are starting immediately with full services due to roll out once both companies are pleased with a full customer experience during all phases of their transactional processes. 

AppSwarm

HerbSwift’s CEO, Michael Silvia, stated, “We are impressed with the DeliverySwift technology and the product team at AppSwarm. They have been able to get our new CBD delivery service up and running incredibly quickly. We can’t wait to start our trials and be fully operational ASAP.”

AppSwarm has created some very dynamic custom software enabling HerbSwift to be able to offer web and mobile ordering, as well as the ability to empower it to integrate the product track/trace into their existing website technology. Leading the technology development for AppSwarm, Tim Page stated, “We have been able to overcome several technology hurdles for the HerbSwift team with some custom software pieces we are sure they are going to be very happy with.”

About DeliverySwift

DeliverySwift is an On-Demand logistics last mile delivery platform that acts as an intermediary between merchants and prospective buyers who wish to get products from local merchants delivered to their doorstep. DeliverySwift’s focus is direct to consumer deliveries for such products as groceries, furniture, pharmacies, Cannabis dispensaries and small bulk job site materials based on local driver transport capacities. www.deliveryswift.io

About APPSWARM

AppSwarm is a technology company specializing in the accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs

About HerbSwift

HerbSwift is a mobile app and E-commerce platform, powered by DeliverySwift that will marry together the disruptive LEGAL Endocannabinoid System Support & Wellness industry with the mobile On-Demand Economy. Users will be able to rate, review and purchase all of the most reputable brands of Endocannabinoid Support Supplements, enjoy friction-less checkout, live-track their orders, receive their order at their doorstep same day and even schedule future orders of their supplements for themselves, friends, relatives or their pets.www.herbswift.com

For more information, visit us at www.app-swarm.com, or follow us on www.facebook.com/AppSwarm or Twitter https://twitter.com/AppSwarmhttps://deliveryswift.io/ or https://www.facebook.com/deliveryswift

Request More Information

To receive status updates on our company we invite you to register to our investor mailing list at http://www.app-swarm.com/investors/

Forward-Looking Statements:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

AppSwarm, Inc.
888-886-8583
info@app-swarm.com
Primary Logo

RJD Green Inc. Specialty Contracting Division Silex Holdings Announced the Hiring of National Sales Executive

Mar 26, 2019 by OTC PR

Tulsa, OK, March 26, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green Inc. announced the hiring of Kyle Schmidt to assist in the growth and expansion program of Silex Holdings.

RJD Green Inc

Mr. Schmidt has a success record in both the commercial and homebuilder markets in the kitchen and bath product sales. As well he has served in the roles of National Sales Manager and National Marketing Director within Silex Holding’s target markets.

Ron Brewer, CEO of RJD Green Inc., states, “Kyle is an important addition to the Silex team. His industry expertise and reputation for team building adds a key component to Silex’s continued growth and expansion. We feel Kyle’s addition solidifies the Silex team’s ability to create the required sales for the successful progression and expansion of the Silex Holding’s business platform. We continue to cautiously broaden our product base and enlarge our regional expansion in Silex Holdings.”

About RJD Green, Inc. 

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers:Earthlinc Environmental Services Division, which provides green environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. Visit http://www.rjdgreen.com

For additional information contact, Ron Brewer, CEO at ronb@rjdgreen.com, or at (918) 551-7883, or Douglass Baker, OTC PR Group at corp@otcprgroup.com or at (561) 807-6350

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

AppSwarm, Corp. (OTC: SWRM) announces it has executed an agreement with HerbSwift, an Endocannabinoid supplement company, to utilize the DeliverySwift last mile delivery technology.

Mar 6, 2019 by OTC PR

DeliverySwift Announces Agreement with HerbSwift for Last Mile Delivery Technology

AppSwarm

AppSwarm announced it had signed an agreement with HerbSwift to utilize DeliverySwift’s technology for their CBD and Endocannabinoid line of products.

HerbSwift is a mobile app and E-commerce platform, powered by DeliverySwift that will marry together the disruptive LEGAL Endocannabinoid System Support & Wellness industry with the mobile On-Demand Economy. Users will be able to rate, review and purchase all of the most reputable brands of Endocannabinoid Support Supplements, enjoy friction-less checkout, live-track their orders, receive their order at their doorstep same day and even schedule future orders of their supplements for themselves, friends, relatives or their pets. www.herbswift.com 

The U.S. Hemp Authority™ Certification Program is our industry’s initiative to provide high standards, best practices, and self-regulation, giving confidence to consumers and law enforcement that hemp products are safe and legal. The U.S. Hemp Authority™ Certification Program is an effort funded by the US Hemp Roundtable and joined by organizations such as the Hemp Industries Association, industry-leading firms, top-tier testing laboratories, and quality assessors to develop comprehensive guidance for growers and processors of hemp. www.ushempauthority.org

HerbSwift, Inc. aims to distribute only those brands that are meeting the stringent self-regulatory standards of the U.S. Hemp Authority™ and passing a third-party audit. Once these standards are met, participants will be licensed to use the Certified Seal of the U.S. Hemp Authority™ on their products beginning in early 2019.

Ron Brewer, the CEO of AppSwarm, commented, “We are very pleased to announce HerbSwift as our new partner in the cannabis distributor network. The deal with HerbSwift comes on the heels of our agreement with ‘I Heart Canna’, which is only the first of what we project will be many more cannabis distributors and dispensaries coming on to the network for the first half of 2019. DeliverySwift offers a ‘track and tracing’ technology solution for cannabis retailers and dispensaries to adhere to compliance, but also adds direct to consumer sales to their business model.”

About DeliverySwift

DeliverySwift is an On-Demand logistics last mile delivery platform that acts as an intermediary between merchants and prospective buyers who wish to get products from local merchants delivered to their doorstep. DeliverySwift’s focus is direct to consumer deliveries for such products as groceries, furniture, pharmacies, Cannabis dispensaries and small bulk job site materials based on local driver transport capacities. www.deliveryswift.io

About APPSWARM

AppSwarm is a technology company specializing in the accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.

For more information, visit us at www.app-swarm.com, or follow us on www.facebook.com/AppSwarm or Twitter https://twitter.com/AppSwarm 

Request More Information

To receive status updates on our company we invite you to register to our investor mailing list at http://www.app-swarm.com/investors/

Forward-Looking Statements:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

AppSwarm, Inc.
888-886-8583
info@app-swarm.com

Optimize your Website for the right keyphrases

Jan 23, 2019 by OTC PR

At OTC PR Group using the tools provided in the Google Search Console offers many valuable insights into your site’s performance. Optimize your Website for the right keyphrases to fix: low rankings and low click-throughs. For example: how often a page is shown, or how often people clicked on your website in Google’s search results. But, once you have a list of posts that could do better, how to decide on the next step? What’s the best strategy to improve your SEO based on Search Console data? Should you improve low ranking posts first, or low CTR posts?

Optimizing for the right keyphrases

Google Search Console offers a wealth of information for Optimizing for the right keyphrases for site owners. For instance, you can find out which pages don’t rank well or get few clicks.

We’re obsessed about #speed! Faster websites are better for users, and better for search engines. That’s why we spend a lot of time working out how to make our own site faster. It’s also why we stay on top of the latest trends in browser technology and performance techniques. Website design tips.

That’s all well and good, but while speeding up our own site, we kept hitting a bottleneck — no matter how many things we tweaked, our CSS was slowing us down.

So we thought about ways in which WordPress might handle CSS differently, and better, and we’ve come up with a new, faster approach. If you want to squeeze every last drop of performance out of your site, this might be just the thing for you!

Make sure you get the first step in SEO right!

That first step? Optimizing for the right keyphrases, of course! The keyphrases you aim to rank for should contain the words your customers use. Imagine yourself selling dresses for gala events. In your marketing, you refer to these dresses as [gala dresses]. However, Google Trends shows people do not search for [gala dress]. They search for [gown]! You won’t get much traffic if you optimize for [gala dress]. So, make sure you target the right keyphrases. 

Why is investor relations so important?

Nov 27, 2018 by OTC PR

Investors play a major and vital role in the success and growth of a company. Because of that fact, it is important for companies to maintain strong, transparent relationships with investors

Why is investor relations so important?

Why is investor relations so important?

Investors are essential to a company. It is important for businesses to communicate effectively and honestly with investors. Depending on the size and scale of a business, as well as on the number of investors the business has, an effective IR department keeps the lines of communication and information open between investors and the company.

We help companies market and position their corporate messages to the investment community. We raise awareness levels regarding your company in the minds of existing investors and prospective investors. We foster understanding and a sense of partnership between you and your investors so that they stick with you when times get tough.

At OTC PR Group we develop and extend the base of investor relationships, establishing and maintaining direct relationships between you and key institutional and retail shareholders, sell-side analysts, brokers, market makers and specialists. We work with you to achieve the appropriate investor mix.

A companies ability to attract and retain new investors is based on its ability to expose prospective and existing investors to positive messages about their company. Your base communications plan will indirectly expose investors to your key messages, but a well-crafted, targeted investor relations communications program can transform passive awareness into active investor interest, investment, and support.

We will become your “total” Public Relations firm. As a result of our extensive experience with particular client’s needs, we’ve developed programs that meet your specific goals.

Why is investor relations so important? Many growth companies have great potential but no real retail buying. We have powerful systems of investor participation throughout the world targeting not only investors… we also market to stockbrokers as well by using all the latest digital and social marketing venues available.

INVESTOR UPDATE FOR VISIUM TECHNOLOGIES, INC. (OTCPK: VISM)

Nov 14, 2018 by OTC PR

INVESTOR UPDATE FOR VISIUM TECHNOLOGIES, INC.

FAIRFAX, VA, Nov. 13, 2018 (GLOBE NEWSWIRE) — Visium Technologies, Inc. (OTCPK: VISM), (the “Company”) today released an Investor Update from the Company:

Visium Technologies, Inc
Benchmark cyber risk

In an effort to provide all of Visium’s shareholders and future investors with the most current information, Visium’s management team is providing an update to our announcement of September of 2018.

Through our acquisition of Threat Surface Solutions Group, LLC (“TSSG”) in October 2018, we now operate a world-class cybersecurity/digital risk management company that delivers comprehensive cybersecurity services which protect connected devices such as the Internet of Things, (“IoT”) and Industrial Internet of Things (“IIoT”) systems, and mitigates cybersecurity risks. Our focus is on test and measurement (“T&M”), test and evaluation (“T&E”), and the cybersecurity of software and hardware platforms.

The TSSG acquisition provides us with capabilities to secure industrial systems from external penetration and internal threats through our proprietary IoT test platform, the Cyber Automated Test Bench (“CATB”). Our patented cyber toolsets and our world-class T&M and T&E platforms provide a visualization of threats which allows for timely and effective remediation of technology risks. In addition, we are quickly becoming the industry leader in cybersecurity curriculum development and training for IoT and IIoT cybersecurity.

Our proprietary CATB platform has the unique ability to analyze up to 500,000 IoT devices and/or data flows simultaneously. TSSG uses the CATB platform alongside Visium’s patented cyber toolsets in a proprietary cyber methodology that provides state-of-the-art Network Risk Assessments and Red Team services.

These cyber services enable our customers to make cybersecurity investments and risk mitigation plans based on the objective analysis of identified vulnerabilities and the prioritization of remediation tasks that are a natural result of our cyber assessment and visualizations.

Our capabilities enable us to quantify and benchmark cyber risk which includes (but is not limited to):

A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/7bc7c485-ba5c-42c2-a8d3-c4efd81b73ff

This month we will be partnering with leading professional training and certification organizations in the US and Europe to advocate for and utilize our cybersecurity curriculum based on the latest approved ISO standards.

In addition, during this quarter, we will be engaging customers to deliver penetration testing and network risk assessment and other cybersecurity services.

In closing, we continue to focus on our accelerated growth track and remain committed to pursuing initiatives that maximize value for all Visium stakeholders.

Sincerely,

Jamie Holcombe
CEO, Visium Technologies, Inc.

About Visium Technologies, Inc.

Visium Technologies, Inc. (OTCPink: VISM) is a Florida corporation based in Fairfax, Virginia, focused on global cybersecurity, advancing technology and cybersecurity tools and services to support enterprises in protecting their most valuable assets – their data, on their networks, in the cloud, and IoT.

For more information please visit www.visiumtechnologies.com

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, whether the reverse stock split will be beneficial to the Company and its shareholders, any inability to meet the NYSE American continued listing standards in the future for any reason, and those other factors described in our filings with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.

Contact:

Visium Technologies, Inc. 
Corporate: Mark Lucky, Chief Financial Officer 
mlucky@visiumtechnologies.com

RJD Green Inc. Subsidiary, IOSoft Procures First Insurance Sector Contract to Provide Payment Services of the Unified Payment System Software Platform

Oct 30, 2018 by OTC PR

RJD Green Inc.

RJD Green Inc. (OTCPK: RJDG) TULSA, OK, Oct. 30, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green Inc. (OTCPK: RJDG) CEO, Ron Brewer, announced today the IOSoft Division of RJD Green Inc. has executed its first non-medical insurance sector contract. The contract is a private labeling agreement to provide payment services and the licensing of their recently launched Unified Payment System technology platform including Vcheck, a patent pending virtual check technology.

The Company is a twenty-year-old third party administrator with a client focus in the insurance sector. IRG Resource Group introduced and facilitated the transaction with IOSoft.

The initial implementation of services will begin in the first quarter of 2019.

After research and review, IOSoft was chosen to provide “best in class” payment technology to include its industry leading Virtual Check.

IOSoft

IOSoft provides proprietary software for medical billing, Healthcare claims adjudication, automotive warranty payments, and electronic payments between healthcare Payers and Providers, along with payment software platforms for corporations, government & institutional organizations. Since formation, IOSOFT has been a third-party developer of software and provides IT support for the platforms developed.

The primary focus of IOSoft is in healthcare payment systems where IOSoft can provide unique payment technologies and services or software that can be integrated with legacy or existing systems of healthcare payers and providers such as, major health insurance carriers and third-party administrators.  IOSoft provides targeted product offerings for healthcare providers, provider networks, physicians and hospitals; and clearinghouse companies.

About RJD Green, Inc.

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which owns IOSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers; Earthlinc Environmental Services Division, which provides green environmental services and technologies; and Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer.http://www.rjdgreen.com/

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Company Contact: 

RJD Green, Inc. 

Ron Brewer, CEO 

918.551.7883

ronb@rjdgreen.com

Visium Technologies (OTCPink: VISM) Announces Partnership with CTIA North America

Oct 26, 2018 by OTC PR

Visium Technologies

Visium Technologies, Inc. (VISM) announced  that its wholly-owned subsidiary Threat Surface Solutions Group, LLC (“TSSG”) has entered into a partnership with CTIA to Launch Program to Create Certification Requirements for Manufacturers of Managed IoT Devices

 

Fairfax VA, Oct. 26, 2018 (GLOBE NEWSWIRE) — Visium Technologies, Inc., announced today that its wholly-owned subsidiary Threat Surface Solutions Group, LLC (“TSSG”) has entered into a partnership with CTIA North America (“CTIA”) to assess and validate the CTIA Certification Program test plan for the Cybersecurity of managed Internet of Things (IoT) devices. CTIA plans to compile data from participating labs to provide the final CTIA Cybersecurity Certification requirements to all IoT manufacturers. To further strengthen TSSG’s role with CTIA, Michelle Lawson, TSSG’s Vice President of Operations has been named the Secretary of the CTIA Cybersecurity Certification Working Group.

CTIA has recently focused on IoT Cyber Security in the wake of a growing need for Cyber Security Standards and associated testing and certification. CTIA provides guidance on both functional and cybersecurity safety. CTIA is the world’s leading inspection, verification, testing and certification company.

“Having Michelle serve as the Secretary for the CTIA working group will have tremendous benefit for TSSG as we move forward with CTIA” said Kevin Anderson, TSSG’s president. “As one of their trusted experts in cyber security for IoT devices, we plan to find other ways to partner with CTIA and its member organizations. This partnership will only continue to grow as we find synergies in our Cybersecurity platform and the CTIA Cyber mission.”

About Visium Technologies, Inc.

Visium Technologies, Inc. (OTCPink: VISM), through its wholly owned subsidiary Threat Surface Solutions Group, LLC, provides innovative cybersecurity solutions to businesses to protect and secure the operating landscape of the enterprise and their data assets. Our focus is on test and measurement (T&M), test and evaluation (T&E), and cybersecurity solutions to protect connected devices (Internet of Things, or “IoT” and Industrial Internet of Things “IIoT”). This includes securing industrial systems from penetration. We do this through a proprietary IoT test platform which we call the Cyber Physical Test Bench (“CPTB”), and by visualizing and prioritizing remediation of technology risks.

For more information please visit www.visiumtechnologies.com and tssgsolutions.com

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, whether the reverse stock split will be beneficial to the Company and its shareholders, any inability to meet the NYSE American continued listing standards in the future for any reason, and those other factors described in our filings with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.

Contact:

Visium Technologies, Inc.
Corporate: Mark Lucky, Chief Financial Officer
mlucky@visiumtechnologies.com

Cybersecurity Stocks Investors Should Follow

Oct 18, 2018 by OTC PR

Cybersecurity Stocks Investors Should Follow

Cybersecurity Stocks Investors Should Follow Due to Favorable Long-Term Growth Prospects 

Cybersecurity stocks investors should follow this year are ramping up due to the start of an upgrade cycle. Many large companies are buying next-generation firewall products. Firewalls are located between private networks and the internet, and they block unauthorized traffic. Cybersecurity firms in the firewall market include Palo Alto Networks (PANW) and Fortinet (FTNT).

Many fast-growing cybersecurity firms are in the endpoint market — detecting malware on laptops, mobile phones and other devices that access corporate networks. These fast-growing cybersecurity firms focus on providing secure connections between a company’s internal business apps and authorized users that work remotely. Palo Alto, Carbon Black (CBLK) and privately held Cylance are pushing into the endpoint market vs. incumbent Symantec (SYMC).

Hackers often aim to compromise networks by targeting employees or management with administrative access to computer systems. CyberArk Software (CYBR) and other cybersecurity firms monitor and manage privileged accounts. Okta (OKTA) provides identity management services. Proofpoint (PFPT) specializes in email and data-loss protection.

Cybersecurity stocks investors should follow are some recent initial public offerings among cybersecurity firms. Cybersecurity IPOs include Carbon Black, Sailpoint Technologies (SAIL), Mimecast (MIME), Zscaler (ZS), and Tenable Holdings (TENB).

Visium Technologies, Inc. (“Visium”) (OTCPink: VISM) has also stepped into the arena with the recent  acquisition of Threat Surface Solutions Group LLC (“TSSG”). The TSSG acquisition means that Visium will provide a leading-edge portfolio of analytic and remediation tools to the expanding Internet of Things (IoT) market.

The cybersecurity sector has extremely favorable long-term growth prospects, and regulatory and technology changes provide an increasingly attractive environment for growth.

TSSG will operate as a subsidiary of Visium under the leadership of President Kevin Anderson. The combination of TSSG and their Research & Development (R&D) partners creates a unique approach to cyber solutions. TSSG is the exclusive cyber security partner in North America for the global testing conglomerate SGS-TUV. The merging of Visium/TSSG is ground breaking in the Cyber Physical approach to training, IoT/IIoT penetration testing and Network Risk Assessments.”

Visium Technologies, Inc. (OTCPink: VISM) is a Virginia based company focused on providing innovative cybersecurity solutions to businesses which protect and secure the operating landscape of the enterprise and their data assets. Our focus is on test and measurement (T&M), test and evaluation (T&E), and cybersecurity solutions to protect connected devices (Internet of Things, or “IoT” and Industrial Internet of Things “IIoT”). This includes securing industrial systems from penetration. We do this through a proprietary IoT test platform which we call the Cyber Physical Test Bench (“CPTB”), and by visualizing and prioritizing remediation of technology risks.

Threat Surface Solutions Group (TSSG) is a partnership of premier cybersecurity companies whose principals have directly encountered cyber adversaries, dissected their motivations, and thwarted their attempts to breach critical infrastructure and national security assets.

Their focus on test and measurement (T&M), test and evaluation (T&E), cybersecurity, software and hardware platforms, and risk mitigation, allows us to offer comprehensive solutions to protect connected devices such as Internet-of-things (IOT) products, and Industrial IoT (IIOT) systems from penetration; mitigating the liability of manufacturers, and protecting the consumer from possible catastrophic loss.

 

Visium Technologies, Inc. (VISM) Names New Board Member

Oct 17, 2018 by OTC PR

Visium Technologies

Visium Technologies, Inc., (VISM) Fairfax VA, Oct. 17, 2018 (GLOBE NEWSWIRE) — Visium Technologies, Inc., announced today the appointment of a new member to its Board of Directors. Dr. Emmanuel Esaka resumes his position immediately.

“We are thrilled to have Dr. Esaka’s expertise on our Board,” said Mark Lucky, Visium’s Chairman of the Board. “He brings a wealth of knowledge from the medical field as well as an entrepreneurial background and considerable management leadership skills. The rapid spread of connected medical devices has left the health care sector increasingly exposed to cyberattacks. With the growing need to provide cybersecurity to the medical field, Dr. Esaka’s addition to the board is invaluable as we enter the next phase of Visium’s global growth.”

Dr. Esaka earned an MBA from Auburn University, and graduated Cum Laude with Highest Honors from Università Degli Studi di Bologna, Italy School of Medicine and Surgery. He is the Founder, Owner, and CEO of Advanced Care Obstetrics and Gynecology PA in Wilmington, Delaware, Co-Founder and Managing Director of 3N Pharma USA, Inc., Founder and CEO of Cameroon American Health System, Inc., and Co-Founder of Caritas Home Health Services, Inc. Dr. Esaka is currently an Attending Obstetrician and Gynecologist at the Christiana Care Health System in Newark, Delaware. He also served as Attending Obstetrician and Gynecologist at Irwin Army Community Hospital in Fort Riley, Kansas. He serves as a Board Director of Meiger Health, Inc.

The Visium board moves from three to four members.

About Visium Technologies, Inc.

Visium Technologies, Inc. (OTCPink: VISM) is a Virginia based company focused on providing innovative cybersecurity solutions to businesses which protect and secure the operating landscape of the enterprise and their data assets. Our focus is on test and measurement (T&M), test and evaluation (T&E), and cybersecurity solutions to protect connected devices (Internet of Things, or “IoT” and Industrial Internet of Things “IIoT”). This includes securing industrial systems from penetration. We do this through a proprietary IoT test platform which we call the Cyber Physical Test Bench (“CPTB”), and by visualizing and prioritizing remediation of technology risks.

For more information please visit https://visiumtechnologies.com/ and https://tssgsolutions.com/

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, whether the reverse stock split will be beneficial to the Company and its shareholders, any inability to meet the NYSE American continued listing standards in the future for any reason, and those other factors described in our filings with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.

Contact:

Visium Technologies, Inc. 
Corporate: Mark Lucky, Chief Financial Officer 
mlucky@visiumtechnologies.com

VISIUM TECHNOLOGIES (OTCPink: VISM) ANNOUNCES CLOSING OF THREAT SURFACE SOLUTIONS GROUP TRANSACTION

Oct 16, 2018 by OTC PR

Visium Technologies

Visium Technologies Announces Launch of Cybersecurity Training Initiative; 
Set to Generate Immediate Revenue from IoT Security Testing

Fairfax VA, Oct. 16, 2018 (GLOBE NEWSWIRE) — Visium Technologies, Inc. (“Visium”) (OTCPink: VISM) announced today that it has completed the acquisition of Threat Surface Solutions Group LLC (“TSSG”). The TSSG acquisition means that Visium will provide a leading-edge portfolio of analytic and remediation tools to the expanding Internet of Things (IoT) market.

“Now that we have finalized this acquisition, we will immediately begin delivering solutions to our customers, both here in the US and in Europe. Our initial revenue will come from customers who are looking for both IoT penetration testing services, as well as from network risk assessment services,” said Jamie Holcombe, CEO of Visium.

“In addition, we have an extraordinarily talented team of cybersecurity experts that have developed cybersecurity training curricula that are in high demand world-wide. We will deliver cybersecurity training curricula and services to key international customers beginning this month. We anticipate recognizing as much as $500,000 in revenue in our fiscal 2nd quarter ending December 31, 2018, and an estimated $3 million in revenue for the full fiscal year ending June 30, 2019”.

The cybersecurity sector has extremely favorable long-term growth prospects, and regulatory and technology changes provide an increasingly attractive environment for growth. With the cybersecurity industry projected to grow from $153BB in 2018 to $250BB by 2022, it is safe to say that Visium has positioned itself for accelerated growth in an extremely attractive sector.

TSSG will operate as a subsidiary of Visium under the leadership of President Kevin Anderson, who added “Our recent acquisition by Visium Technologies represents a significant paradigm shift in the cybersecurity ecosystem. The combination of TSSG and their Research & Development (R&D) partners creates a unique approach to cyber solutions. TSSG is the exclusive cyber security partner in North America for the global testing conglomerate SGS-TUV. The merging of Visium/TSSG is ground breaking in the Cyber Physical approach to training, IoT/IIoT penetration testing and Network Risk Assessments.”

About Visium Technologies, Inc.

Visium Technologies, Inc. (OTCPink: VISM) is a Virginia based company focused on providing innovative cybersecurity solutions to businesses which protect and secure the operating landscape of the enterprise and their data assets. Our focus is on test and measurement (T&M), test and evaluation (T&E), and cybersecurity solutions to protect connected devices (Internet of Things, or “IoT” and Industrial Internet of Things “IIoT”). This includes securing industrial systems from penetration. We do this through a proprietary IoT test platform which we call the Cyber Physical Test Bench (“CPTB”), and by visualizing and prioritizing remediation of technology risks.

For more information please visit www.visiumtechnologies.com and tssgsolutions.com

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, whether the reverse stock split will be beneficial to the Company and its shareholders, any inability to meet the NYSE American continued listing standards in the future for any reason, and those other factors described in our filings with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.

Contact:

Company:
Visium Technologies, Inc. 
Corporate: Mark Lucky, Chief Financial Officer 
mlucky@visiumtechnologies.com

RJD Green (OTCPK: RJDG) Announced the Silex Holdings Divisions Symmetrical Acquisition Discussions

Sep 26, 2018 by OTC PR

RJD Green Inc.

RJD Green TULSA, OK, Sept. 26, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green (OTCPK: RJDG) announced the Silex Holdings Division’s Symmetrical Acquisition Discussions.

RJD Green Inc. announced Silex Holdings has entered into a Memorandum of Understanding with a well-established cabinet manufacturer in the Mid-West United States market. The agreement calls for initial due diligence and binding Letter of Intent completion by November 30, 2018, and a targeted closing of sixty days post execution of the letter of intent.

Ron Brewer, CEO of RJD Green Inc., states, “The two companies offer an excellent fit with additional cabinet distribution revenues offered by Silex Holdings, and increased profitability to Silex in their cabinet revenues. The initial projections by the companies reflect a ten percent increase in profitability. Upon consummation of this acquisition, the Silex Holdings Division total annual revenue would be over $10,000,000 annually prior to the organic revenue growth expected.”

About RJD Green, Inc. 

The Company operates as a holding company with a focus of acquiring and managing assets and companies with tangible growth capabilities. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers: Earthlinc Environmental Services Division, which provides green environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. Visit http://www.rjdgreen.com.

Forward-looking Statement: 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings.

Company Contact: 

RJD Green, Inc. 

Ron Brewer, CEO 

918.551.7883

ronb@rjdgreen.com

RJD Green Inc. (RJDG) Subsidiary, IOSoft, Procures Private Label Contract to Provide Payment Services and Licensing of the Unified Payment System Software Platform to a North American Metals Provider

Sep 4, 2018 by OTC PR

RJD Green

RJD Green Inc., TULSA, OK, Sept. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – RJD Green Inc. (OTCPK: RJDG) CEO, Ron Brewer, announced today the IOSoft Division of RJD Green Inc. has reached a private labeling agreement to provide payment services and the licensing of their recently launched Unified Payment System technology platform.

The Company procures metals internationally and configures products for clients throughout the Unites States and Canada from three locations in the United States. Revenues of the Group are over $200,000,000.

The stated implementation date of the agreement is stated no later than a ninety-day period of August 27, 2018 with a projected beta testing period of sixty days.

After extensive of research and development, IOSOFT was chosen to provide “best in class” payment technology to include its industry leading Virtual Check.

IOSoft

IOSoft provides proprietary software for medical billing, Healthcare claims adjudication, automotive warranty payments, and electronic payments between healthcare Payers and Providers, along with payment software platforms for corporations, government & institutional organizations. Since formation, IOSoft has been a third-party developer of software and provides IT support for the platforms developed.

The primary focus of IOSoft is in healthcare payment systems where IOSoft can provide unique payment technologies and services or software that can be integrated with legacy or existing systems of healthcare payers and providers such as, Blue Cross, Aetna, CIGNA and others.  IOSoft provides targeted product offerings for healthcare providers, provider networks, physicians and hospitals; and clearinghouse companies.

About RJD Green, Inc.

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which owns IOSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers; Earthlinc Environmental Services Division, which provides green environmental services and technologies; and Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer.

Forward-looking Statement:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Company Contact:

RJD Green, Inc.
Ron Brewer, CEO
918.551.7883
ronb@rjdgreen.com

SEO is important for Public Companies

Aug 9, 2018 by OTC PR

SEO is important for Public Companies

SEO is important for public companies for many reasons and in today’s competitive market, SEO marketing is more important than ever.

Search engines serve millions of users per day looking for answers to their questions or solutions to their problems. A properly executed SEO investor relation optimization program can help public companies develop and maintain market value. Without a doubt SEO is important for public companies!

Search engine optimization is essential because:

  • The majority of search engines users are more likely to click on one of the top 5 suggestions in the results pages (SERPS), so to take advantage of this and attract potential investors, analysts and journalists to your web site you need to be in the top positions.

 

  • SEO is not only about search engines but good SEO practices improve the user experience and usability of a web site.

 

  • Users trust search engines and having a presence in the top positions for the keywords the user is searching, increases the web site’s trust.

 

  • SEO is important for public companies because it is good for the social promotion of your web site. People who find your web site by searching Google or Yahoo are more likely to promote it on Facebook, Twitter, Google+ or other social media channels.

 

  • SEO is important for public companies because the smooth running of a big web site. Web sites with more than one author can benefit from SEO in a direct and indirect way. Their direct benefit is increase in search engine traffic and their indirect benefit is having a common framework (checklists) to use before publishing content on the site.

 

  • SEO can put you ahead of the competition. If two web sites are selling the same thing, the search engine optimized web site is more likely to have more customers and make more sales and investor exposure.

Everyone has their own opinion on what makes a “Great Investor Relations Website”, keeping up with regulations and disclosure is always top of the list.  But without good SEO practices you will not be able to attract new clients and potential investors. SEO is a must for every web property.

To sum it up, Search engine optimization or SEO is a way to optimize your website so that search engines will understand it better and give you higher rankings. It’s not just the general public that locates you on the web to keep in mind; you must consider potential investors, current shareholders, analysts and journalists. This is where working with an experienced IR firm can make this difficult job much easier.

At OTC PR Group we provide a full suite of investor relation’s services utilizing the latest web and SEO solutions coupled with relationship building processes to develop and maintain interest from your shareholder base. We work to build shareholder value by engaging with key-stakeholders and effectively following up and communicating your message, investment potential and corporate vision.

SEO is important for Public Companies

 

Investor relations is all about grabbing attention and creating an audience.  OTC PR Group networks with only the “Top Rated” service providers and advertising partners, which include our In house and external newsletter publishers, social media specialist, editors, analysts, research writers, and video talk show producers, are utilized in our corporate outreach visibility programs.

Working closely with our clients and professional network partners in conjunction with our newsletter publishing sites we can create and implement marketing and advertising programs that deliver high impact exposure campaigns.

RJD Green Inc. Announces Commercial Contract Awarded To Their Silex Holdings Division

Aug 7, 2018 by OTC PR

RJD Green

RJD Green-TULSA, OK, Aug. 07, 2018 (GLOBE NEWSWIRE) — RJD Green (OTCPK: RJDG), announced a contract for cabinets and counter tops has been awarded to the Silex Holdings division for $265,000.

RJD Green Inc. announced the awarding of the contract for countertops and cabinets on a north Dallas loft project with The Equitas Group. The contract is to be completed in the second quarter 2019.

Ron Brewer, CEO of RJD Green Inc., states, “The continued commercial contracts awarded Silex are expanding the 2019 backlog and adds to Silex’s commercial division’s continued growth and geographic expansion.”

About RJD Green, Inc.

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which holds interest in IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers:Earthlinc Environmental Services Division, which provides green environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. Visit http://www.rjdgreen.com.

Forward-looking Statement:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings.

Company Contact:

RJD Green, Inc.

Ron Brewer, CEO

918.551.7883

ronb@rjdgreen.com

How Site Speed Influences SEO

Jul 27, 2018 by OTC PR

When trying to get exposure and gain investor attention it’s crucial that you maintain your web presence. Site Speed Influences SEO. Performing Site speed SEO optimization practices is more important than ever!

 

Site Speed Influences SEO and Google has said time and again that a fast website helps you rank better. Recently, Google launched the  ‘Speed Update’ making site speed a ranking factor for mobile searches. Google stressed it would only affect the slowest sites and that fast sites getting faster won’t get a boost, but they are surely looking at site speed across the internet.

For now the slowest sites take the hit, but what about the future?

Site Speed Influences SEO

New articles are published almost daily, telling us that optimizing for speed is one of the most important things you can do right now. And they’re right, of course! Site speed influences SEO in many ways. Here’s a small overview of how site speed and SEO go together.

If you don’t put in a lot of effort to make sure that your site works well there will be a significant drop-off and a lot fewer people will visit your site. It’s important to have great structure that includes fabulous targeted and relevant content. You need the first experience your potential visitor/investor/consumer has with your site to be flawless. They need to load your site first before they can access company content. If it takes ages to load,  A much faster competitor is just a single click away. Site Speed Influences SEO and not investing in a fast site is almost like you don’t care about your corporate image. No reason for them to stay, right?

On mobile, site speed is even more of an issue. According to research by Google, the average mobile site takes over fifteen seconds to load while people expect them to load in less than three seconds before they consider leaving altogether. Every second counts, as conversions drop sharply with every second longer, your site takes to load.

OTC PR Group founders utilize over 25 years of experience in managing awareness campaigns. We understand that SEO optimization, increasing investor recognition, as well as broker awareness through network advertising, can be an extremely daunting task. Having a properly coordinated marketing plan can provide a positive impact and accelerate trading activity, brand and investor awareness.

We use our knowledge of the markets and industry to provide our clients with a better understanding on how to approach their marketing decisions. Your goals are our goals, which is why OTC PR engages in a true partnership with our clients. OTC PR has worked with a diverse group of talented and respected professionals whom have joined forces with us in order to create a cost effective advertising network dedicated to publicly traded Companies.

 

 

 

What can internal linking do for your website?

Jun 29, 2018 by OTC PR

internal linking

You’re cheating yourself if you’re not spending some effort on internal linking, this is one of the most important ways to optimize your pages!

If you have interesting content, your visitor wants to read it and you should help them get there. Also, internal links make for a better site structure, which we know improves crawlability. A win-win situation!

Internal linking is one of the most important ways to optimize your pages. Internal links contribute to a better site structure, easier crawling, and indexing of your pages, and might increase your time-on-site in Google Analytics. It’s a way to point Google to your main pages about a topic.

SEO is a marketing discipline focused on growing visibility in organic (non-paid) search engine results. SEO encompasses both the technical and creative elements required to improve rankings, drive traffic, and increase awareness in search engines. There are many aspects to SEO, from the words on your page to the way other sites Link to you on the web. Sometimes SEO is simply a matter of making sure your site is structured in a way that search engines understand.

SEO isn’t just about building search engine-friendly websites. It’s about making your site better for people too. At OTC PR Group Inc. we believe these principles go hand-in-hand.

OTC PR Group not only knows exactly how to use SEO to enhance an investor relations platform, we’re constantly tracking the progression and adapting our strategies to our clients’ advantage.

Internal linking is one of the many ways to optimize your pages. We use extensive arrays of SEO solutions to make sure our clients are rapidly, accurately and powerfully presented to the public and company shareholders.

OTC PR Group is an investor relations firm specializing in comprehensive programs for micro-cap, small-cap and mid-cap public companies increase stock visibility in a range of industries. We combine knowledge of capital markets communications, and an unparalleled reputation for integrity and client service with evolving industry best practices to design and execute investor relations programs that help deliver long-term shareholder value. Read more.

AppSwarm Begins Development of The Mad Gambler Sports Betting App

Jun 6, 2018 by OTC PR

AppSwarm

TULSA, Okla., June 06, 2018 (GLOBE NEWSWIRE) — AppSwarm, Inc. (OTC Pink: SWRM), a technology company specializing in the accelerated development and publishing of mobile apps, announces it has commenced the development of its new sports betting and social community app “The Mad Gambler.”

The recent US Supreme Court decision striking down the Federal ban on sports betting has now opened the door for AppSwarm to develop its first sports betting related app called “The Mad Gambler.”

The Mad Gambler sports betting and community app will offer a platform for sports fans to interact and discuss upcoming games, who they like based on points, and real-time discussions as games are in progress.

Revenue Model

The app’s V.I.P. section, for a monthly paid subscription of $4.99, will offer exclusive content such as outlooks for the best bets that week, game projections, and the ability for users to build their own following based on their picks, and betting history. The Mad Gambler will look to partner with other gaming companies to provide their insight, outlook on particular games, and additional gaming content right to our paid subscribers’ smartphones.

In addition to advertising sponsorships, the app will also link to a number of licensed gaming and betting affiliate programs to add alternative revenue streams as user engagement increases.

Expansion to Other Gaming Platforms

The Mad Gambler, based on its very name, does not have to be specific to sports alone. In the future, based on potential changes in current laws, the app can offer access to other gaming content and affiliates such as online casinos, horse racing, and other gaming products.

The Mad Gambler app is a social community where amateur and professional gamblers can gather to discuss and exchange ideas on upcoming sports games, and is NOT directly involved with gambling or betting in accordance to applicable state and federal laws.

The Company programmers have already begun the initial phase of development and we hope to have further updates on this unique app shortly.

Register for Updates

To receive status updates on this application under development, we invite you to register to our investor mailing list at www.themadgambler.com

About APPSWARM:

AppSwarm is a technology company specializing in the accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.

For more information, visit us at www.app-swarm.com, or follow us on www.facebook.com/AppSwarm or Twitter https://twitter.com/AppSwarm

Forward-Looking Statements:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

RJD Green Inc. Announces the Initial Contract of the WellBen Joint Venture for $240,000

Jun 4, 2018 by OTC PR

RJD Green Inc.

TULSA, OK, May 30, 2018 (GLOBE NEWSWIRE) — RJD Green (OTCPK: RJDG), announced the WellBen joint venture received its initial contract of $240,000 in annual services. The joint venture launched in March is focused in delivery of health and wellness benefit programs.

RJD Green Inc. announced the initial contact of their joint venture with WellBen Group, a certified counselors group, offering health and wellness programs. WellBen, as a service organization, creates customized wellness programs that are designed to uniquely achieve best outcomes for both the employee and employer while meeting all the employer’s needs and expectations.

RJD Green and WellBen are launching the mutual marketing of products and services offered by the combined companies.

Initial RJD Green offerings are the products and services of IoSoft Inc. IoSoft offers innovative and proprietary payment processing platforms for firms with 100 employees to 1,00,000 employees.

Ron Brewer, CEO of RJD Green Inc. states, “We feel the WellBen Group is doing an excellent job of launching their comprehensive regional to national marketing and business development program. They are bringing forward multiple business opportunities to explore as the joint venture is launched.”

Jeff Bebee, WellBen Group President stated, “We are pleased with our reception and interest from municipalities and business corporations in launching. We are also creating market awareness of RJD Green’s IoSoft payment platform of services for businesses in multiple sectors.”

Both IoSoft Inc. and WellBen Group offer a platform of services and products that are unique to their fields of endeavor, yet are soliciting client contacts with common needs of both company’s offerings.

WellBen’s market focus is municipalities and government agencies, along with business owners with 100 employees to corporations with 1,000,000 employees. This gives IoSoft potential market penetration in markets we have not entered yet. The same principle applies for WellBen as they have no marketing presence in health services, which is IoSoft’s focus in launching its unique payment processing platforms.

About RJD Green, Inc., 

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which owns IoSoft Inc, a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers: Earthlinc Environmental Services Division, which provides green environmental services and technologies; Silex Holdings Division, which is engaged in specialty construction and industrial manufacturing and fills a market niche between the Home Depots and local contractors. Silex offers installed granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and retail customer. Visit http://www.rjdgreen.com.

Forward-looking Statement:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

AppSwarm Announces Launch of New Features to its Cryptocurrency Tracking App

Jun 4, 2018 by OTC PR

AppSwarm

TULSA, OK., May 30, 2018 (GLOBE NEWSWIRE) — AppSwarm, Inc. (OTC Pink: SWRM), – a technology company specializing in the accelerated development and publishing of mobile apps, is pleased to announce new features have been added to its ‘Bitchart’ cryptocurrency tracking app.

The Company is pleased to announce it has received approval from Apple’s iTunes for the addition of new features to its Bitcoin tracking app ‘BitChart’ 1.1.

New Features 

The updated app has now added quotes and charts for the following coins.

– Bitcoin
– Litcoin
– Ethereum
– Ripple
– ZCash
– Dash
– Monero
– Cardano
– Stellar
– IOTA

News Feed 

BitChart has also added an in-app newsfeed, which will provide market updates such as most active, percentage winners and losers, what’s trending, research analysis, featured interviews, and much more.

Portfolio Tracking Wallet

The app has now added a wallet where users can add their coins, or just build a portfolio to track the value of their coin holdings on their phone. Now with the enhanced features, the Company will embark on forming new strategic partnerships to help build content and increase user acquisitions within the cryptocurrency community. To download the app please visit the Apple Store here: https://itunes.apple.com/us/app/bitchart-bitcoin-analytics/id1327581647?ls=1&mt=8

Sports Betting Application

The recent US Supreme Court decision striking down the Federal ban on sports betting now opens the door for AppSwarm to explore a host of new mobile ideas geared towards sports and sports betting. The Company is excited to announce it will be developing a smartphone app geared towards the sports, and sports betting arena.

The sports betting app will offer a platform for sports fans to interact and discuss current and upcoming games, who they like based on points, and real-time discussions as games are in progress. V.I.P. members, for $4.99 a month, will have access to exclusive content, analysis, projections for best bets, and ability for users to build their own following based on their picks, and betting history.

More details on this sports betting project, such as time frame and marketing plans, are expected sometime in late June of 2018.

To be added to the AppSwarm email distribution list, please register at: http://www.app-swarm.com/investors/

About APPSWARM:

AppSwarm is a technology company specializing in the accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.

For more information, visit us at www.app-swarm.com, or follow us on www.facebook.com/AppSwarm or Twitter https://twitter.com/AppSwarm

Forward-Looking Statements:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

IR Firms insights to the importance of having a Mobile Friendly site

Mar 20, 2018 by OTC PR

IR Firms mobile friendly sites

When evaluating different IR firms, ask yourself, Does the IR firm have all the skill sets I need? Does it have the experience and people to get the job done? Consider IR Firms that understand the Power of the Internet.

Investors are increasingly dependent on the Internet as a primary source of information about the financial markets and their investments. Good communication with your investors includes a well developed website that satisfies their information needs.

In 2015 Google announced a new update which included the performance of websites on mobile devices as a ranking factor.

In the SEO world this update is known as ‘Mobilegeddon’. The consequences of this update are rather simple: if your website isn’t deemed mobile friendly, it won’t rank well in mobile search results. 50-60% of searches are conducted on a mobile device. With that number rising every year, not ranking well in those search results means you’re not ranking well for the majority of investors searching for ideas.

An investment profile that is mobile friendly is one of the most important facets of your company’s investor relations program. It is your company’s face to investors. For many emerging companies, the investment profile created by the IR firm is the only profile on the company available to investors.

Check whether or not your site is mobile-friendly using these simple tools.

Google made a complete guide to mobile-friendly sites.

There’s also mobile-friendly test,

Which will give you either of these responses:

 If your website isn’t shown in the mobile results, People who searched for one of your keywords on their mobile devices won’t be able to click on your site. Your total CTR will therefore decrease. Also: if 50% of searches happen on mobile devices, it’s a major discovery method. People can only share URLs or link to them when they’ve actually found your site. This ties back to rankings, so this will impact desktop search quite heavily in the long run.

And when you get the message that your page is not mobile-friendly, they’ll obviously also tell you why not. If your website is not mobile-friendly according to this test, you really have to evaluate your IR Firms credentials.

At OTC PR Group we can provide a regularly updated mobile friendly website with information about your company that will significantly expand the reach of your story. The websites of effective IR firms attract the attention and help gain the confidence of investors, analysts, fund managers, brokers, market makers and others. Make sure the company you choose has a website strategy that will work for you.

 

Attract Brokers and Venture Capital

Oct 30, 2017 by OTC PR

Attract Brokers and Venture Capital.

We specialize in targeting qualified stockbrokers and investors who are actively seeking small cap investment opportunities.

Our clientele are Public Companies, like you who are making a real effort to attract brokers and venture capital and broaden their shareholder base with Real Retail Buying?

The pace at which your company develops – and even your ultimate success – can hinge on your availability of capital, costs and on-going capital. We maintain relationships with many private investors as well as institutional sources for capital. In addition to presenting your company with sources, we provide an analysis of the benefits and risks that underline different finance options.

Want to Get a VC’s Attention? Make Sure You Do These 6 Things.

 

There are over 100,000 publicly traded companies in the world. In the US, less than 4000 companies are actively traded in NYSE or Nasdaq. There are another 15000 stocks that are traded over the counter. The majority of them are thinly traded. When the time comes to make an investment, stockbrokers and investors alike are swamped with decisions, choices and alternatives. Your company is lost in the shuffle – just another needle in the haystack, unless brokers and investors are familiar with your company’s name and business. The only way to build that familiarity is to put your company’s name, story and pertinent information in front of targeted brokers as often as possible. A well-organized, professional Investor Relations and Broker Network Program can help build the familiarity your company needs in order to get its share of attention in today’s competitive markets and increase the liquidity in your company stock.

OTC PR Group can reach qualified and targeted stockbrokers for your company. Our experience has shown that a properly coordinated out reach program can attract brokers and venture capital. We have integrity and a high-quality database of stockbrokers and VC Groups who we are able to target for your company.

How to increase shareholder value when stock price is overvalued

Aug 30, 2017 by OTC PR

Increase Shareholder Value.

We all know that stocks are sometimes undervalued or for the fortunate sometimes overvalued. 

In most cases this can be due to general market conditions, such as a trending industry sector. If you are lucky enough to be in an industry that is in the news the positive side can be enormous.

Nothing motivates investors to buy a stock more than a rising share price. Such situations can become self-fulfilling prophecies when a rising stock price attracts more investors, who are willing to pay more for the stock. Momentum traders buy stocks simply on the assumption that once an uptrend starts, it is likely to continue.

Most CEOs or CFOs ever admit their share price is too high — at least not to the public. This obsession with seeing your company shares as “cheap” can lead to some unfortunate corporate actions. 

Given all the time corporate executives spend generating investor interest in their stock, it would be very hard for them to ever see, much less say, their stock is overvalued. 

First and foremost is the desire to buy back shares at the peak of the market.  In the peak stock market year of 2007, many members of the S&P 500 index bought back billions worth of their own stock, which was much more stock than they repurchased in 2009 when the S&P 500 index hit their lows.

The problem of course is that investors used the same approach, however, undervalued most stocks were during the credit crisis of 2009.  The problem is often recognizing this at the time.  Overvaluation or undervaluation can also be applied to an industry or individual company that is running hot or cold.

It’s troubling that even when the overall market is hot, most senior executives tend to believe their own stock is undervalued.  This mindset is often reinforced by investment bankers who won’t even use the term “overvalued,” preferring instead to refer to companies using terms such as “fully valued.”

If you are fortunate enough to have a share price that is overvalued now is the time to “strike the match”  following these four actions can increase shareholder value when the share price is high. 

  1. Issue Shares. This might be a good time to reduce leverage below the long-term target to build in a cushion to soften the next downturn. This can also help build the financing capacity needed to make opportunistic acquisitions when stocks again become undervalued in bad times. As a general rule, it is better to have more leverage during an up-cycle to increase the share-price appreciation and to have less leverage during a downturn to dampen the decline.

But be careful, since investors may react negatively in the short term, it’s crucial that management have a disciplined process of making only investments that truly create value.

  1. Issue Convertible Debt. For managements concerns that they cannot convince investors of the merits of stock issuance, issuing convertible debt is a good way to at least take some advantage of an unusually high share price.

When stock prices are at cyclical peaks, they are less likely to rise in the coming years and so convertible debt is less likely to convert — making this a attractive form of financing when stock prices are high.

  1. Use Your Stock to Make Acquisitions. Cash acquisitions usually don’t create value at the top of the stock market cycle. In many cases exchanging your companies overvalued stock for the stock of the acquired company mitigates the risk of overpaying. 

This strategy can lead a company that believes they are particularly overvalued to actually seek acquisitions to take advantage of the high-valued currency their shares represent.

  1. Avoid Buybacks. Companies that buy back stock when the price is high earn much lower returns on their buybacks than those that buy when the price is low.  Refraining from share repurchases should go without saying. But it’s worth repeating that most companies should avoid the temptation to buy back stock when the market is high. 

Always assess your valuation and maintain objectivity. If the company appears overvalued or undervalued, make sure to take strategic actions. At OTC PR Group we can help you capitalize on any given condition and help increase shareholder value.

Build a Social Media Marketing Blog for Investors

Jun 13, 2017 by OTC PR

If you think about the ways people find your company it will become very clear that blogging can provide a effective strategy to increase traffic and investor awareness. Learn How to Build a Social Media Marketing Blog for Investors.

Learn How to Build a Social Media Marketing Blog for Investors
Learn How to Build a Social Media Marketing Blog for Investors.

Are you using your blog for business?

Wondering how to combine blog posts with social media content to increase shareholder awareness?

In this article, you’ll discover how to use blog posts to create social media content at every stage of your marketing funnel.

#1: Define Your Marketing Goal

At OTC PR Group we know that creating a social media marketing funnel is directly tied to your marketing goals. To begin, think of one marketing goal you want to accomplish. Beginning with a single short-term goal is much easier than tackling long-term goals. Also, choose a realistic, measurable goal so you can identify whether you’ve reached it.

Here are a few examples of goals that would make a great starting point for a social media marketing funnel:

  • If you’re launching a new business or acquisition, aim for a specific number of blog posts describing new business and the positive aspects of that sector.
  • If you’re reaching out to new investors, focus on making a certain number of press or company updates for your first quarter of business.
  • If you want to grow your email subscriber list, concentrate on increasing your rate of new subscribers from 8% per week to 10% per week.

#2: Publish Six Blog Posts to Create a Funnel to Support the Stake Holder Journey

After you identify your goal, you want to ensure you publish content that leads people toward that goal. To do that effectively, your content must cater to people at different stages in the funnel. For each stage, write two blog posts that support your goal at each stage: awareness, trust, and conversion.

Stage 1: Blog Posts That Create Awareness

To create awareness, think about blog posts that would attract new people to your brand and demonstrate what you can offer. Also, if your blog posts give people a quick-fix solution to a problem, you’ll earn enough trust for them to hang around and learn more.

In this first stage of the exposure process, these types of blog posts work well:

  • Top resources post: Share your best resources with your audience.
  • Product and guides: Share about and rank products and/or services that suit a specific purpose.
  • How-to posts: Present a problem and demonstrate a solution (or many solutions) to that problem.
  • Question-and-answer posts: Write a post in Q&A format to answer your readers’ burning questions about a product.

Stage 2: Your Prospect Wants to Know, Like, and Trust You

At this stage, the word “want” is important. Marketers often assume that loyalty is hard-won. However, when you help people, they naturally want to like and trust you. Your prospect becomes eager to learn more and figure out if you can help. The higher the price tag, the more content you’ll need at this stage.

Here are five blog post types that work well for building trust, like-ability, and loyalty:

  • Customer case studies: Share a customer’s experience to show readers how your business helped that customer.
  • Expert interviews: You might ask an expert to give insight into an issue that’s relevant to your readers.
  • Inspirational and motivational stories: Tell a personal story to motivate and inspire your readers.
  • Opinion pieces: Persuade readers to consider an alternative point of view by challenging conventional wisdom on an issue.
  • Research breakdown: Analyze the takeaways from several current surveys or studies about a trend in your industry. Or summarize an industry report to help your readers understand how the information may affect them.

Stage 3: Your Prospects Are Warm and Ready to Take the Relationship Further

Conversion doesn’t necessarily mean asking for the sale. To illustrate, you might ask the reader to subscribe to your email newsletter so you can nurture the sale via email. However, it’s a myth that blog posts should never contain sales information.

When you’re in business, you’re supposed to ask for the sale. It’s absolutely okay and necessary for you to tell your potential customers how you can help them and why they should buy from you. Focus on attracting and nurturing relationships 80% of the time, but you can focus on conversions with the other 20%.

Here are three types of blog posts that work well for conversions:

  • Call the reader to action: Run a challenge that motivates your readers to take action. You can organize a formal challenge where readers must sign up to participate or an informal challenge designed to foster a sense of community.
  • Invite the reader to enter a competition/giveaway: Promote a product or service by enticing readers to enter a competition by writing no more than 25 words about a given topic.
  • Launch a new product or service: Write a blog post announcing a new product and explain how the product helps your customers.

#3: Re-purpose Published Blog Posts to Create Social Media Marketing Collateral

After your six blog posts are published, break your posts down into smaller chunks you can use on social media. Create graphics, videos, and so on to support each piece of content as you roll it out.

Because you’ve started with blog posts, you can easily re-purpose the content in other formats for use on Facebook, Instagram, LinkedIn, Twitter, and other channels.

From content in each example blog post, you can create social media content chunks such as the following:

  • Why I dropped everything to found a tech startup: Behind-the-scenes video, inspirational quote graphics
  • Create your content calendar in 7 days – Join the challenge: Lead generation ad with downloadable document, live video Q&A for each day of the challenge, Facebook group for challenge participants
  • Small beginnings: Our content tech experiment has begun: Conversion ad with a call to action to purchase, recorded video that demonstrates the product, infographic that shows the product’s value

Creating the Right Amount of Content for Your Prospects

Depending on your product, prospects may take their time to make a purchase, especially if what you’re selling is at a higher price point. In that case, it helps to allow a longer lead time in your marketing campaigns. Your audience’s tolerance for information frequency will determine your lead time.

Conclusion

When you build a social media marketing funnel that supports a goal, you create more targeted and relevant content on both your blog and social media. Also, you can easily re-purpose your blog posts for your social media marketing.

Remember to create content for each stage of the shareholder journey and adjust how much content you post based on your knowledge of your product and audience.

This demonstrates the scalability of business blogging. While you might not see immediate results, over time, you’ll be able to count on a predictable amount of traffic and leads for your business without any additional resource investment — the work to generate that traffic and those leads is already done. There are other reasons businesses might want to blog, they also become great outlets through with marketers can communicate other PR-type important information — things like product releases or event information and press releases. It’s certainly easier to get attention for more company-focused initiatives if you’ve built up your own audience on your own WEBSITE, as opposed to pitching your story to journalists and hoping one of them bites. These are all great side effects or uses of a business blog that must be implemented to ensure an effective marketing and shareholder outreach campaign.

OTC PR Group is a complete financial public relations firm. Our unique and persistent market exposure techniques have consistently motivated the investor/brokerage community to take action on our clients’ stock offerings.

We Deliver Your Message

We will become your “total” Public Relations firm. As a result of our extensive experience with particular client’s needs, we’ve developed programs that meet your specific goals.

Our program affords you the greatest coverage in developing stock support and higher market capitalization utilizing the largest and most popular database providers in the industry who can take positions in your company stock.

These services have proven to help create and maintain strong relationships with a corporation’s investor base, resulting in strong valuations in the marketplace and the establishment of leadership positions for our clients.

Let us  help bring your company to the forefront of the investment community.

For more information on our services contact us today at  561-807-6350

Email: corp@otcprgroup.com

Good web design helps investor exposure!

Mar 9, 2017 by OTC PR

According to Econsultancy, “88% of online consumers are less likely to return to a site after a bad experience” and this explains why brands invest big in UX design. Once you frustrate a user, they’re probably gone for life – and that’s a lead you’ll never get back again. This really hurts your profit margins when you’ve worked so hard to get each of these visitors to your site.

Good web design helps investor exposure.

Good web design helps investor exposure

Which mistakes annoy users the most?

Web designers and developers have come up with thousands of ways to annoy users over the years, but here are some frustrations that really stand out, even today:

Slow loading times: Almost half of users leave a site that doesn’t load within two seconds. Poor navigation: If users can’t find their way around your site, you’ve already lost them. Shoddy mobile experience: Despite all the talk about mobile optimisation, too many sites fail to deliver for users on the go. Annoying popups: There’s a reason ad blocking has become such a thing – take the hint. Complex forms: People don’t like giving away personal information and they certainly don’t like filling out forms more than once because of an error. Checkout problems: Making it difficult for people to hand over their hard-earned cash is never a good idea.

What is UX and how can it help my business?

UX design is one of those topics you can’t ignore as a marketer because it has deep roots in everything you do for an online brand. It’s something you and everyone in your team must understand, even if you’re not experts in the field. So what exactly is UX and why is it important to every business?

This is the question we’ll be answering today so there’s no more confusion about the role of UX design in marketing.

What is UX design?

At its most basic, UX design simply stands for user experience design, but what do we really mean when we say ‘user experience’?

When a user lands on a website or opens an app, they’re locked into that platform for a certain period of time. Everything that happens during this session builds a mental experience in that user’s mind about the platform and the brand it represents.

The role of UX design is to ensure this experience is a positive one.

What makes a good user experience?

The answer to this question depends on the kind of platform you intend to design/market and the users it’s targeting. The concept of a ‘good’ user experience can vary from one person to another – and this is why it’s so important to test and tweak your designs over time.

That said, there are a number of key factors in creating a user experience that maximises your marketing efforts:

Information architecture and navigation

Information architecture is the structural design of information – pages, content, labels, etc. – and navigation is the pathway that connects them all. Mastering these two principles is vital to getting your brand story across and creating sales funnels for users to, you know, navigate.

Speed and performance

In most cases, website performance refers to the speed of a website – how long pages and content take to load. However, performance should also consider mobile optimisation, bugs and other quirks that might get in the way of people using a site/platform.

UI design

User interface (UI) design is the visual and functional design of elements people use to interact with a website or application. This includes buttons, icons, navigational elements, advanced search options and anything else users click or touch. The trick is these things need to visually communicate what they do so users quickly understand what they can do and how.

Getting the job done

You could argue this is the most important element of UX design. In most cases, users land on your website looking to do something, to achieve some kind of tasks. The same goes for mobile apps, chatbots and any other platform you design. They have to be useful, intuitive and get the job done in the most efficient way possible.

Another element of user experience that often gets forgotten these days is the enjoyment factor. If users love using your site, app or whatever else, they’re going to be a lot more forgiving about the occasional UX gripe. So don’t forget the human element and strive to create something people actually enjoy using.

Why is UX important to every business?

UX design has become one of the most important aspects of modern marketing. Take a look at the leading brands in any industry and you’ll see how much time and money they invest in creating and maintaining a user experience that keeps people involved with their brand and coming back for more.

Generally speaking, the goals of UX design are as follows:

Make a positive first impression with users Create a pleasing experience that people associate with your brand Reduce the percentage of users who leave before completing an action Increase the percentage of users who come back to your website/platform Encourage users to come back to your site in the future

UX design’s role in marketing is growing, though. Google now considers user experience factors in its search algorithm (e.g: mobile optimisation) but even its core metrics are influenced by UX design. The number of pages people visit, the time they spend on them, the moment they choose to leave and various other factors are a reflection of the user experience you create.

That gives you an idea of some of the things users hate the most but there’s more to UX design than suppressing internet rage. Creating a profitable user experience means analysing every detail of your brand – down to the colours of your CTA buttons and your choice of fonts – to understand what generates the most conversions.

It’s impossible to overstate the importance  of UX design in modern marketing. In fact, with the rise of chatbots, personal assistants and the latest wave of web technologies, UX design is fast becoming the new web design. It’s something that incorporates every interaction between users and brands, from the moment they see you in search until they confirm their payment – on your website, in-store or via a third-party platform.

Good web design helps investor exposure, if your website isn’t performing as well as it should be, we would highly recommend a UX review before investing any further budget in your current site. A UX review will reveal under-performing areas and provide you with a list of recommendations that will have the biggest impact on your site. This removes any guess work and means your budget will be spent in the right areas.

OTC PR Group specializes in creating modern and esthetically pleasing-attention grabbing websites that cater to potential investors along with your existing clientele. While many company website’s today are outdated; we understand the importance of design and provide our business partners with the most modern website designs.

Increase Stock Awareness with Google AdWords

Dec 21, 2016 by OTC PR

When we talk about advertising on Google AdWords we tend to focus on selling products or services. Increase Stock Awareness with Google AdWords.

Selling products isn’t the only reason to advertise on AdWords.

There are times where your goal is to increase brand awareness and find new shareholders at an earlier stage of the research process. So today we’ve got some tips on how to do this effectively in AdWords.

Start with the Display Network to Increase Stock Awareness with Google AdWords

The most obvious place to start with your brand awareness campaigns is the Display Network. Google has refined its targeting options over the years, which means you can narrow down your target audience with a combination of settings:

Keyword targeting: Target pages on relevant websites containing your chosen keywords.

Topic targeting: Target websites based on the topic of their content.

Placement targeting: Target specific websites, known to be of interest to your target audience.

Affinity audiences: Target users who have shown an interest in certain topics or products.

In-market audiences: Target customers who are actively searching for products or services related to your brand.

Location and language targeting: Target languages and specific countries, regions or cities.

Device targeting: Choose which device types you want users to see your display ads.

Demographic targeting: Target users based on gender and age.

That list gives you a lot of control over who sees your display ads – so you can really hone in on the kind of people you want to introduce your brand to. You can also combine a number of those targeting options, depending on how narrow/specific you want your reach to be.

Use the Search Network to build brand awareness

Google’s Search Network may not be the most obvious place to build brand awareness, but text ads can be one of the fastest ways to reach a wider audience. The first thing you need to do is to create a new list of keywords – search terms that will give you an opportunity to reach your target audience, even if there’s minimal buying intent.

Most of these will probably be long-tail keywords, but they’re the kind of queries that should already be inspiring your blog content anyway. However, for these campaigns, you’ll want to step up the content efforts even more and create something noticeably better than everything else that appears on page one for each keyword. Create eBooks, video reviews, detailed guides and put the time into creating headlines that really grab attention.

Next, you’ll promote these pieces of content with AdWords text ads. The great thing about this approach is your content will jump right to the top of page one and, assuming your content is good enough, people won’t hesitate to click for a moment.

Now for the magic part. Before your ads go live, set up AdWords remarketing on each landing page so you can continue to target them even after they’ve finished with your content.

This approach is doing three things. First, it introduces your brand to a wider audience and then it provides them with content that actually has something to offer. Second, remarketing means they see your ad as they continue to use the web, reminding them about your brand for a set period of time.

Just remember to use frequency capping and end date for remarketing to stop people getting fed up with seeing the same adverts.

So there you have it – AdWords isn’t just for promoting product and services pages. You can use both the display and search networks to build brand awareness and find new shareholders at an earlier stage of the buying process.

We Deliver Your Message

We will become your “total” Public Relations firm with strategic Network Advertising. As a result of our extensive experience with particular client’s needs, we’ve developed programs that meet your specific goals.

Many growth companies have great potential but no real retail buying. We have powerful systems of investor participation throughout the world targeting not only investors… we also market to stockbrokers as well by using all the latest digital and social marketing venues available.

 Working closely with our clients and professional network partners in conjunction with our newsletter publishing sites we can create and implement marketing and advertising programs that deliver high impact exposure campaigns.

 

got press? Submit Public Company Press Releases!

got news? Newsletter Publishing Site!

We use our publishing sites and knowledge of the markets and industry to provide our clients with a better understanding on how to approach their marketing decisions. Your goals are our goals, which is why OTC PR engages in a true partnership with our clients. OTC PR has worked with a diverse group of talented and respected professionals whom have joined forces with us in order to create a cost effective advertising network dedicated to publicly traded Companies

Business Facebook Marketing

Dec 15, 2016 by OTC PR

Change always comes fast in the Social Media Arena, all the tech giants are making big things happen as we move into the next stage of marketing and Business Facebook marketing has been particularly active.

Business Facebook marketing
Business Facebook marketing

Not only did Facebook establish itself as pretty much the only genuine rival to Google’s online dominance but it has also been rapidly cornering the social commerce arena. 

Facebook has established itself as the only genuine rival to Google’s online dominance and it’s rapidly cornering the social commerce arena.

The network’s latest innovations will be where just about every business type can turn Facebook into a valuable marketing tool – one that can even converts leads from inside the app.

Business Facebook marketing looks very different compared to earlier years – at OTCPRGroup we understand the importance of utilizing all the Social Media Solutions that this medium has to offer ! so let’s take a preview at what’s ahead.

Facebook page conversions
The days of Facebook business pages being static profiles are way behind us. Users can now reach out to you directly via Messenger bots, click to buy products and complete a range of other conversion types – all from your business page.
People can book appointments, request quotes, book tickets and order takeaway directly from Facebook pages. So consider 2017 the year where Facebook becomes a genuine social commerce tool, where users go to find brands and buy on the spot.

Facebook Live
The other big Facebook headline this year (from all the way back in April) was Facebook Live. Now anyone on the network can post live videos of themselves or anything around them – and the race is on for brands to dominate Facebook Live first. This medium can be a great way for CEO’s to better communicate their message and news directly to stakeholders.

Messenger chatbots
The biggest news for Facebook advertisers this year is the release of Messenger Platform. Sign up and you can build your own chatbot in a matter of minutes (or longer if you want more functionality).

A lot has been said about chatbots this year and Facebook is among the biggest players in the technology right now. Finally, we have a mobile shopping experience that makes buying products easier on the go – even down to making payments without leaving the Messenger app. Chatbots are the first platform to give us that one-on-one connection with shoppers, providing you with a channel to target consumers with 100% personalised marketing messages – something we’ve been talking about for years.It’s still a new concept for marketers to work with and there have been some early teething problems. BuzzFeed’s ‘live interview’ with Barack Obama comes to mind, where the feed cut out before the president even sat down. However, we’ve also seen a number of success stories this year from brands and publishers of all size who are using Facebook Live to expand their reach and engage with viewers.

Facebook Marketplace
Facebook is looking to create a unique shopping experience on the network with the introduction of Facebook Marketplace. This is where Facebook’s 1.7+ billion users can buy and sell products. The focus is on users finding items in their local area – a kind of digital version of local classified listings.

Of course, you can buy products from anywhere you like – as long as it’s in the UK, US, Australia or Canada. At least for now anyway, but Facebook promises to add more countries in the near future. What we’re really interested in, though, is what Facebook has planned for local retailers and advertising on Marketplace in the future. So stay tuned for news on these two crucial points.

Facebook Workplace
Another new venture for Facebook comes in the shape of Workplace, an enterprise platform that hopes to replace email and make the working day easier for all of us. It’s pretty much Facebook for the workplace with a few extra features chucked in to make communication/collaboration easier.

If you’ve ever used corporate messaging tools like Slack, you’ll know what Facebook is trying to do with Workplace – basically integrate the same concept into its social network.

What’s more important from a marketing perspective is that this is Facebook’s first venture into enterprise software. This puts one foot in the same pool as LinkedIn and Microsoft (who just bought LinkedIn). Plus, Facebook has just announced that companies will soon be able to post job listings on the network. Watch your back, LinkedIn!

This all comes down to Facebook wanting its share of corporate data – something it lacks in comparison to Google, Microsoft and other big rivals. Workplace will aim to fix this, making Facebook more competitive across a wider range of ad channels and bring additional B2B clout to Facebook advertising.

Recommendations from friends
Having your target audience’s friends recommend your business to them is the gold standard of marketing leads – and Facebook wants to make more of this. Soon users will be able to ask their friends for recommendations within a matter of clicks and get advice from their trusty pals.

The idea is their friends will recommend local restaurants, services, events and other businesses in the nearby area. So all those good impressions you make on people can turn into new leads as soon as their friends or family are in need of something similar.

Facebook marketing in 2017 will see the tech giant offer new opportunities to retailers and B2B companies as it expands its reach across the web. 

OTC PR Group not only knows exactly how to use social media to enhance an investor relations platform, we’re constantly tracking the progression and adapting our strategies to our clients’ advantage.

OTC PR Group provides a full suite of investor relation services utilizing modern technologies coupled with long lasting relationships and relationship building processes to develop and maintain interest from your shareholder base. We work to build shareholder value by engaging with key-stakeholders and effectively following up and communicating your message, investment potential and corporate vision to Main Street, Wall Street and the media.

Let us  help bring your company to the forefront of the investment community.

For more information on our services contact us today at  561-807-6350

Email: corp@otcprgroup.com

Increase Investor Exposure with Youtube

Sep 13, 2016 by OTC PR

videoAt OTC PR Group we know in order to survive and grow, small business owners must overcome the hurdle of garnering business exposure. You need to Increase Investor Exposure with Youtube! The days of simply going public and putting out press releases about your business is long gone. Now small business owners and entrepreneurs must make considerable efforts to promote and get more exposure.

When it comes to increasing your brand’s presence online, then search engines and social media is where your focus should be. Video are often the top search results and are up to 50 times more likely to appear on the first page of search results. Search engines love fresh and engaging content because it’s likely to be consumed, shared and liked and video often tops the content list due to its social and engaging nature.

Video Productions at OTCPRGroup learn more:

In the past, written content was king. Today, you can attract stakeholder and customers who are more comfortable watching a quick video than reading through a long list of company press releases or a boring article. A well thought out video can also help you appeal to a broader demographic and extend the reach of your marketing efforts, seeing as people can share your video content on social media and reach thousands of friends, contacts and followers in an instant.

Nothing beats a creative YouTube video to captivate an audience. The exposure any company can get on this site is extraordinary. A statistic from YouTube states that viewers watch hundreds of millions of hours of YouTube videos every day. Each minute, an estimated 300 hours of YouTube videos are uploaded.

There are more than 1 billion users on YouTube and the number of hours each month that viewers are watching videos has been steadily increasing by 50% year over year. YouTube provides the best opportunity for your business message to reach millions of people that all have the potential of becoming prospective customers.

Creating and posting a YouTube video is a powerful asset to any online marketing strategy. The mass appeal and widely recognizable format makes it the perfect ground for staging a product or service. Any business can benefit from YouTube’s video suggestions and shares. This benefit of using YouTube in video marketing efforts is undeniably successful in this regard alone.

YouTube videos are very easy to share online. This makes integrating them into any social media strategy plan just as simple. By distributing YouTube videos on other popular media sites such as Facebook, Twitter, LinkedIn, StumbleUpon, and Reddit, your business exposure can instantly increase exponentially. Social media and video is the new SEO that’s why we incorporate it in our PR campaigns. Social media adds social proof to your video because if people are prepared to share it on their networks, it bolsters confidence in your company and product.

 OTC PR Group provides a full suite of investor relation services utilizing modern technologies coupled with long lasting relationships and relationship building processes to develop and maintain interest from your shareholder base. We work to build shareholder value by engaging with key-stakeholders and effectively following up and communicating your message, investment potential and corporate vision to Main Street, Wall Street and the media.

Let us  help bring your company to the forefront of the investment community.

For more information on our services contact us today at  561-807-6350

Email: corp@otcprgroup.com

 

Secrets to having a successful investor day

Jul 27, 2016 by OTC PR

Secrets to having a successful investor day
Secrets to having a successful investor day

Hosting an investor day can have a positive impact if you know the secrets to having a successful investor day —both during the event and in the weeks and months to follow. It can be a powerful way to raise management visibility and credibility, highlight the depth of your management team, and clarify your company’s growth strategy. Here are some tips to help you begin the process.

 

DEFINE YOUR OBJECTIVES

 

Why are you hosting the event at this particular time? What messages do you want to communicate? Who should deliver prepared remarks? There’s nothing that says an investor day must be held every year. In fact, they shouldn’t be held annually if there’s no new or exciting information to share. Companies should feel free to hold the event when the timing is right and the information is relevant. Make sure the event is relevant don’t want the information to get too stale for the investment community

 

For example, if your planning an investor day around a major announcement this can give you the opportunity to provide investors an additional incentive to attend the event. It also can make sense to include third-party speakers in addition to your management team, depending on the focus of your investor day. For example, a company that recently announced a new medical device might invite a physician to speak about its benefits.

 

PICKING LOCATION AND TIME

 

Many companies like to have their investor day at their headquarters because it gives them a chance to show off their facilities, equipment, and operations. It can be helpful to reach out to your sell-side analysts and key shareholders in advance for their opinions about the timing or location you are considering.

 

Companies can boost attendance, awareness, and participation by taking the event to a location that is more likely to draw attendance. Major cities like New York, Chicago, San Francisco, or Miami can be big draws because they’re convenient and because they’re attractive destinations. One idea that can encourage attendance is to piggyback off of a big industry conference or trade show. If analysts will already be in town for the conference, they may be willing to stay one extra day for the investor event.

 

DEVELOP AN ONLINE PRESENCE

 

A company could really promote the event online by giving the event its own splash page or even its own mini-site. The site could contain the event’s agenda, speaker bios, and event check-in info. When the event is over, attendees could reference the site to listen to the audio or download slide decks and other relevant information, such as the event transcript. The microsite or splash page will work best if designed in conjunction with all of the other collateral for the event including the invitations, save-the-date emails, and presentations. A design company with experience marketing investor days can create a cohesive package that accurately reflects a company’s brand and captures the event’s theme.

 

USE TWITTER TO BUILD ATTENDANCE

 

Not every company is up to speed on the power of Twitter. However, it’s likely that many of the attendees use Twitter regularly. Live tweeting the event serves two purposes. First, it relays information to those who aren’t in attendance and builds buzz around the event. However, it also provides a documented transcript of the day’s happenings. If a company creates and pushes an event-specific hashtag, they can then monitor and review all tweets surrounding the event. Those tweets can provide critical information about how the day was received and what information should be communicated better going forward.

 

PREPARE AND REHEARSE

 

Rehearsing for the investor day is essential. It allows your speakers to practice their delivery as well as make sure they are successfully communicating the key messages you want the audience to take away from the presentations.

 

An investor day can be as fun and original as a company wants it to be. Far too many companies fall into a default program that isn’t compelling and provides too little helpful information. By thinking creatively and embracing non-traditional ideas, a company can makes its investor day a positive experience for both the business and the attending analysts and investors.

Properly executed investor relations can help companies develop and maintain market value. Working with our experienced team at OTC PR Group allows client companies to achieve solid and positive results from their IR initiatives. Additionally, we can help clients avoid the many challenges of developing and maximizing a strong investor base. Learn More:

Get our “FREE REPORT REVEALS… The 5 (Easy Secrets)

Tools we use TO SUCCESSFULLY USE SOCIAL MEDIA FOR INVESTOR COMMUNICATIONS”

Sign up and request free report below:

    Social Media Improves Investor Communications

    May 25, 2016 by OTC PR

    news and media logo

    Social Media Improves Investor Communications. Social media usage also improves the company’s information environment. Companies may benefit from developing different approaches to disseminating positive versus negative earnings news.

    Conventionally, when a company wants to publicize investor-related information such as an earnings announcement, it would do so by sending a press release to intermediaries such as newswire services, equity research databases, and brokerage firms. A company does not know if or when any of its existing or prospective investors received the information.

    With social media platforms such as Twitter, a company can send one or more short messages directly to a known number of followers with a link to a press release on its corporate website. As such, a company can use Twitter to target its news dissemination, increase the speed and flexibility of the news dissemination, and reduce information acquisition costs for its investors and the traditional media outlets that follow it.

    Twitter and Facebook are the two most frequently adopted social media platforms for corporations and is highest for customer-facing industries such as meals, retail, books and services and lowest for industrial sectors such as oil and steel.

    searchQuarterly earnings-related tweets are the most prevalent type of investor-focused tweets, far outnumbering tweets related to executive turnover, dividends, board of directors, and even new products and customers. The number of firm-quarters with earnings announcements on Facebook is approximately half the number on Twitter, suggesting that the preference for Twitter is even stronger when it comes to earnings news.

    Using Twitter, rather than other social media data is advantageous because earnings announcements have been shown to be of first-order importance to investors and the information content of earnings announcements can be controlled more effectively than the information content of other financial disclosures. Also, the precise time that earnings announcements are disseminated through Twitter can be identified.

    There can be a significant increase in the mean volume, primarily due to an increase in large trades. Therefore, while social media is commonly viewed as a dissemination channel that provides timely access to information for all investors, the results suggest that larger investors react more quickly to earnings-related tweets.

    Studies show that the usage of social media by corporations has grown dramatically over a relatively short period of time, from less than 5 percent of S&P 1500 companies in 2008 to more than 50 percent in 2013. This trend suggests that social media usage for communicating with investors has the potential to become an integral part of many companies’ disclosure policies. The findings show that even in the absence of the Securities and Commission’s approval of social media as a channel for investor communication, companies used it to disseminate a variety of information, including earnings news, board and executive changes, new contracts, and dividends.

    Appropriate social media policy for investor communications differs from social media usage for other business purposes, such as marketing campaigns, in which companies often want to generate viral reactions to social media dissemination. At OTCPRGroup we incorporate the latest Social Media Solutions in order to maximize the investor communications. Companies that adopt social media disclosure policies benefit from developing different approaches to disseminating positive versus negative earnings news. Social media usage improves the company’s information environment and it improves investor communications.

    Get our “FREE REPORT REVEALS… The 5 (Easy Secrets)

    Tools we use TO SUCCESSFULLY USE SOCIAL MEDIA FOR INVESTOR COMMUNICATIONS”

    Sign up and request free report below:

       Learn How To

      Target Investors

      Call or email if you would like further information, we are here to help.

      Douglas Baker, 561-807-6350- corp@otcprgroup.com

      Click here and connect with us

       

      OTC PR Group is a complete financial public relations firm. Our unique and persistent market exposure techniques have consistently motivated the investor/brokerage community to take action on our clients’ stock offerings.

      We Deliver Your Message

      We will become your “total” Public Relations firm. As a result of our extensive experience with particular client’s needs, we’ve developed programs that meet your specific goals.

      Our program affords you the greatest coverage in developing stock support and higher market capitalization utilizing the largest and most popular database providers in the industry who can take positions in your company stock.

      These services have proven to help create and maintain strong relationships with a corporation’s investor base, resulting in strong valuations in the marketplace and the establishment of leadership positions for our clients.

      WHAT WE DO
      Investor Relations

      We have more than 20 years of experience helping clients navigate a wide range of investor relation issues. Our approach to investor relations delivers action orientated results for our clients including new business contacts, ideas and exposure that can save time and money while delivering the right outcomes. Read more: https://otcprgroup.com/investor-relations/

       

      Corporate Communications

      We help company’s structure and communicate their message to Wall Street through a combination of old school practices and the latest media and marketing methods.  Having extensive experience as past stock brokers in the early eighties, the principles of OTC PR Group are equipped to approach analysts, brokers and portfolio managers in the language they understand. – Read more: https://otcprgroup.com/corporate-communications/

      Social Media Solutions 

      OTC PR Group works in partnership with the leading Social Media Marketing professionals in the industry to develop custom social strategies to achieve the greatest return on investment. Whether you are just getting started or need better results from your campaign, our networks can help. Read more: https://otcprgroup.com/social-media-solutions/

       

      Video Productions

      The reason we encourage clients to incorporate video in investor relation campaigns is that it is simply the most powerful digital marketing tool available. It’s better for recall, it’s more persuasive and search engines love it. A professional interview can draw out plenty of information, which is why the interview format is so effective in relaying information to others. Read more: https://otcprgroup.com/video-productions/

      OTC PR Group provides a full suite of investor relation services utilizing modern technologies coupled with long lasting relationships and relationship building processes to develop and maintain interest from your shareholder base. We work to build shareholder value by engaging with key-stakeholders and effectively following up and communicating your message, investment potential and corporate vision to Main Street, Wall Street and the media.Let us  help bring your company to the forefront of the investment community.

      For more information on our services contact us today at  561-807-6350

      Email: corp@otcprgroup.com

       

      Communicate a Compelling Investment Story

      May 4, 2016 by OTC PR
      Learn How to Communicate a Compelling Investment Story.

      For those IROs and CFOs new to the investor relations sector, the practice of investor relations can seem like a whole new field – with new players, metrics and ways to communicate. And while best practices and the fundamentals of IR still hold true, there is a lot to learn before you can expertly communicate your company’s story to the investment community.

      The OTC PR Group model employs a variety of conventional and non-conventional programs and tools to communicate your company’s story and increase your exposure in the small-cap equity markets. We pride ourselves on the honest and unfiltered feedback we gather from the brokerage community and we use this feedback to constantly evolve the messaging. Learn more:

      Here are five tips to get you started.

      1) Explain what is Unique About Your Company as an Investment.

      No matter your specific business, the competition for investors is challenging as they have thousands of investment options, from technology and specialty Internet sites to medical and the latest hot button trend. Therefore, a company needs to stand out from its investment competition with a powerful investment thesis that explains its differentiators.

      For example, what is your target demographic? Is it based on age? Gender? Geography? If you have a subscription-based service, what brings people in the door and keeps them coming back (and paying your monthly fee)? How expensive is the delivery of that unique customer experience, and is that model sustainable? The more obvious the differentiators, the more appealing your investment thesis will be to investors.

      2) Define Your Customer Engagement Strategy.

      In any industry, one of the key areas of investor interest is a company’s customer engagement strategy. This is especially true as it pertains to how channel growth and innovation can be a key competitive differentiator. In this age of 24/7 mobility, investors are keenly interested in your ability to create an omni-channel customer experience. Whether it’s in the store, through a mobile app or via the corporate website, your shareholders will be analyzing not only whether the business experience is seamless but whether it creates an advantage that can translate into higher revenues and profits.

      For example, has your company adopted a new technology solution to make the shopping experience easier, faster or more personalized? How are you gaining insight into your customer’s buying behavior? Data and anecdotes that address these areas can provide investors with a clear picture of how you distinguish yourself from competitors.

      3)Be Transparent.

      Investors in large cap stocks are accustomed to receiving robust and quality information about the companies they follow. Some key metrics may include inventory and receivables, because they indicate how efficient a company is in managing that inventory – inventory turns – and the overall health of the supply chain operation. Other key examples are cash flow and cost of goods sold. Provide as much detail as possible without giving away competitive information. The reason for this is simple: If a company can manage its inventory efficiently, control expenses and produce a quality product, that information will give investors increased confidence in the firm’s earnings power.

      Transparency is about more than financials, though. In a franchise model, for example, investors often want to speak directly to the franchisees themselves. Such requests can set off management’s risk meter, but the best-in-class companies enable this type of communication. They may select just a few franchisees to be investor facing and prepare them to engage with the Street. In effect, they become spokespeople for the company. It’s important not to restrict investor access too tightly, either. If they aren’t getting the type of interaction and information they expect, some investors won’t ask management for permission and will go straight to the franchisees.

      4) When Challenges Arise, Communicate in a Way that Engenders Confidence.

      A rising tide, as they say, lifts all boats. But when the economic cycle is against you or the new product you rolled out is a miss, management’s ability to navigate both macro and micro issues becomes critical. You must be able to communicate management’s strategy to investors effectively. That means being able to articulate what the issue is, what the action plan is and how long it will take to affect the fix, because in business, misses and economic downturns are relatively common. No one ever stays on top forever. The key is to be able to contain an issue, articulate the action plan to address it, and – at all times be forthcoming and honest.

      5)Communicate Your Company’s Market Opportunity.

      Investors are keenly interested in how you view your company’s market opportunity, particularly the size and dynamics of the addressable market. Given the market opportunity as you have defined it, what is your strategy to penetrate that market, where do you see brand/product strength and why do you believe you will be successful?

      Communicating this information and providing ongoing updates, which highlight progress, changes in trends and the impact of those changes on your business – and how you are addressing them – will instill confidence in management.

      Like any investors, those who take positions in companies want to know as much as they can about their investments. Tying together these five key points will help you create a compelling investment story no matter what your company is selling. Overall, the more clear and comprehensive the story is, and the better management articulates it, the better you will do in terms of gaining investor confidence and driving long-term shareholder value.

      Get our “FREE REPORT REVEALS… The 5 (Easy Secrets)

      Tools we use TO SUCCESSFULLY USE SOCIAL MEDIA FOR INVESTOR COMMUNICATIONS”

      Sign up and request free report below:

        Learn How To

        Target Investors

        Call or email if you would like further information, we are here to help.

        Douglas Baker, 561-807-6350- corp@otcprgroup.com

        Click here and connect with us

         

        OTC PR Group is a complete financial public relations firm. Our unique and persistent market exposure techniques have consistently motivated the investor/brokerage community to take action on our clients’ stock offerings.

        We Deliver Your Message

        We will become your “total” Public Relations firm. As a result of our extensive experience with particular client’s needs, we’ve developed programs that meet your specific goals.

        Our program affords you the greatest coverage in developing stock support and higher market capitalization utilizing the largest and most popular database providers in the industry who can take positions in your company stock.

        These services have proven to help create and maintain strong relationships with a corporation’s investor base, resulting in strong valuations in the marketplace and the establishment of leadership positions for our clients.

        WHAT WE DO

        Investor Relations

        We have more than 20 years of experience helping clients navigate a wide range of investor relation issues. Our approach to investor relations delivers action orientated results for our clients including new business contacts, ideas and exposure that can save time and money while delivering the right outcomes. Read more: https://otcprgroup.com/investor-relations/

         

        Corporate Communications

        We help company’s structure and communicate their message to Wall Street through a combination of old school practices and the latest media and marketing methods.  Having extensive experience as past stock brokers in the early eighties, the principles of OTC PR Group are equipped to approach analysts, brokers and portfolio managers in the language they understand. – Read more: https://otcprgroup.com/corporate-communications/

        Social Media Solutions 

        OTC PR Group works in partnership with the leading Social Media Marketing professionals in the industry to develop custom social strategies to achieve the greatest return on investment. Whether you are just getting started or need better results from your campaign, our networks can help. Read more: https://otcprgroup.com/social-media-solutions/

         

        Video Productions

        The reason we encourage clients to incorporate video in investor relation campaigns is that it is simply the most powerful digital marketing tool available. It’s better for recall, it’s more persuasive and search engines love it. A professional interview can draw out plenty of information, which is why the interview format is so effective in relaying information to others. Read more: https://otcprgroup.com/video-productions/

        OTC PR Group provides a full suite of investor relation services utilizing modern technologies coupled with long lasting relationships and relationship building processes to develop and maintain interest from your shareholder base. We work to build shareholder value by engaging with key-stakeholders and effectively following up and communicating your message, investment potential and corporate vision to Main Street, Wall Street and the media.

        Let us  help bring your company to the forefront of the investment community.

        For more information on our services contact us today at  561-807-6350

        Email: corp@otcprgroup.com

        Improve M&A success

        Apr 7, 2016 by OTC PR

        Learn how to improve M&A success
        Learn how to improve M&A success

        Improve M&A success with these strategies.

        The essential in any strategic initiative – is careful planning. Unfortunately, mergers and acquisitions often develop so rapidly that time for preparation is limited. This is why one of the mainstays of investor relations is an ongoing program of skillful relationship building with a company’s key stakeholders. Management teams that stay in touch with their priority constituencies, including institutional shareholders, will be in a better position to understand, in advance, the different mindsets these interests will bring to an impending deal.

        In addition to keeping your shareholders updated on company developments, management should obtain feedback from your top 25 shareholders on issues that matter. How do your institutional holders feel about M&A as an element in your company’s growth strategy? Are they more concerned about dilution or debt? Do they require all deals to be immediately accretive? How does their thinking about industry consolidation align with yours? Do they have concerns about your management team’s M&A experience? A comprehensive third-party perception audit of your investor base can help answer these questions.

        Develop Your Strategy

        Armed with this insight, the company can develop an effective M&A messaging strategy. From the announcement of a deal through the closing, this strategy should be aimed at two outcomes. The first is to support successful completion of the deal. The second is to ensure that, whether the deal goes through or not, your company will emerge from the process with even stronger positioning on Wall Street.

        Messaging based on an understanding of your shareholders’ perceptions and concerns can convert them into advocates for the deal. Current shareholders will want to know how the transaction benefits them. Assess the transaction through their eyes, particularly when dilution is involved. Whether a deal is strategic or tactical is often crucial in determining how much dilution Wall Street will support. Are you acquiring the target for its products, its technology platform, its customers or the geography of its operations? An explanation of expected synergies and long-term benefits can help offset dilution concerns.

        Consider Contingencies

        Sound planning for M&A communications always considers “what if” scenarios. Chief among them: What if the deal fails to close? It is imperative to communicate that, as attractive as the deal may be, it is by no means your company’s sole option for achieving its long-term goals.

        Successful M&A messaging also must reflect the perceptions of stakeholders on the other side of the deal. (Value is in the eyes of the beholder.) Both companies will emphasize that they are getting the best possible price, but they may come from opposite directions in the reasoning and messaging. Your success in M&A communications can hinge on the ability to mediate the contradictory nature of the messaging on opposite sides of the transaction.

        Negotiate the Outcome

        It often can take as much diplomacy to coordinate messaging strategy as to reach agreement on deal terms. The best M&A communication outcomes result from both parties clearly understanding their respective roles, as well as their IR messaging objectives. Coordinated planning also is crucial. It is imperative for each company to be systematic in maintaining open communications with its institutional shareholders – and to get in touch with these constituents immediately after the transaction is announced.

        Overnight, the management teams on both sides of the deal will find themselves encountering new universes of shareholders, often with very different investment objectives and horizons. As closing approaches, the acquiring company should become thoroughly familiar with the target’s shareholder base and be prepared for the necessary outreach once the deal is complete. This should include personal phone calls to welcome inherited shareholders or outgoing e-mails with IR contact information. These actions engender goodwill and can make a lasting positive impression.

        Cultivate Broad Support

        Although CFOs and investor relations officers tend to bear the primary responsibility for spearheading M&A communications, the scope of the effort must extend beyond these functions. Senior management should assemble an internal task force that also consists of the legal department, corporate communications, HR and the business unit where the acquisition will reside. Working together, these groups can cover the entire range of external and internal constituencies.

        Too often, communications with non-financial stakeholders get short shrift from management during the frenzy of activity surrounding a deal. Employees will be asking: Will I have a job? What will happen to my pay and benefits? What are the implications for my career, my lifestyle and my security? Customers and suppliers will have their own sets of questions about the transaction and its potential impact on their business relationships with both companies involved.

        Coordinate the Details

        In addition to crafting messages that respond to these questions, a number of logistical communications issues will need to be addressed. For example, will both companies conduct a joint conference call when announcing the transaction? If so, which members of the executive teams will participate in the call? If each company is conducting its own conference call, answers to potential analyst and media questions should be carefully scripted and rehearsed to ensure consistency.

        If the current trend is any indication, M&A communications will be an important tool this year for companies and their executive teams. Communicating effectively before and throughout the M&A process will enhance relationships with all constituencies and possibly even enable a more successful transaction. Learn More:

        We help company’s structure and communicate their message to Wall Street through a combination of old school practices and the latest media and marketing methods. Having extensive experience as past stock brokers in the early eighties, the principles of OTC PR Group are equipped to approach analysts, brokers and portfolio managers in the language they understand. We communicate directly with investment professionals understanding their goals, attention, and the type of companies they look for.

        Making connections

        We strive to find stories that resonate well with our networks and with our direct communication practices our clients get their attention.

        Investment professionals such as: stockbrokers, registered investment advisors (RIAs), certified financial planners (CFPs) don’t have the time to research the thousands of OTC companies that currently trade. If you don’t have an experienced professional speaking with them directly about your story, they will never know you exist.

        Our approach is centered around properly educating Investment professionals and cultivating trust in order to uphold and protect management’s long-term credibility and reputation on Wall Street. Our company was founded on a strategic and professional approach to corporate relations that builds awareness of our clients through tailored outreach programs that target institutional investors, analysts and the financial media.

        The OTC PR Group model employs a variety of conventional and non-conventional programs and tools to communicate your company’s story and increase your exposure in the small-cap equity markets. We pride ourselves on the honest and unfiltered feedback we gather from the brokerage community and we use this feedback to constantly evolve the messaging.

        Get our “FREE REPORT REVEALS… The 5 (Easy Secrets)

        Tools we use TO SUCCESSFULLY USE SOCIAL MEDIA FOR INVESTOR COMMUNICATIONS”

        Sign up and request free report below:

           

          Address: 1825 NW Corporate Blvd.Suite #110 Boca Raton FL. 33431

          Phone: 954-821-2609
          Email:corp@otcprgroup.com

          Join Our Free Newsletter for the Latest Investor Relation Marketing Tips!!!

            Raising Capital

            Mar 21, 2016 by OTC PR

            image VENTURE CAPITALThe pace at which your company develops – and even your ultimate success – can hinge on your availability of capital. Learn these basic rules of raising capital. Our experience has shown that a properly coordinated out reach program can attract attention and increase awareness.

            There are over 100,000 publicly traded companies in the world. In the US, less than 4000 companies are actively traded in NYSE or Nasdaq. There are another 15000 stocks that are traded over the counter. The majority of them are thinly traded. When the time comes to make an investment, stockbrokers and investors alike are swamped with decisions, choices and alternatives. Your company is lost in the shuffle – just another needle in the haystack, unless brokers and investors are familiar with your company’s name and business. The only way to build that familiarity is to put your company’s name, story and pertinent information in front of targeted brokers as often as possible. A well-organized, professional Investor Relations and Broker Network Program can help build the familiarity your company needs in order to get its share of attention in today’s competitive markets and increase the liquidity in your company stock.

            Angel investing in start-ups has been accelerating with many high-profile success stories that have spurred angel investors to make multiple bets with the hopes of getting outsized returns. Many angel investors may not be as wealthy as you think but they are financially savvy. Most are looking for a way to grow their money by promoting innovative new business.

            In today’s business climate, there are literally hundreds of ways to fundraise.

            Here are some basic rules to keep you on the right road to raising capital.

            1. Establish clear, realistic goals. From day one, clearly state your objective. If you can’t explain your vision in concrete terms to potential investors, you can’t expect them to give you their money.
            Be realistic about what you are trying to accomplish. By laying out your plan in detail, you should be able to say with confidence what you can expect to accomplish. Investors deserve transparency and truth. Your partnership must be based on trust — and only credibility can breed it. Making a good impression with a solid pitch presentation is important, but it won’t guarantee funding. Credibility invokes confidence, which mitigates risk and opens wallets.

            2. Have a solid team in place. Any startup is only as good as its people. A strong, efficient and success-driven team is absolutely necessary. Your team represents the company, its goals, its vision and credibility. Recruiting people with sound reputations for honesty and integrity helps attract investments. After all, you are your team.

            3. Focus on the “real” market. Exhaustive, in-depth market research is the only way to map a blueprint for success. Many early stage businesses are too eager to get started and end up setting out in the wrong market. The best market for a new business is not always the biggest or the steadiest. You have to do your homework. There is no replacement for in-depth market research.
            You and your startup team should profile a variety of markets. That is the only way to determine which one is the best fit for your business. Market research can be tedious, but it is the bedrock of a solid business plan.

            4. Get your name out there. The biggest irony in raising capital? You need some capital to do it. Investors won’t know every detail about your project, so you have to decide what essential information to deliver. Fortunately, the Internet is the best advertising medium invented, and it’s always open for new business.
            The web is without a doubt the most powerful place to advertise. Even better, it’s cheaper than broadcast TV, radio or print media. Social media can also be a real boon, as solid networking can help you connect directly with potential investors. That’s how you create the support network for your project.

            5. Consider crowdfunding for validation. Crowdfunding is one of the best fundraising tools available for startups today. The concept is simple: You advertise your business idea in a number of difference dedicated platforms and users vote with their wallets. A crowdfunding pitch can also be a good litmus test. If you don’t attract investors (or interested customers), you should consider tweaking your pitch or your business model.

            Raising capital can be a very time-consuming process and it will always take longer to raise angel financing than you expect.
            Not only do you have to find the right investors who are interested in your sector you have to go through meetings, due diligence, negotiations on terms, and more. There are a variety of ways to find angel investors, including through:
            AngelList
            • Angel investor networks (groups that aggregate individual investors)
            • Venture capitalists and investment bankers
            • Crowdfunding sites like Kickstarter and Indiegogo

            After finding investors you should determine whether a prospective angel is a good fit for your company, questions you should ask:
            • How do you like to help your portfolio companies?
            • What amount of follow-on investment do you think our company will need to succeed?
            • How do you think you can be helpful to us in growing the business?
            • How do you like to interact with your portfolio companies?

            Angels will often invest in the company through a convertible note. They key terms negotiated are:
            • Unsecured or secured on the assets of the company – this is almost always unsecured.
            • Interest rate and payment – the interest is usually accrued and not paid currently.
            • Discount rate – this is the discount rate the investors enjoy for taking the early risk in the company, expressed as a discount from the company’s Series A round of financing. A discount rate of 20 percent is typical.
            • Valuation cap – this is the maximum valuation of the company where the note can be converted in the next round of financing.

            We specialize in targeting qualified stockbrokers and investors who are actively seeking small cap investment opportunities. Our clientele are Public Companies, like you who are making a real effort to broaden their retail stockbroker and shareholder base with Real Retail Buying?

            OTC PR Group can reach qualified and targeted stockbrokers for your company. Our experience has shown that a properly coordinated out reach program can attract attention and increase awareness. We have integrity and a high-quality database of stockbrokers and VC Groups who we are able to target for your company. Learn More:

            Get our “FREE REPORT REVEALS… The 5 (Easy Secrets)

            Tools we use TO SUCCESSFULLY USE SOCIAL MEDIA FOR INVESTOR COMMUNICATIONS”

            Sign up and request free report below:

               

              Address: 1825 NW Corporate Blvd.Suite #110 Boca Raton FL. 33431

              Phone: 954-821-2609
              Email:corp@otcprgroup.com

              Join Our Free Newsletter for the Latest Investor Relation Marketing Tips!!!

                Raising Capital & Getting VC’s Attention? Make Sure You Do These 6 Things.

                Mar 8, 2016 by OTC PR

                Raising Capital & Getting VC’s Attention is perhaps the most difficult challenge any entrepreneur faces, and for many, it’s unavoidable.

                In today’s business climate, there are hundreds of ways to fundraise.

                Here are six rules to keep you on the right road to Raising capital & Getting VC’s Attention.

                Establish clear, realistic goals. From day one, clearly state your objective. If you can’t explain your vision in concrete terms to potential investors, you can’t expect them to give you their money.

                Be realistic about what you are trying to accomplish. By laying out your plan in detail, you should say what you can expect to achieve confidently. Investors deserve transparency and truth. Your partnership must be based on trust — and only credibility can breed it. 

                Making a good impression with a solid pitch presentation is essential, but it won’t guarantee funding. Credibility invokes confidence, which mitigates risk and opens wallets.

                Raising capital & Getting VC's Attention

                At OTCPRGroup we encourage that you follow these basic rules to get started:

                Have a solid team in place. Any startup is only as good as its people. A strong, efficient, and success-driven team is necessary. Recruiting people with sound reputations for honesty and integrity helps attract investments. After all, you are your team.

                Focus on the “real” market. Exhaustive, in-depth market research is the only way to map a blueprint for success. Many early-stage businesses are too eager to get started and end up setting out in the wrong market. The best market for a new business is not always the biggest or the steadiest. You have to do your homework. There is no replacement for in-depth market research.

                You and your startup team should profile a variety of markets. That is the only way to determine which one is the best fit for your business. Market research can be tedious, but it is the bedrock of a solid business plan.

                Get your name out there. The biggest irony in raising capital? It would help if you had some means to do it. Investors won’t know every detail about your project, so you have to decide what essential information to deliver. Fortunately, the Internet is the best advertising medium invented, and it’s always open for new business.

                The web is, without a doubt, the most powerful place to advertise. Even better, it’s cheaper than broadcast TV, radio, or print media. Social media can also be a real boon, as reliable networking can help you connect directly with potential investors. That’s how you create the support network for your project.

                Consider crowdfunding for validation. Crowdfunding is one of the best fundraising tools available for startups today. The concept is simple: You advertise your business idea on several different dedicated platforms, and users vote with their wallets. A crowdfunding pitch can also be a good litmus test. If you don’t attract investors (or interested customers), you should consider tweaking your angle or business model.

                Ways to find and raise capital from Angel Investors

                Choosing the right platform is paramount. Again, do your homework, this time in the form of due diligence of the companies managing your crowdfunding initiative. It would be best if you verified the platform’s solidity and validity, including the track records of those running the forum.

                Keep them close. In the end, your success will depend upon the credibility you’ve built and the connections you’ve established. A successful venture is the result of a series of positive interactions between the business and its investors. Keeping investors in the fold will make them comfortable and confident about how things are being run. Remember, they will keep the engine running, but only as long as they are sure you are moving in the right direction.

                Raising capital & Getting VC’s Attention

                The road to raising capital can be a bumpy ride. But with the right approach, the right people, and the right funding avenue, it’s one worth taking.

                OTC PR Group provides a full suite of small-cap public relations services utilizing the latest technologies coupled with relationship building processes to develop and maintain interest from your shareholder base.

                We work to build shareholder value by engaging with key-stakeholders and effectively following up and communicating your message, investment potential, and corporate vision to investors, Brokers, and the media.

                Unlike other firms with a similar focus, We connect our clients with groups that invest in many of its clients, putting its own earned capital into positions to safeguard management’s interests while fulfilling their goals and objectives.

                Introducing our clients to experienced teams leads clients throughout the mandate, constructing and communicating the business’s investment potential while negotiating to secure funding under the best possible terms and conditions.

                Call us to learn more: 561-807-6350

                How Top Public Relations Firms Increase Exposure

                Mar 8, 2016 by OTC PR

                Top Public Relations FirmsInvestor and Public relations professionals do more than draft press releases. Top Public Relations Firms craft persuasive messages and implement key communication tactics while building relationships with media representatives. Good PR is the telling of a good story. We all know the public wants to hear a good story. The better the story, the better the acceptance by the public and the better the public relations. Of course if the story is especially appealing, hitting on the all the hot buttons of investors and clients, then you could have a PR slam-dunk. In this case, it is communication with not just your target market but also all possible media outlets that puts your company on the map.

                At OTCPRGroup.com we feel there is nothing more rewarding than helping an organization overcome business challenges with all the benefits outlined below. Learn More:

                Public relations produces media results including articles, radio interviews, and op-eds that provide strong marketing materials and credibility. As an example: a well-executed media placement can be distributed as an e-mail blast, physical mailer, and social media post. Further, that content can be sent to existing customers or member bases, as well as potential ones, to demonstrate company value.

                Brand visibility, placing your company name, products and expertise in front of your target audience is powerful. In most forms, media coverage often validates a company in the eyes of the public, and makes them more familiar with the brand when they see it again, be it from an e-mail blast, sales call, and other marketing technique.

                Top Public Relations Firms know how to influence an audience, and can position a company or individual as an expert within their industry. For companies with very targeted audiences, when impactful news occurs or trends develop, it is important to make your voice heard through a story in the press, blog, or a strategically placed op-ed/byline.

                Driving lead generation for your brand, effective PR can influence and motivate your target audience. As people continue to see your company or product in the media, it increases the chance of them making a call, sending an e-mail requesting more information, subscribing to a newsletter, visiting a website, and/or other calls to action.

                Public relations addresses brand competition by ensuring that your company is presented with the same opportunities to get in front of targeted audiences as others in your industry. It is important to be seen in similar media coverage as your competitors in terms of story ideas, trends, product features, and more.

                Over the course of time, PR can certainly improve a company’s rankings based on a high volume of high quality media placements. Public relations efforts can be leveraged across social media to drive more traffic to the article, which will result in better SEO for the page and the links within it, and will continue establishing the brand publishing via social media to increase visibility.

                The bottom line is to get the word out about your company, your products and services to those who could potentially be interested in you. If your business is able to do this, PR may help your company look more influential, bigger, and more important in the public eye. Public relations are an important part of marketing and advertising and needs to be considered in your advertising budget. The good news about PR is when done effectively can lead to strong community and industrial partnerships, and even financial support.

                Top Public Relations Firms for Emerging Companies

                www.OTCPRGroup.com is a complete financial public relations firm. Our unique and persistent market exposure techniques have consistently motivated the investor/brokerage community to take action on our clients’ stock offerings.

                 We Deliver Your Message

                We will become your “total” Public Relations firm. As a result of our extensive experience with particular client’s needs, we’ve developed programs that meet your specific goals.

                Many growth companies have great potential but no real retail buying. We have powerful systems of investor participation throughout the world targeting not only investors… we also market to stockbrokers as well by using all the latest digital and social marketing venues available.

                Our program affords you the greatest coverage in developing stock support and higher market capitalization utilizing the largest and most popular database providers in the industry who can take positions in your company stock.

                These services have proven to help create and maintain strong relationships with a corporation’s investor base, resulting in strong valuations in the marketplace and the establishment of leadership positions for our clients. From day one you will be on your way to an effective and well-organized program with short-term results. By delivering effective communications and investor relation services entrepreneurs, corporate executives and investors can realize their visions and achieve their goals.

                Get our “FREE REPORT REVEALS… The 5 (Easy Secrets)

                Tools we use TO SUCCESSFULLY USE SOCIAL MEDIA FOR INVESTOR COMMUNICATIONS”

                Sign up and request free report below:

                   

                   

                  Address: 1825 NW Corporate Blvd.Suite #110 Boca Raton FL. 33431

                  Phone: 954-821-2609
                  Email:corp@otcprgroup.com

                  Join Our Free Newsletter for the Latest Investor Relation Marketing Tips!!!

                    Small Cap Stock & OTC Investor Relations

                    Feb 25, 2016 by OTC PR

                    Small Cap Stock & OTC Investor Relations
                    Small Cap Stock & OTC Investor Relations

                    Small Cap Stock & OTC Investor Relations for Emerging Companies.Your company should have clear objectives from the get-go of what you want to achieve in broadening your investor base and retaining the current ones.  Keeping both institutional and retail investors apprised of your company’s evolving business model in real-time — and measuring your investor relations program’s success for your entire management team is critical. Also, the investor relation function is now becoming more strategic in the organization, as they are now working closely on M&A, market analysis and corporate governance, which is a new and exciting pattern for this role. Measuring your effectiveness by your stock price alone is not enough; there are too many other external factors that affect it during the year. Rather your best measurement is found from gathering feedback from the buy- and sell-side analysts and what the general market says about you (i.e. retail investors, the media and general public.).

                    In this fast-paced market, Small Cap Stocks can easily be overlooked. Without the resources and funding of Fortune 500 firms, it can be difficult to maintain a consistent presence in the public’s eye. Whether you choose to hire an in-house professional or put an external advisor on retainer, your IR specialist must create buzz and guide your company’s strategic communication and beyond. The investor relations function involves educating the public about the company’s position in the industry, providing a regular update of forecasts and identifying any key business issues that could impact the company.

                    What should you look for in a Small Cap Stock & OTC Investor Relations firm?

                    • Persuasiveness: He or she should be able to draw the market’s interest and attract sell-side coverage and potential investors.
                    • Creating buzz: Your IR professional should also be able to continually publish and generate articles for your company “Get you in the press”
                    • Risk awareness: Your IR professional should also be able to manage the risks associated with the external messaging.
                    • Storytelling: Your IR professional will have to continually retell the company’s story and fine-tune the investment value proposition, as well as provide the appropriate guidance on milestones and financial performance.
                    • Integrity: Your IR professional must be transparent and honest, and instill confidence in your organization.

                     

                    OTC PR Group is a complete Small Cap Stock & OTC Investor Relations firm. Our unique and persistent market exposure techniques have consistently motivated the investor/brokerage community to take action on our clients’ stock offerings.

                    We Deliver Your Message

                    We will become your “total” Public Relations firm. As a result of our extensive experience with particular client’s needs, we’ve developed programs that meet your specific goals.

                    Many growth companies have great potential but no real retail buying. We have powerful systems of investor participation throughout the world targeting not only investors… we also market to stockbrokers as well by using all the latest digital and social marketing venues available.

                    Our program affords you the greatest coverage in developing stock support and higher market capitalization utilizing the largest and most popular database providers in the industry who can take positions in your company stock.

                    These services have proven to help create and maintain strong relationships with a corporation’s investor base, resulting in strong valuations in the marketplace and the establishment of leadership positions for our clients. From day one you will be on your way to an effective and well-organized program with short-term results. By delivering effective communications and investor relation services entrepreneurs, corporate executives and investors can realize their visions and achieve their goals. 

                    Here are some of the main services and solutions we offer our clients:

                     

                      • News Releases

                      • Newspaper and Magazine Articles

                      • Media Relations and Publicity

                      • Public Relations Strategy and Branding

                      • Radio and Television Interviews

                      • Social Media Applications

                      • Social Media News

                      • Videos Production

                      • Web Site Content

                      • Blogs and Micro Blogs

                      • Bylined Articles

                      • Case Studies

                      • Crisis Communications 

                      • Customer Communications

                      • EBooks and E-Newsletters

                      • Illustrations and Graphics

                      • Online Magazines

                      • Investor Communications

                    Small Cap Stock & OTC Investor Relations firm

                    We will work with you to develop an investor relation awareness strategy that meets your company’s needs. Based on that strategy, we will develop an effective profile that focuses on the key messages that you want to convey to potential investors in addition to an ongoing narrative telling your story. In addition to reaching our extensive and targeted database, we also work with other investment professionals to distribute your company story. Through our years of networking with selected professionals we have expanded our distribution substantially. Learn More:

                     

                     

                    Address: 1825 NW Corporate Blvd.Suite #110 Boca Raton FL. 33431

                    Phone: 954-821-2609
                    Email:corp@otcprgroup.com

                    Join Our Free Newsletter for the Latest Investor Relation Marketing Tips!!!

                      Increase shareholder recognition with video

                      Feb 23, 2016 by OTC PR

                      Increase shareholder recognition with video
                      Increase shareholder recognition with video

                      A good corporate video is one of the best ways you can bring visibility and corporate recognition. If you are a public company you can increase shareholder recognition with video. If you are not communicating your story with a corporate video whether it’s an interview style format or a well-developed commercial video you are missing out on what is a tremendous marketing tool. Online video has been gaining strength as a source for content marketing the benefits can be increasing shareholder recognition; increase sales, web presence, along with exposure to media. The statistics speak for them selves in fact take a look pertinent data from http://www.videobrewery.com/blog/18-video-marketing-statistics

                       

                      A commercial video is the first chance to show the world exactly what your company is doing giving investors or potential partners the opportunity learn about your business and goals. Yet another advantage for preparing commercial videos from video production companies is that you can use the video for press release exposure and distribution. Videos have the ability to reach the right venues and create the right impact.

                       

                      The reason we encourage clients to incorporate video in investor relation campaigns is that it is simply the most powerful digital marketing tool available. It’s better for recall, it’s more persuasive and search engines love it. A professional interview can draw out plenty of information, which is why the interview format is so effective in relaying information to others. The exposure of video content continues to grow, and it’s more important than ever for investor relation professionals to develop an engaging video marketing strategy In fact, research has found that using the word “video” in an email subject line boosts open rates.

                       

                      An interview by itself shows that both parties are experts in their chosen niche, which means people watching or listening to the interview will consider the information being talking about as valuable. This video interview can then be placed on various video blogging or streaming websites so that it gets plenty of exposure for your business. The modern way of advancing this tradition of oral communication is through video blogging. Through interviews that can be posted online, people are simply able to capture knowledge in a very effective way. There are different types of learners in this world, and when it comes to content, your goal is to gain exposure. You may be informing someone why they need your services, how they can use your products or when they will need your expertise. No matter what you sell, your basic content creation goals will all boil down to attracting a targeted audience.

                       

                      One of the best things about video content is that you can post it on YouTube. While video can dramatically increase your website’s visibility on the major search engines (Google, Bing, Yahoo), few businesses understand how to take advantage of YouTube, the world’s second largest search engine.

                       

                      Depending on your marketing objectives, your videos can live either on YouTube or on your website. If your video is on YouTube, you can increase your brand’s visibility in search fairly quickly, but the traffic will go to YouTube. But if your video lives on your website, the traffic goes to your site, but it takes longer to build up your rankings and traffic. That’s what video does: it increases email click-through rates, ensuring that your email campaigns get the highest ROI possible. If you’re ready to become an expert in your niche, then it’s time to see what a good video marketing team can do with an online interview. Learn More:

                      Get our “FREE REPORT REVEALS… The 5 (Easy Secrets)

                      Tools we use TO SUCCESSFULLY USE SOCIAL MEDIA FOR INVESTOR COMMUNICATIONS”

                      Sign up and request free report below:

                         

                         

                         

                        Address: 1825 NW Corporate Blvd.Suite #110 Boca Raton FL. 33431

                        Phone: 954-821-2609
                        Email:corp@otcprgroup.com

                        Join Our Free Newsletter for the Latest Investor Relation Marketing Tips!!!